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ALT alanine transferase 
AST aspartate transferase
CDC Centers for Disease Control and Prevention
CHC chronic hepatitis C
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DAA direct-acting antiviral (agents)
DBS dried blood spot
DU drug use
EVR early viral response
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HDI human development index
HIV human immunodeficiency virus 
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OR odds ratio
PAT parenteral antischistosomal therapy
PCR polymerase chain reaction
PTA positive testing advice
PTPD post-test probability of disease
RVR rapid viral response
SD standard deviation
SMS short message service
STD sexually transmitted disease
STI sexually transmitted infection
SVR sustained virological response
TMA transcription-mediated amplification
VA veterans affairs
WHO World Health Organization
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CHAPTER 1
INTRODUCTION
Adapted from:
FR Zuure, S Hahné,  TJ van de Laar, M Prins, J van Steenbergen (2009). Bloodborne and sexual 
transmission: hepatitis B and C. In AE Kramer, M Kretzschmar & K Krickeberg (Eds.), Modern 
Infectious Disease Epidemiology: Concepts, Methods, Mathematical Models, and Public Health 
(pp. 333-356). New York, USA: Springer
A Kok, FR Zuure, CJ Weegink, RA Coutinho, M Prins. Hepatitis C in Nederland: schaarse 
gegevens over actuele prevalentie en de noodzaak van epidemiologisch onderzoek en innovatieve 
opsporingsmethoden. NTvG 2007;151(43):2367-2371
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1.1 Hepatitis C virus
Hepatitis C virus (HCV) infection is caused by a mainly bloodborne virus and was first identified 
in 1989. It affects an estimated 2-3% of the world’s population (1). Approximately 75% of 
HCV infections progress to chronic infection, posing the patient at risk for the development of 
cirrhosis, liver cancer, and death (2;3). In chronically infected patients, the onset of HCV itself and 
the development of cirrhosis are usually asymptomatic (2;4). Therefore, many infections remain 
undetected or are diagnosed late. HCV infection was the most common cause of post transfusion 
non-A/non-B hepatitis, as it was especially recognized among individuals who had received 
contaminated blood products. In 1991, the first commercial HCV antibody test became available, 
leading to a dramatic decrease in the incidence of transfusion-acquired HCV infection in countries 
that introduced the routine screening of donor blood (4). However, based on mathematical modeling, 
it has been estimated that HCV-related morbidity and mortality will at least double over the next 
two decades in various medium- to high-income countries (5;6). Three quarters of liver cancers 
worldwide are related to chronic hepatitis B virus (HBV) and HCV infections (7). In both Europe 
and the United States, HBV and HCV-infection related mortality exceeds that of HIV (8;9).
Global pattern
The World Health Organization (WHO) estimates that the African and Eastern Mediterranean regions 
have the highest prevalence of HCV infection, but reliable population based studies are lacking for 
many countries (1). The world’s highest prevalence of HCV infection in the general population (15-
20%) has been reported in Egypt, as a result of injection therapy against schistosomiasis in mass 
settings without sufficient sterilization of reused injection materials (10;11). Although health-care 
associated HCV transmission incidentally occurs in high-income countries, its current contribution 
to the overall prevalence in these countries is low (12). In contrast, non-sterile injection practices, 
lack of HCV screening of donor blood, and other iatrogenic routes still account for a significant 
route of HCV transmission to the general population in medium- and low-income countries (13).
In most high-income countries, prevalence of HCV infection among the general population is low. 
In the Netherlands, HCV prevalence in the general population has been estimated at 0.22% (min: 
0.07%; max: 0.37%) (14) and somewhat higher in the larger cities (15). Non-western migrants and 
(former) injecting drug users are considered to account for the majority of HCV infections in the 
Netherlands (14). 
Risk groups for hepatitis C virus infection
Injection drug users are at high risk of HCV-infection (prevalence 60 to >80% (16)). Other risk 
groups for HCV-infection are those who received blood products before 1992 (i.e., hemophiliac 
patients, prevalence ~70% (17)); hemodialysis patients (prevalence 3 to 23% (18)); individuals who 
underwent non-sterile medical procedures abroad (prevalence unknown); non-injection drug users 
(prevalence 2 to 35%), though the causal pathway to infection in this group remains unclear (19); 
individuals who experienced a needle-stick injury and health-care professionals dealing with patient 
blood (prevalence unknown) (20); household contacts with HCV-infected individuals (possible 
transmission through the shared use of toothbrushes, razors, etc, prevalence 0 to 11% (4)); and 
children born to HCV-infected mothers, with transmission rates of ~4%, increasing in maternal 
HCV/HIV co-infection to ~20% (21). Other activities that may cause blood-blood contact have been 
identified as possible routes for HCV infection, such as tattooing, body piercing, and cultural/
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religious practices (e.g., scarification, circumcision, acupuncture). However, results are inconsistent 
and it is uncertain whether these risk factors make any measurable contribution to overall HCV 
transmission (22;23).
Even in the presence of HIV co-infection, HCV is rarely transmitted through heterosexual intercourse 
(24). Since 2000, however, HCV infection has emerged among HIV-infected men who have sex with 
men (MSM) (25). Most infected MSM denied injecting drug use. It has been suggested, mainly through 
case studies, that HCV infection is associated with HIV-infection, presence of ulcerative sexually 
transmitted diseases, sexual techniques causing mucosal damage, and sex under the influence of 
non-injecting drugs (25). Phylogenetic analyses have shown clusters of MSM-specific HCV strains, 
indicating a sexual route of HCV transmission (25).
Clinical course of infection
In the majority of cases acute HCV infection is asymptomatic. Less than one third of individuals 
with an acute HCV-infection experiences mostly mild and aspecific symptoms such as a loss of 
appetite, fatigue and flu-like symptoms, and occasionally jaundice (26). The majority (~75%) of 
patients develop chronic HCV infection (3), defined as the persistence of HCV RNA after 6 months 
of infection. Approximately 20 years after onset of chronic HCV infection, the infection may lead 
to liver cirrhosis in 6-25% of patients, 1-4% of whom develop hepatocellular carcinoma per year 
(27-29). Several host-related and external factors have been associated with accelerated HCV disease 
progression, such as male sex, heavy alcohol intake, elevated alanine transferase (ALT), higher 
grade of histological inflammation, HIV coinfection, and genetic factors (28;30-33). Although HCV 
infection is a slowly progressing disease, it is the main cause of liver transplantations in the US and 
Europe (34).
Molecular epidemiology
HCV is a single stranded RNA virus. The high genetic variability of the HCV genome has led to 
a classification of the virus in six major genotypes (1 to 6), which, except for genotype 5, are each 
further divided into more than 80 related subtypes (a,b,c,…) (35;36). As HCV genotype distribution 
varies over time and depends on geographic area and mode of transmission, it provides clues about 
the historical origin and spread of the virus. Some HCV subtypes are found globally, due to a swift 
spread in the 20th century through needle sharing among injecting drug users (types 1a and 3a), 
and contaminated blood products (types 1b, 2a and 2b). These genotypes represent the majority 
of infections in Europe and Northern-America. In contrast, the presence of numerous and highly 
diverse subtypes in western/central Africa and the Middle East (genotypes 1, 2 and 4) as well as 
Southeast Asia (genotype 3 and 6) suggest that these genotypes originate from these areas where 
they have been endemic for a long time (37-39).
Therapy
Recently, important advances in the treatment of chronic HCV infection have been made. Boceprevir 
and telaprevir, two HCV-protease inhibitors, have recently become available and have demonstrated 
significant improvements in the effectiveness of treatment of HCV genotype 1 infections (40;41). 
Currently, the recommended therapy for HCV infection consists of the use of a modified form 
(pegylated) of interferon alpha (protein with immunomodularity and antiviral properties) and 
ribavirin (a nucleoside analogue with antiviral activity), in combination with boceprevir or telaprevir 
for HCV genotype 1 infections (42). HCV treatment duration is usually 24 weeks (genotype 2 and 
3), or 48 weeks (genotype 1 and 4) (43). In patients with baseline HCV RNA <600,000 IU/ml and 
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in patients without cirrhosis treated with boceprevir or telaprevir in addition to peginterferon and 
ribavirin, response-guided therapy can result in a shortened duration of therapy (i.e., 12-16 weeks 
for genotype 2 and 3, 24-28 weeks for genotype 1 and 4) (42;43). The aim of treatment is to eradicate 
viral RNA and to reach a sustained virological response (SVR), which is defined as the absence of 
HCV RNA at 24 weeks after the end of treatment (44). 
One of the most important predictors of SVR, which occurs in 42-90% of the cases, is HCV genotype 
(45). Genotype 4 is a difficult-to-treat genotype, with approximately 50% of treated patients achieving 
SVR (43), compared with an SVR up to 65-75% for genotype 1-infected patients who are treated with 
standard therapy plus boceprevir or telaprevir (40;41), and up to 80-85% in patients with genotypes 
2 and 3 (46). Other predictors of therapeutic outcome that may influence treatment duration include 
interleukin-28B (IL28B) polymorphisms (especially for genotype 1 and 4 patients), low HCV RNA 
level prior to treatment, rapid viral response (RVR) (undetectable HCV RNA levels at week 4), 
and early viral responses (EVR) (≤2 log decrease in viral load during the first 12 weeks) (45;47). 
Approximately 10-14% of all patients discontinue treatment because of serious side effects such 
as influenza-like symptoms and neuropsychiatric symptoms (44). All patients should be considered 
for treatment. However, patients with mild disease activity may defer therapy as future treatment 
of chronic HCV infection will probably be more effective and of shorter duration (48). The further 
development of direct-acting antiviral (DAA) agents and drugs targeting host cell factors that are 
essential for efficient HCV replication indicate a promising future for the treatment of HCV infection.
Prevention and control
In contrast to hepatitis B virus (HBV), for HCV there is no vaccine available, nor are there drugs 
for post-exposure prophylaxis or prevention of mother-to-child-transmission. Prevention relies 
completely on precautionary measures preventing further spread. In low- and medium income 
countries, improvement of blood transfusion safety and health-care conditions are important for 
reducing HCV transmission. In high-income countries, screening of donor blood products in 1991 
significantly reduced the incidence of iatrogenic HCV transmission. In the Netherlands, incidence of 
HCV infection among drug users has declined, most likely due to decreasing injection risk behavior, 
probably resulting from comprehensive harm reduction programs including needle exchange 
programs and methadone provision (49;50). In HIV-infected MSM, a group in which incidence of HCV 
infection has increased in recent years (51;52), HCV infection could be prevented through condom use 
and hygienic measures when practicing rough sexual techniques that could cause mucosal damage. 
Since in many high-income countries incidence of HCV infection is low and effective treatment is 
widely available, identification of those who became infected in the past is of major importance to 
reduce future HCV-infection related morbidity and mortality. Besides treatment, these individuals 
can benefit from vaccination against hepatitis A virus (HAV) and HBV infection, and can adjust their 
lifestyle (e.g., limiting alcohol use) which can improve prognosis of HCV infection. 
Screening for hepatitis C virus infection 
Standard HCV testing includes screening for anti-HCV antibodies using an anti-HCV EIA confirmed 
by immunoblot or HCV-RNA testing. In a clinical setting, a positive anti-HCV test is directly 
followed by RNA testing to establish the presence of ongoing infection. In the case of a potentially 
acute infection, RNA testing will be done since it might take several weeks (20-150 days) before 
HCV antibodies develop (53). In immunosuppressed patients (e.g., HIV-infected individuals) HCV 
antibody seroconversion can be delayed, or HCV antibody may even remain undetectable despite 
HCV viremia (54;55).  
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Because of the asymptomatic onset and disease in the first decades of HCV infection, many HCV-
infected individuals are not aware of their condition and therefore do not seek help or perceive a 
need to screen for HCV infection. As a result, a potentially large number of infected individuals are 
still unidentified. Diagnosis of these individuals is vital to treatment and prevention of future HCV-
infection related morbidity and mortality. In high-income countries, the Wilson and Jungner criteria 
for screening are considered applicable for chronic HCV infection (56): HCV infection is considered to 
be an important health problem; there is an accepted treatment for patients with recognized disease; 
facilities for diagnosis and treatment are available; there is a recognisable stage of disease; there is 
a suitable and acceptable test for diagnosis of HCV infection; the natural history of HCV infection 
is understood; there is an agreed policy on whom to treat as patients; treatment is considered cost-
effective; and case-finding should be a continuing process and not a ‘once and for all’ project (57).
There are several types of screening strategies such as case finding (i.e., opportunistic screening 
(58)), mass population screening, and selective screening. As HCV spread among individuals who 
received contaminated blood products before the introduction of the first HCV antibody test in 
1991, various high-income countries introduced look-back programs in which recipients of blood 
products from HCV-infected donors were notified and encouraged to be tested (59;60). The costs, 
however, were high and the yield low (61;62). Selective screening of risk groups for HCV infection 
has been recommended (63;64). Some of the high risk groups for HCV infection are relatively easy to 
reach and have been targeted by screening programs as part of specialized medical care (e.g., current 
drug users on methadone treatment (65;66), HIV-infected individuals receiving clinical care (67), and 
hemophiliac patients (68;69)). However, other risk groups are more difficult to target for screening. For 
example, persons at risk for HCV infection through occasional injecting drug use in the remote past 
will not attend programs targeted at active drug users and might not identify themselves as being at 
risk for HCV infection. The same holds true for individuals who received a blood transfusion before 
1992. These risk groups can be considered hidden among the general population. The size of this 
hidden population may be substantial. A recent study estimated that of the total population of HCV-
infected individuals in the Netherlands, only 34% are in relatively easy to reach high-risk groups 
such as hemophiliac patients, HIV-infected patients, and current injecting drug users; 41% are first-
generation migrants and 25% belong to other risk groups (14). 
Hepatitis C screening of risk groups hidden within the general population
A few studies have evaluated screening tools for determining risk for HCV infection (e.g., establishing 
individual risk for HCV infection as a condition for screening) to support efficient screening of 
the hidden population of HCV-infected individuals in healthcare facilities (70-72). Such selective 
screening is promising and more affordable than mass screening (73;74), but the use of these tools 
will not reach the pool of undiagnosed HCV-infected individuals who do not visit such facilities. In 
many countries, the general practitioner (GP) is an essential part of medical care, and the first point 
of contact for most medical services. However, HCV awareness, testing, and referral for those who 
test positive in the GP clinic has been suboptimal (75-78). A study showed that even when risk factors 
for HCV infection were documented, a small proportion of those at risk was screened (75). 
Hepatitis C screening in the Netherlands 
Soon after the first HCV antibody test became available, in 1992, the Blood Transfusion Council of the 
Netherlands Red Cross advised hospitals to inform recipients of HCV-infected donor blood and offer 
them screening. As in many other targeted look-back programs, the yield was limited as only a relatively 
small number of recipients could be traced, and a large proportion of those had already died (79;80). 
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Routine HCV screening was introduced in care programs for various high risk groups such as active 
injecting drug users and hemophiliac patients in the Netherlands. Awareness for HCV infection 
among the general population was low. In 1997, the Health Council of the Netherlands recommended 
that populations at risk for HCV infection should be identified and provided with information, and 
that epidemiological research should be conducted in order to gain additional insight regarding how 
HCV infections can best be identified and prevented in the Netherlands (79). In 2004, the Health 
Council reiterated the urgency of this recommendation given the improved treatment options for 
chronic HCV infection (81). In accordance with these recommendations, epidemiological research 
was conducted (e.g., 14;15;23;82-85) and several HCV screening programs targeting risk groups in the 
general population were initiated in the Netherlands. 
1.2 Facilitation of hepatitis C screening of individuals at risk hidden 
among the general population 
This thesis focuses on two of the HCV screening programs that have been carried out in the 
Netherlands. One of them is a risk- and Internet-based screening pilot program, described in 
1.2.1 and in more detail in chapter 3. The other is a community-based HCV and HBV screening 
program targeting first generation Egyptian migrants (see 1.2.2 and chapter 4). In both programs, 
screening was organized beyond the GP clinic. The evaluation of screening beyond the GP clinic 
was considered useful for two reasons. First, not all individuals visit their GP regularly, and the 
time that individuals generally spend with their GP is short. In the Netherlands, in 2010, 72.3% of 
the population visited a GP at least once, with a mean number of 5.9 GP visits in that year (86), each 
taking about 10.2 minutes (87). Hence, it is unlikely that GPs are aware of all of their patients’ risk 
factors for HCV infection or have time to investigate these during their consultations. Second, those 
who practiced experimental injecting drug use in the past, including those who injected only once, 
present a group at increased risk for HCV infection that may not easily disclose their past injecting 
behavior to their GP. In the following paragraphs the background, rationale, and organization of the 
internet-based and community-based programs are outlined. 
 
1.2.1 Use of the Internet for the promotion of hepatitis C screening 
With the advent of the Internet as a popular communication platform in many high-income countries, 
new possibilities arose for health care professionals to not only distribute up-to-date information 
24 hours a day, 7 days a week, but also to reach and interact with a large audience beyond the 
setting of health care facilities, and to provide low threshold access to health care services. Internet 
use in health care has been defined as ‘eHealth’: “an emerging field in the intersection of medical 
informatics, public health and business, referring to services and information delivered or enhanced 
through the Internet and related technologies” (88). The interactive nature of the Internet offers the 
possibility to tailor information and services to the needs of the individual. Research has shown that 
tailored health information can be more effective than generic information in establishing health 
behavioral change, such as healthy dieting (89) or mammography screening (90). For HCV infection, a 
stigmatized disease that is associated with drug use, the discrete character of the Internet may appeal 
to those who wish to get tested anonymously. Considering these advantageous characteristics, the 
Internet was considered a potentially useful medium, through which to provide a self-selecting tool 
for the identification of risk groups for HCV infection and arrange a testing trajectory for those at 
risk for infection.
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Besides the advantages relative to other media, the reach of the Internet throughout the general 
population increases its potential effectiveness. The Netherlands are among the countries with the 
highest Internet penetration rate in Europe. In 2012, the Internet penetration rate reached almost 
93%, representing over 15.5 million Dutch Internet users (91). The majority uses the Internet on a 
daily basis, at home, and more than 50% indicated to have searched for health related information 
in the past three months (92). Internet use has virtually spread throughout the Dutch population. Only 
among the elderly and those with lower education Internet access is somewhat lower, estimated at 
61% among those aged 65-75 versus 91% or higher in the younger age groups, and 85% among 
those with low educational levels versus 97% and higher among those with higher educational levels 
(92). Data from 2005-2009 indicate that Internet access, use and skills among migrant groups has 
increased, equaling that among the native Dutch population (93). Therefore, eHealth offers a good 
opportunity to facilitate HCV screening for a large audience in a relatively anonymous way.
Organization of the Internet-based screening program
With the potential advantages of the Internet in mind, we set up a screening program for HCV for 
risk groups that are hidden among the general population. The program aimed to inform individuals 
about their personal risk for HCV infection by offering them an interactive online questionnaire 
assessing risk for HCV infection through structured multiple-choice questions that addressed the 
prominent risk factors for infection. The questionnaire was available in six languages (i.e., Dutch, 
English, Spanish, French, Turkish and Arabic) to facilitate participation of first-generation migrants 
without sufficient knowledge of the Dutch language. Those who reported at least one risk factor 
for HCV infection were informed and advised to seek HCV blood testing. When they were living 
in the project’s pilot regions Amsterdam and South Limburg, they were offered a low-threshold 
testing procedure; they could visit one of the associated laboratories for a free and anonymous 
blood draw and obtain their test results within a week, via the Internet. Those found with a reactive 
test result were offered a face-to-face follow-up trajectory at their Public Health Service in which 
a confirmation anti-HCV antibody blood test and, if positive, follow-up HCV-RNA testing were 
arranged. For those with a chronic HCV infection, referral to a hepatologist was arranged. The 
program was promoted through regional media campaigns.
Health behavior theory and hepatitis C screening
In order to promote participation in our screening program, the program incorporated information and 
features that addressed (potential) determinants of health behavior as derived from health behavior 
theories. Health behavior theories help to understand why people do or do not follow public health 
and medical advice, and give insight into factors that can be modified to promote healthy behavior 
(94). Research has shown that health promotion programs that are theory-based are more likely to be 
effective than those without a theoretical base (95). Therefore, concepts from the revised health belief 
model, the theory of planned behavior, and the extended parallel process model were applied to the 
Internet-based HCV screening program.
Revised health belief model
One of the most widely used theoretical models is the health belief model. This model was developed 
in the 1950s to explain screening and disease detection behavior in people in response to a disease 
threat (96). Today, the revised health belief model is applied more broadly, and is used to explain 
why people take action to prevent, detect, or control a disease. The health belief model focuses on 
perceived severity of and vulnerability to a disease (perceived threat), perceived barriers to and 
benefits of executing the preventive behavior (expectations regarding the outcomes of the positive 
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health behavior), perceived self efficacy (the degree to which one perceives oneself capable of 
executing the health behavior), and cues to action (external stimuli which activate ‘readiness to act’ 
and stimulate the execution of the health behavior). 
For HCV infection, awareness among the general population is relatively low. Hence, for the majority 
of those at risk for HCV infection, the infection will be perceived as a new emerging health threat 
that does involve apparent physical symptoms. In that context, the health belief model is particularly 
relevant for explaining HCV screening behavior, because of its beliefs related to perceived threat. 
Applied to the context of HCV screening, the likelihood of HCV testing increases when perceived 
threat of HCV infection is high, perceived barriers of testing are low, perceived benefits of testing 
are high, self efficacy for testing is high, and relevant cues to action are present. 
Theory of planned behavior
Another widely used theory is the theory of planned behavior that evolved from the theory of 
reasoned action. According to the theory of planned behavior, attitudes (personal evaluations of the 
behavior based on behavioral beliefs), subjective norms (perceptions of other people’s evaluations 
of the behavior based on normative beliefs), and behavioral control (perceived control over the 
execution of the behavior based on control beliefs; similar to self-efficacy) determine the intention to 
engage in a behavior (97). Behavioral intention is presumed to best predict behavior. However, actual 
behavioral control (e.g., lack of control due to environmental factors) can also directly influence 
behavior. Applied to the context of HCV screening, the intention to take an HCV test increases 
when attitudes towards testing are positive, when subjective norms favor HCV testing, and when 
perceived behavioral control is high. 
Extended parallel process model
The extended parallel process model also focuses on health beliefs but is more specific than the 
health belief model with regard to the role of emotion in responses to a perceived health threat. 
According to the extended parallel process model, health threats can cause individuals to engage in 
either danger control or fear control processes. Danger control is aimed at reducing the health threat 
through cognitively processed adaptive responses (e.g., seeking testing and treatment), whereas 
fear control is aimed at reducing unpleasant feeling related to the health threat. Fear control often 
results in maladaptive responses such as message avoidance and defensive reactions (e.g., denial 
of risk). Whether individuals engage in danger or fear control processes depends on the degree to 
which threat, self efficacy, and response efficacy (the extent to which the recommended behavior is 
expected to effectively reduce the threat) are perceived to be present (98). Medium to high perceived 
threat combined with high perceived efficacy will most likely result in danger control responses 
while high perceived threat combined with low perceived efficacy will most likely lead to fear 
control responses. Applied to the context of HCV screening, the extended parallel process model 
would suggest that the likelihood of HCV testing is greatest when individuals perceive the threat of 
HCV infection as moderate to high and possess high levels of perceived self efficacy and response 
efficacy.
Application of theory to the Internet-based screening program
Various concepts from the theoretical models described above were operationalized through the 
screening program. Our communication attempted to increase sense of vulnerability. For example, 
through communication of risk factors for acquiring HCV infection, possibility of infection without 
any experience of symptoms, and provision of information that was tailored to individuals’ reported 
risk factor(s). We aimed to increase sense of perceived severity, for instance by addressing the 
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potential severe long time health outcomes of chronic HCV infection. For increased understanding 
of the benefits of testing, factors such as the availability of treatment were mentioned. In the project 
we also aimed to increase sense of perceived self efficacy by communicating the ease with which 
personal risk for HCV infection can be assessed, and the low threshold blood testing procedure that 
allowed individuals confronted with threatening information to take a test the next working day. 
Email and SMS reminders were sent, in order to provide cues for action. 
Research objectives
The aim of the Internet-based screening program for HCV was to identify individuals at risk for 
HCV infection, to motivate, and arrange for them to go for HCV testing. The key research objective 
was to evaluate whether a hidden population of individuals at risk for HCV infection could be 
reached through a public media information campaign combined with an Internet screening tool. 
More specific research objectives were to evaluate:
- the reach of the media campaign in attracting those potentially at risk for HCV infection to the 
project’s website;
- the extent to which those who completed the risk assessment questionnaire were at risk for HCV 
infection, and their characteristics;
- the blood test uptake and determinants of test uptake among those at risk;
- reasons for complying or not complying with test advice that was given online;
- the proportion of individuals that tested positive for HCV infection and their characteristics;
- the clinical outcomes of the screening;
- and the usability and acceptability of the service as perceived by the participants.
1.2.2 Community-based outreach to promote hepatitis C screening 
The Internet-based screening program aimed to offer an anonymous screening service to attract a 
hidden population of individuals at risk for HCV infection such as former injecting drug users, those 
who received a blood transfusion in the past, and also migrants at risk. The latter group however 
was underrepresented in the Internet program. We hypothesized that this group may be better 
reached through a community-based program. Because of their shared background and common 
characteristics such as religion and culture, migrants may be identified at venues specific to their 
community, such as churches and mosques. Therefore, we set up a program for first-generation 
migrants from Egypt (see chapter 4). 
Theory of community based health programs
A community can be recognized as a unit of identity (99). The sense of community, i.e., the sense of 
belonging to and of sharing common desires with other members (99), can vary between weak and strong 
and is based on aspects of membership, influence over what occurs within the community, shared 
values and needs fulfillment, and a shared emotional connection (100). A strong sense of community 
is associated with community mobilization, whereas community heterogeneity reduces engagement 
and participation (99). Hence, the sense of community (”community focus”) is an important principle 
to acknowledge when planning a community-based screening program. Another important principle 
on which many community-based health programs are based is the beneficial result of community 
member participation. Although there is little evidence that community involvement is associated 
with program effectiveness (99), collaboration between health program planners and community 
leaders, and active participation of those community leaders and participants in the health program 
are increasingly valued (100). Theory assumes that participation increases individual empowerment 
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and serves as a method to incorporate community values and attitudes into the program. More 
importantly, when a program is supported by community leaders, it can increase local confidence in the 
benefits of the program and therefore may become more acceptable to the community members (99). 
Besides community member participation, intersectoral collaboration in the health program 
(i.e., collaboration among different community organizations), the availability of substantial 
resources and a long term program view, and a multifaceted intervention addressing both behavioral 
and environmental components are assumed to increase the effectiveness of community-based 
health programs (99).
Organization of the community-based screening program
The community-based screening program was designed for first-generation migrants from Egypt 
living in the Amsterdam region. Migrants comprise a group at increased risk for HCV infection (and 
other infectious diseases such as HBV infection) because of their increased risk of exposure to risk 
factors in their country of origin before migration. The program focused on migrants from Egypt, 
since Egypt is the country with the world’s highest prevalence of HCV infection (nearly 15%) (11). 
Although data on the prevalence among migrants was lacking, we considered that screening this 
population would be useful to detect undiagnosed infections and bring infected individuals into 
health care. First-generation Egyptian migrants represent an ethnic minority community in the 
Amsterdam region with an estimated size of 3200 adults. We considered the community sense to be 
relatively strong, and even stronger for sub-communities on the basis of religion (i.e., Coptic and 
Islamic Egyptians). 
We actively involved the Egyptian community in the screening program. In order to increase the 
potential reach of the program and create community-wide awareness for HCV infection, various 
community organizations were approached to discuss HCV infection and the proposed screening 
program (e.g., a Coptic church, an Islamic mosque, an Egyptian trade organization, a Sunday school, 
and an organization for Egyptian women). The attempts were successful; community leaders agreed 
to participate in the organization and promotion of the program, and provided accommodation 
for educational and screening sessions. Moreover, collaboration with the community leaders 
highlighted the community’s desire to organize simultaneous screening for both HCV and HBV. 
Egypt is a medium endemic country for HBV infection, risk factors for HCV and HBV infection 
overlap, and HCV and HBV infection are often confused (that is, people are often not aware of the 
differences between the two virus infections). Therefore, HBV screening was incorporated into the 
program. The screening was free of cost for participants, and was promoted via announcements by 
the community leaders and flyers which were distributed through the community organizations. 
All information materials were in both Dutch and Arab, and native Arab speaking educators had 
a central role in the program. It was considered that, although most first-generation migrants from 
Egypt are highly educated and have sufficient knowledge of the Dutch language, migrants may 
better express themselves in their native language, especially with regard to sensitive topics (101). 
The educators were trained on the topic of viral hepatitis and led the educational sessions. They 
highlighted transmission routes, potential symptoms, the epidemic in Egypt, treatment options and 
prevention measures. During the testing sessions they were present to answer participant questions.
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Research objectives
The aim of the community-based screening program for HCV and HBV infections was to identify 
undiagnosed infections and bring these individuals into care. More specific research objectives were 
to evaluate:
- the reach of the program in attracting first-generation migrants from Egypt;
- the prevalence of HCV and HBV infections and determinants of infection;
- the clinical outcomes of the screening;
- and the phylogenetic evidence for infection acquisition before migration.
1.3 Thesis outline
This thesis describes and discusses the feasibility and effectiveness of HCV screening programs 
targeting risk groups in the general population, focusing in particular on the Internet-based and the 
community-based approach. 
Chapter 2 describes the results of a systematic literature review that summarizes characteristics 
and outcomes of international HCV screening programs for risk groups for HCV infection that are 
hidden in the general population.
 
Chapter 3 describes three studies that cover the development and results of the Internet-based 
screening program for HCV. In the first study, a risk assessment questionnaire for HCV infection 
was developed and evaluated using liver patients with a known HCV infection status. The second 
study describes the implementation of that questionnaire as an online pre-screening selection tool 
in an HCV screening service targeting risk groups hidden among the general population, and the 
outcomes of that service. The third study describes the results of qualitative research on reasons for 
compliance and noncompliance with the HCV test advice obtained through the online risk screening 
tool, and focuses particularly on the role of the online blood testing procedures in that process. 
Chapter 4 describes the results of the community-based screening program for HCV and HBV aimed 
at first generation Egyptian migrants. 
Chapter 5 concludes with a general discussion and summarizes the work described in this thesis. 
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Abstract
Objective: Effective screening programs are urgently needed to provide undiagnosed hepatitis 
C virus (HCV)-infected individuals with therapy. This systematic review of characteristics and 
outcomes of screening programs for HCV focuses on strategies to identify HCV risk groups hidden 
in the general population.
Methods: We conducted a comprehensive search of MEDLINE and EMBASE databases for articles 
published between 1991-2010, including studies that screened the general population using either 
a newly developed (nonintegrated) screening program or one integrated in existing health care 
facilities. Look-back studies, prevalence studies, and programs targeting high-risk groups in care 
(e.g., current drug users) were excluded.
Results: After reviewing 7052 studies, we identified 67 screening programs: 24 non-integrated; 41 
programs integrated in a variety of health care facilities (e.g., general practitioner); and 2 programs 
with both integrated and nonintegrated strategies. Together, these programs identified approximately 
25700 HCV-infected individuals. In general, higher prevalence of HCV infection was found in 
programs in countries with intermediate to high prevalence of HCV infection, in psychiatric clinics, 
and in programs that used a prescreening selection based on risk factors for HCV infection. Only 
6 programs used a comparison group for evaluation purposes, and 1 program used theory about 
effective promotion for screening. Comparison of the programs and their effectiveness was hampered 
by lack of reported data on program characteristics, clinical follow-up, and type of diagnostic test.
Conclusions: The published studies identified a relatively small proportion of the estimated HCV-
infected population. A prescreening selection based on risk factors can increase the efficiency of 
screening in low-prevalence populations, and we need programs with comparison groups to evaluate 
effectiveness. Also, program characteristics such as type of diagnostic test, screening uptake, and 
clinical outcomes should be reported systematically. 
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Introduction
Hepatitis C virus (HCV) infection, primarily a blood-borne virus and first identified in 1989, is a 
major public health problem. Worldwide an estimated 123 million individuals are HCV-antibody 
positive (1), of whom approximately 75% are chronically infected and at risk for the development 
of cirrhosis, which can lead to liver cancer and death (2;3). In chronically infected patients, the onset 
of HCV infection and the development of cirrhosis are usually asymptomatic (2;4); many infections 
remain undetected or are diagnosed at a late stage. In the United States of America (USA), an 
estimated 43% to 72% of HCV infections are undiagnosed (5-7). In 2001, successful combination 
therapy for HCV infection became widely accessible (8-12) and more effective therapeutic options 
are becoming available (13;14). Effective screening programs are urgently needed to provide 
undiagnosed HCV-infected individuals with therapy and to spread information about preventive 
measures that each person should take (e.g., reducing alcohol intake, other precautionary measures 
against further spread), thus decreasing future morbidity and mortality.
There are several types of screening strategies such as mass population screening, selective 
screening, or case finding (i.e., opportunistic screening (15)). Selective screening of risk groups 
for HCV infection (see Box 1) has been recommended (16;17). Some of the high risk groups 
for HCV infection are relatively easy to reach and have been targeted by screening programs as 
part of specialized medical care (e.g., current drug users (DUs) on methadone treatment (19;20), 
hemophiliacs (21;22), and HIV-infected individuals receiving clinical care (23)). However, other 
risk groups are more difficult to target for screening. For example, persons at risk for HCV infection 
through occasional IDU in the remote past will not attend programs targeted at active drug users and 
might not identify themselves as being at risk for HCV infection. The same holds true for individuals 
who received a blood transfusion before 1992. These groups can be considered as ‘hidden risk 
groups’ among the general population. The size of this hidden population may be substantial. A 
recent study estimated that of the total population of HCV-infected individuals in a high-income 
country, only 34% are in relatively easy to reach high-risk groups such as hemophiliac patients, 
HIV-infected patients, and current IDU; 41% are first-generation migrants and 25% belong to other 
risk groups (24). 
Finding an effective strategy to identify the hidden population of undiagnosed HCV-infected 
individuals is challenging. An overview of screening programs for HCV infection provides insight 
into strategies that have been used so far and their outcomes, and can provide insight into the best 
way forward. In our review, we systematically review characteristics and outcomes of screening 
programs for HCV infection targeted at risk groups hidden in the general population. We focused 
in particular on the promotion of the screening program, whether or not prescreening selection 
criteria were used, and the use of psychosocial theory or knowledge about determinants facilitating 
participation in screening programs, since health promotion programs that are based on theory are 
more likely to be effective than those that are not (25). We discuss the implications of these findings 
for future screening strategies for HCV infection. 
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Methods
Search strategy
We searched in the MEDLINE (PubMed) and EMBASE databases for articles published in any 
language before July 27, 2010. A comprehensive strategy was used to include all possible studies 
in which individuals were screened for HCV. Search terms included hepatitis C (Medical Subject 
Headings [MeSH] for PubMed and Explosion search [Exp] for Embase) or HCV or “hepatitis 
C” in title or abstract combined with search terms in title or abstract that refl ect screening (i.e., 
mass screening [MeSH/Exp], screen*, “case fi nding*”, “case identifi cation*”, “case detection*”, 
“hepatitis C testing”, “HCV testing”) or search terms in title or abstract and/or MeSH/Exp that refl ect 
campaigns or evaluation of health programs (i.e., campaign*, health promotion, health service*”, 
feasibility, pilot*, “program* evaluation*”, “program* effect*”, “*health care quality”). The search 
was limited to articles published after 1990 since a more sensitive second-generation HCV antibody 
test was introduced in 1991 (26). The complete search strategy including truncation characters is 
available from the authors. In addition, we screened the reference lists of the articles that were 
included in the prefi nal selection for potentially relevant publications. 
Study selection
Studies were included if they reported screening of individuals in the general population, including 
screening in primary care facilities that are not related to specifi c risk groups for HCV infection. 
Exclusion criteria pertained to ‘look-back’ studies, in which recipients of HCV-infected donor blood 
are notifi ed and offered screening and studies conducted in specifi c, identifi able risk groups for HCV 
that are in specialized care: current drug users, HIV-infected individuals, incarcerated individuals, 
hemodialysis patients, or multitransfused patients such as hemophiliac patients. In addition, studies 
were excluded if 1) the study was designed to assess the prevalence in a given population, and/or 2) 
if the study was undertaken to investigate transmission rates and determinants (e.g., mother-to-child 
transmission (27)) or the association between HCV infection and another medical condition (e.g., 
diabetes (28;29)), and/or 3) nothing was reported about notifi cation, referral, or medical follow-
up of participants. The latter criterion did not apply to studies describing HCV screening at the 
general practitioner (GP) clinic, since notifi cation of results in this setting is considered to take 
place. Articles in languages other than English, French, German, or Spanish were excluded if there 
was no English abstract of if the English abstract did not yield enough data. 
The fi rst selection round was based on title and abstract (if available) only and was done by four 
Box 1: Risk groups for HCV infection (16, 17)
●	 Individuals with a history of injecting drug use (IDU), including those who injected only 
 a  limited number of times many years ago and do not consider themselves to be drug
 users  
●	 Individuals who received clotting factor concentrates produced before 1987 or a blood 
 transfusion or an organ transplant before 1992 including hemophiliac patients (systematic
 screening of blood donors for HCV antibodies was introduced in 1991) (18)
●	 Individuals with occupational exposure to infected blood 
●	 HIV-infected men who have sex with men (MSM) 
●	 Chronic hemodialysis patients 
●	 Children born to HCV-infected mothers
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authors (Freke Zuure, Anouk Urbanus, Charles Helsper, and Charlotte van den Berg). The database 
including the titles and abstracts obtained through the search was split in four. The reviewers 
independently screened two of the subdatabases each so that each title/abstract was screened in 
duplicate. Studies were included in the second screening round if selected by at least one reviewer. 
The second selection round comprised screening of the full-text articles. Two authors (FZ and AU) 
independently screened all articles for eligibility using the aforementioned criteria. Any discrepancies 
were resolved by discussion until consensus was reached, and unresolved discrepancies were 
arbitrated by a third reviewer (MP).
Data extraction and validity checking
Data regarding program characteristics and program outcomes (see Box 2) were extracted and cross-
checked by two reviewers (FZ and AU). We distinguished two types of settings and presented the 
screening programs according to these: integrated and nonintegrated screening. Integrated screening 
refers to programs that are integrated within already existing health care facilities, whereas in 
nonintegrated screening, the program is exclusively set up for the screening. In addition, since 
screening strategies may differ according to the prevalence of HCV infection in a specific country, 
data are presented not only by the type of setting, but also separately for low prevalence (≤2% 
according to the Centers for Disease Control and Prevention [CDC] (1)) and intermediate to high 
prevalence countries for HCV infection.
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a Since the introduction of the fi rst HCV antibody test in 1991, several improvements have been 
made in HCV diagnostics. Anti-HCV and HCV-RNA prevalence rates of studies were considered 
suboptimal 1) if data was collected prior to 1994 when sensitivity and specifi city of tests were not 
optimal (18, 30)) or 2) if studies did not confi rm reactive HCV antibody test results by immunoblot 
or PCR to eliminate false positives. Tests were considered valid if performed after 1993 and if 
1) second- or higher- generation immunoblot assays from Ortho, Chiron, Novartis (RIBA), 
Innogenetics (LiaTek), Pasteur (DECISCAN HCV), Genelabs Diagnostics (HCV BLOT), or 
Mikrogen (recomBlot HCV IgG 2.0) were used to confi rm HCV antibody reactive results or 2) PCR 
was used to confi rm HCV-antibody reactive results. The validity of outcomes of studies that did not 
indicate which test was used, and studies that used dried blood spot (DBS), oral fl uid screening, or 
immunoblot assays different from those indicated above, was considered undecided. 
b If the study reported HCV prevalence, but without specifying whether it concerned HCV-antibody 
or HCV-RNA prevalence, and if information about the test that was used was lacking, we assumed 
Box 2: Parameters of screening programs
Program characteristics
●	 Country (and region, if applicable) of the study 
●	 Estimated prevalence of HCV antibody in the country
●	 Calendar year(s) of data collection 
●	 Duration of enrolment/screening period 
●	 Setting (i.e., whether screening for HCV infection was integrated within already existing
 health care facilities or whether the program was exclusively set up for the screening [i.e., 
 nonintegrated screening])
●	 Use of psychosocial theory or previous research fi ndings as a basis for communicating the
 screening and for stimulating screening uptake
●	 Size of the targeted population 
●	 Use of media activities and/or personal invitations to promote screening 
●	 Use of screening criteria based on risk factors for HCV infection
●	 Incentive or participant’s costs for screening
●	 Anonymous or nonanonymous participation 
●	 Type of HCV test(s) that was used for screening a 
●	 Screening for other diseases performed 
●	 Use of a comparison group for evaluation purposes 
Program outcomes 
●	 Response rate (i.e., proportion of the target population that was screened)
●	 Number of participants (i.e., number of individuals that were screened)
●	 Number of HCV-infected cases identifi ed
●	 Number of HCV-infected cases already known
●	 HCV-antibody prevalence b
●	 Risk profi le of identifi ed cases 
●	 Proportion of HCV-antibody positives with detectable HCV RNA
●	 Number of referrals to specialist
●	 Start and outcomes of treatment
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it to be HCV-antibody prevalence.
Results
The search strategy identified 5,263 records from the MEDLINE database and 6,300 from the 
EMBASE database. After duplicates were eliminated, 7,052 of 11,563 records remained (see Figure 
1). Of those, 737 were selected as potentially relevant to the review, and full-text articles were 
retrieved and reviewed independently in duplicate. We excluded 677 articles; 652 articles because 
they did not meet the inclusion criteria (the majority because they were prevalence studies, or studies 
that only reported statements about screening guidelines and policy, not including any screening 
results), and 3 Japanese articles and 1 Italian because they did not provide an English abstract. In 
addition, 20 articles (two Chinese (31;32), eight Japanese (33-40), one Icelandic (41), four Russian 
(42-45), two Turkish (46;47), one Czech (48), and two Taiwanese (49;50)) seemed relevant on 
the basis of the English abstracts, but were excluded as the abstracts alone did not yield enough 
information for review. One article was excluded because the same data were reported in two 
papers (51;52). Of the 60 studies remaining, references lists were screened yielding an additional 
106 potentially relevant records. The full-text articles were retrieved and screened independently in 
duplicate, and 7 of the 106 studies were selected for inclusion. In total, 67 studies remained in the 
final selection. 
The 67 studies identified were done in the USA (n=27), Europe (n=27; mostly France and the United 
Kingdom [UK]), Asia (n=4), Australia (n=4), South America (n=3), Egypt (n=1) and Saudi Arabia 
(n=1). We identified 24 nonintegrated and 41 integrated studies, plus two studies that used both 
strategies (the latter are shown in Table 1a for the results of the nonintegrated part of their program, 
and in Table 2b for the results of the integrated part of their program) (53;54). A total of 85% 
(22/26) of the nonintegrated programs and all of the integrated programs were from low prevalence 
countries for HCV infection.Records identified through 
database searching
(n = 11,563)
Records after duplicates 
removed
(n = 7052)
Additional records 
identified through 
reference lists
(n = 106)
Records excluded
(n = 6,315)
Studies selected for data 
extraction
(n = 60)
Full-text articles assessed 
for eligibility
(n = 737)
Full-text articles excluded
(n = 677)
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Full-text articles excluded
(n = 99)
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Figure 1. Overview of search strategy, data collection, and data review and extraction processes
Nonintegrated hepatitis C screening programs in countries with low prevalence rate of HCV 
infection (n=22)
Program characteristics: Table 1a presents the 20 nonintegrated screening programs for HCV 
infection and the 2 programs that combined an integrated and non-integrated screening approach 
that were performed in countries with low prevalence rate of HCV infection. In total, 12 of the 22 
programs were carried out in the USA. The table is sorted by population type; seven studies were 
aimed at screening the general population; the other 15 studies targeted specific groups in which a 
higher prevalence of HCV infection might have been expected (e.g., migrants, homeless individuals, 
firefighters, surgeons). Five of the 22 programs reported the use of personal screening invitations 
either face to face or by mail, and 12 reported the use of media activities to attract individuals 
for screening. None of the programs reported the use of psychosocial theory or knowledge about 
determinants facilitating participation in screening programs. Eight studies reported the possibility 
for individuals to participate anonymously. Only nine of 22 studies reported the costs for participants 
to be screened; in all of them, screening was offered free of cost, and one study offered a t-shirt as 
an incentive for screening (73). 
With respect to screening procedures, except for two, all programs used venipuncture to collect serum. 
A program targeted at firefighters (69) used home specimen collection kits for serum collection. A 
program targeted at migrants (54) initially used oral fluid anti-HCV antibody tests followed by a 
blood test for those who tested positive (no further details reported). In the majority (16/22) of the 
programs, participants were also screened for other infections (mostly HIV and hepatitis B virus 
[HBV] infection) or liver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase 
[AST]).
Program outcomes: In total, the 22 programs screened about 32,000 individuals for anti-HCV 
antibodies (range: 19-8,650) and identified 1,809 HCV-infected individuals (range: 0-604). The 
screening uptake was reported in 13/22 studies, and varied from >20% in a screening program 
at a local health fair in the USA (62) to 100% in a program that used household visits to identify 
transfusion recipients and invite them for screening in Cuba (60). The prevalence of HCV infection 
varied from 0% to 28.3%. The latter was found in a community-based screening program in New York 
City targeted at migrants from the former Sovjet Union. Risk-profile data for HCV infection were 
available for only a subset of the HCV-infected individuals in that study and included intramuscular 
injections and blood transfusions. Some of the programs among a so-called ‘general population’ (see 
Table 1a, row 1-7) that found relatively high prevalence rates of HCV infection (e.g., 10.5% in a 
walk-in clinic (56)), did not collect risk profile data of their participants, limiting the interpretability 
of their findings. Two of 22 studies used a prescreening risk assessment in order to limit screening 
to those with established risk factors for HCV infection: one did not report the prevalence rate nor 
screening uptake (58); the study in Cuba reported the highest screening uptake (100%) and found 
relatively high prevalence rate of HCV infection (8.6%), but absolute numbers were small. 
Four of the 22 programs screened primarily people from Asia, either through screening programs 
in Asia (Japan), or programs in Western countries targeting Asian migrants. In all but one of these 
programs, relatively high prevalence rates of HCV infection were found, varying from 5.2% to 
19.7%. In contrast, the programs targeting those with occupational risk for HCV infection (n=7) 
found relatively low prevalence rates (all <1.1%, except for 3.6% among firefighters and 5.3% 
among health care workers involved with liver transplantations).
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We did not notice clear differences in screening uptake or prevalence of HCV infection related to the 
use of personal invitations for screening, the use of media to attract individuals for screening, and 
whether or not individuals were screened for other infections as well. In general, a lower prevalence 
rate of HCV infection was found in the studies (n=8) that provided anonymous screening; however, 
most of these studies (6/8) targeted those with occupational risk, explaining the lower prevalence. 
Only one study compared the results of their outreach screening program with data collected in 
the same period at a screening clinic that is visited by individuals on their own initiative (72). A 
higher prevalence rate of HCV infection was found during outreach screening (4.9% versus 1.6%, 
respectively). However, the number of individuals that returned to obtain their test results was much 
lower for the outreach approach (65.8% versus 91.8%, respectively).
Six of the 22 studies reported the proportion of viremic patients, which varied from 50% to 96.5%. 
Only one study reported the proportion of identified chronic hepatitis C (CHC)-infected individuals 
that started treatment (37%) (58), but did not report how many of those reached a sustained 
virological response (SVR). 
Nonintegrated hepatitis C screening programs in countries with intermediate to high 
prevalence rate of HCV infection (n=4)
Program characteristics: Table 1b presents the four nonintegrated screening programs for HCV 
infection that were performed in countries with intermediate to high prevalence of HCV infection 
(Taiwan [n=2], Pakistan [n=1] and Egypt [n=1]). All studies targeted the general population; one 
targeted children less than 16 years of age. A study from Egypt reported household visits to personally 
invite individuals for screening (75); the study among children reported personal invitations (method 
not specified) (78). All except the study among children reported the use of media activities to attract 
individuals for screening. None of the programs reported the use of psychosocial theory or knowledge 
about determinants facilitating participation in screening programs. A risk-based screening selection 
was used in the program in Egypt, where screening was limited to those with symptoms and ALT 
levels ≥ 2 times the upper limit of normal. None of the studies reported the possibility for individuals 
to participate anonymously. Two studies reported about the costs for participants to be screened; one 
of them offered screening free of cost, whereas the other program (77) offered screening at 20% 
of the market value. None of the studies used a comparison group for evaluation purposes. With 
respect to screening procedures, all four studies used venipuncture for specimen collection. A study 
from Pakistan (77) used a rapid anti-HCV antibody test. In most (3/4) studies, participants were also 
screened for other infections (mostly HBV) but not for HIV. 
Program outcomes: In total, the four programs screened 161,341 individuals for anti-HCV antibodies 
(range: 47-157,720) and identified 7,488 HCV-infected individuals (range: 11-6,904). The screening 
uptake was reported in two studies; it was very low (<1%) in a city screening program in Pakistan, 
and very high (93.6%) in a screening program in kindergartens and schools in Taiwan. Although 
the screening uptake in the latter was high, the prevalence was low (0.9%). The prevalence rates of 
HCV infection in the other programs varied from 4.4% in a community-based screening program 
in Taiwan up to 78.8% in a program in Egypt that limited screening to those with symptoms and 
increased ALT levels (75). Two of the four studies reported the proportion of viremic patients, which 
was relatively low (27.3%) in the study among children, and 70.2% in the Egyptian study. None of 
the studies reported the proportion of CHC-infected patients that started treatment and/or reached 
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SVR.
Integrated hepatitis C screening programs in countries with low prevalence rate of HCV 
infection (n=41)
We identified 41 screening programs for HCV infection in the following clinics that offer care not 
related to liver disease: sexually transmittable diseases (STD) clinics (n=11); GP clinics (n=10, 
including two programs that also used a nonintegrated approach); Veterans Affairs (VA) health 
centers (n=5); antenatal/obstetric/fertility clinics (n=5); clinics for psychiatric patients (n=3); and 
other clinics or services (n=7). Tables 2a-f present the programs separately for each type of setting. 
All programs were carried out in countries with low prevalence rate of HCV infection.
STD clinics (n=11)
Program characteristics: The majority (7/11) of the screening programs for HCV infection in STD 
clinics were carried out in the USA. None of the studies reported the use of personal invitations 
or media to promote screening for HCV infection inside or outside the clinic. In five of the 11 
programs, screening was limited to high-risk groups for HCV infection, varying from single groups 
(e.g., those with a history of IDU (84), or MSM (80)) to individuals from multiple risk groups, such 
as those who have had body piercing or tattooing in unsanitary conditions, transfusion recipients 
before 1987, or those who have had a needlestick injury (79). None of the studies reported the 
use of psychosocial theory or knowledge about determinants facilitating participation in screening 
programs, and none reported whether or not individuals were charged for screening, or whether 
anonymous participation in the screening program was possible. None of the programs used a 
comparison group for evaluation purposes. All programs used venipuncture for specimen collection. 
Program outcomes: In total, at the STD clinics, the 11 programs screened 150,233 individuals for 
anti-HCV antibodies (range: 618-90,424) and identified 13,397 HCV-infected individuals (range: 
8-8,964). Six of the 11 programs reported the screening uptake, which varied from 14.0% to 95.8%. 
The prevalence rates of HCV infection varied from 0.1% to 28.0%. Only one study reported that 
an opt-out strategy was used, but did not report the screening uptake (88). Of the five studies that 
limited screening to risk groups for HCV infection, four reported a high prevalence rate (>15%). In 
contrast, the prevalence rates in the six studies without a risk selection varied from 0.1% to 4.9%. 
In all programs at the STD clinics, a history of IDU was found in the risk profile of the identified 
HCV-infected individuals, or was found associated with HCV infection.
Only three of the 11 programs reported the proportion of viremic patients, varying from 61.7% to 
69.3%. None of the studies reported the proportion of HCV-infected patients that started treatment 
and/or reached SVR.
GP clinics (n=12)
Program characteristics: The majority (8/12) of the screening programs for HCV infection in GP 
clinics were carried out in France. In most programs (9/12), screening was limited to risk groups for 
HCV infection within the GP-patient population (specific migrant groups (53;54); risk groups such 
as those with a history of IDU and recipients of blood transfusions before 1991 (90;92;93;95-98)). 
One program was carried out in a health care center that attracted people with poor access to health 
care, mostly migrants (52), and one was carried out in an area of low socioeconomic status (91). In 
two of the 12 programs, individuals who were in the GP’s waiting room were approached and invited 
for screening (52;54), and five programs used media activities to attract individuals for screening. 
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None of the programs reported the use of psychosocial theory or knowledge about determinants 
facilitating participation in screening programs. Of the 12 studies, four reported that screening 
was free of cost (90;93;98;119), whereas the others did not report participants’ costs for screening. 
Only the screening program among people with poor access to health care offered the possibility of 
anonymous screening (52). 
In reference to screening procedures, all but two studies used venipuncture for specimen collection. 
Two studies used oral fluid anti-HCV antibody tests, followed by blood tests for those who tested 
positive. The majority (9/12) of the programs focused solely on HCV infection. The three programs 
that screened predominantly migrants also included screening for HBV infection (52-54). 
Program outcomes: In total, the 12 programs screened 30,022 individuals for anti-HCV antibodies 
(range: 117-15,952) and identified 522 HCV-infected individuals (range: 0-276). Six of the 12 
programs reported the screening uptake, which varied from 27.8% to 82.5%. The prevalence of 
HCV infection varied from 0% to 30.8%. Only one study reported an opt-out strategy, with a 
screening uptake of 59% (94). Of the 12 programs, three primarily screened migrants (prevalence 
rates 0%, 1.2% and 5.8%), seven used risk factors other than being a migrant as criteria for screening 
(prevalence rates 1.4% to 30.8%), and one was performed in an area of low socioeconomic status 
(prevalence rate 12.8%). In contrast, one program that did not use risk factors as screening criteria, 
and was not performed in an area of low socioeconomic status, found a relatively low prevalence of 
0.4% (94). We did not notice clear differences in screening uptake or prevalence related to the use of 
media to attract individuals for screening. Further, we could not assess whether personally inviting 
individuals for screening or screening for more than just HCV infection could have influenced the 
screening uptake, since these studies did not report the screening uptake (52;54). 
Four studies checked the results of their screening program against data collected in the same period 
in comparison clinics or data collected prior to the screening program. A study from the Netherlands 
concluded that the addition of primary care practice support (e.g. plenary courses for GPs regarding 
screening for HCV infection) leads to improvements in medical consciousness regarding HCV 
infection in primary care, which is likely to have a positive effect on case finding (that effect, however, 
could not be indisputably demonstrated) (96). A study from France concluded that information and 
training that is adapted to GPs’ medical practice can lead to more active involvement of GPs in 
screening for HCV infection (97). During the intervention the number of GPs that prescribed tests 
increased, and more HCV-infected patients were detected compared with the year before. Another 
study from France compared two interventions in the GP clinic; GPs in intervention 1 prescribed 
HCV testing if risk factors for HCV infection were identified during questioning of patients, whereas 
GPs in intervention 2 placed posters and leaflets on risk factors in their waiting rooms to motivate 
patients at risk to discuss screening (98). The numbers of tests prescribed by GPs was relatively low 
in both interventions, and outcomes of the two interventions with regard to the number of tests and 
the prevalence were comparable. In a study from Scotland showed that offered screening to all GP 
visitors aged 30-54 years, 117 individuals were screened for HCV infection (prevalence: 12.8%, 
15/117), whereas in a comparison clinic, where no intervention for screening was introduced, no 
individuals were screened for HCV infection (91).
Only three of the 12 programs in which anti-HCV-antibody positive individuals were identified 
reported the proportion of viremic patients, varying from 73.3% to 86.4%. Two of these programs 
reported the proportion who started treatment (18% and 38%), but only one of these two programs 
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reported the proportion of treated individuals (n=2) who reached SVR (50%, n=1)(91). 
Veterans Affairs clinics (n=5)
Program characteristics: All five screening programs for HCV infection in VA clinics were carried 
out in the USA. No personal invitations or media activities were reported. All screening programs 
limited the screening to risk groups within the veteran population. In one program, screening was 
limited to veterans who were admitted for an alcohol and noninjecting drug rehabilitation program 
(102), while other programs used an extensive list of risk factors, including history of drug use, blood 
transfusion prior to 1992, and Vietnam veteran. None of the programs reported an opt-out strategy, 
and none reported the use of psychosocial theory or knowledge about determinants facilitating 
participation in screening programs, whether or not individuals could participate anonymously, 
participants’ costs for screening, or a comparison group for evaluation purposes. All programs used 
venipuncture for specimen collection and screened solely for HCV infection.
Program outcomes: In total, the five programs screened 31,483 individuals for anti-HCV antibodies 
(range: 338-12,485) and identified 1,810 HCV-infected individuals (range: 78-681), although in one 
program (100) a large number of individuals were already aware of their infection (n=152). The 
screening uptake was described in three of the five programs, varying from 41.9% to 99.4%. The 
prevalence of HCV infection in most programs was around 5%, but the program among veterans 
who were admitted to an alcohol and noninjecting drug rehabilitation program was substantially 
higher (23.1%). Three programs reported the proportion of viremic patients, varying from 47% to 
97.4%. The proportion of patients that started treatment was described in three studies and varied 
from 15% to 38%. Four studies reported the SVR rate among those who started treatment, ranging 
from 33% to 47%.
Antenatal/obstetric/fertility clinics (n=5)
Program characteristics: Of the five programs, three were carried out in the UK, one in the USA and 
one in Brazil. The programs targeted pregnant women, except for a British study in a fertility clinic 
that was targeted at couples. Media activities to promote the screening programs were described 
in only one of the five studies; this study used information leaflets to inform women about the 
screening program, and a personal invitation for participation by the midwife (107). None of the 
programs reported an opt-out strategy, and none used a risk assessment strategy to limit screening 
to those at risk, and none reported the use of psychosocial theory or knowledge about determinants 
facilitating participation in screening programs. The programs did not report the possibility to screen 
anonymously, or a comparison group for evaluation purposes. The one program reporting screening 
costs was free of cost to participants (108).
With respect to screening procedures, all but one study used venipuncture for specimen collection. 
One study used DBS for anti-HCV screening and a second generation ELISA followed by HCV 
RNA testing using venous blood for confirmation (108). In all but one program, participants were 
also screened for other infections (mainly HIV and HBV) or liver enzymes (ALT/AST). 
Program outcomes: In total, the five programs screened 67,729 individuals for anti-HCV antibodies 
(range: 1,658-31,081) and identified 283 HCV-infected individuals (range: 9-115). In the two studies 
reporting screening uptake, rates were very high (≥98%).
In all but one program, the prevalence rates were low, varying from 0.2% to 0.8%. In women at risk 
for perinatal complications, prevalence was 4.6% (106). In two studies, the proportion of viremic 
patients was reported, varying from 71% to 73%. In one of the five programs, results of the clinical 
follow-up and treatment were reported, showing that 67.9% of those identified with CHC started 
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treatment after delivery, and 80% of those who completed treatment achieved SVR (104).
Psychiatric clinics (n=3)
Program characteristics: Of the three screening programs for HCV infection in psychiatric clinics, 
two were carried out in Australia, and one in the USA. One program aimed to evaluate whether 
screening by risk factors would be effective, and limited the screening program in one unit to those 
with a history of IDU and those exposed to contaminated blood products, whereas in the other 
unit all patients were screened (110). In the other two programs, no risk selection was used for 
participation in the screening program. One program promoted screening by using media (111). 
None of the programs reported an opt-out strategy. The programs did not offer the possibility to 
screen anonymously, and did not report about participants’ costs for screening. Concerning screening 
procedures, all studies used venipuncture for specimen collection, and all studies exclusively 
screened for HCV infection.
Program outcomes: In total, the three programs screened 300 individuals (range: 36-98), and 
identified 40 HCV-infected individuals (range: 3-15). All programs reported the screening uptake, 
varying from 20.5% to 100%. The prevalence rates of HCV infection varied from 3.2% in the unit 
without pre-screening risk selection (110), to 41.7% in the unit where screening was limited to those 
who reported a history of IDU or exposure to contaminated blood products. Noninjecting drug 
use and history of IDU were reported as the main risk factors among the identified cases. All three 
programs referred the HCV-infected individuals to a specialist, but only one study (109) reported 
the outcomes of referral, namely that 50% of patients were viremic, and none had started treatment 
after two years of follow-up. Of interest, in two programs (110;111), post-test counseling addressing 
various topics (e.g., education about the illness, risk behavior, safe injection practices, secondary 
prevention) was also offered to those who reported risk factors but tested HCV negative.
One of the three studies reported that their program was based on psychosocial theory or knowledge 
about determinants facilitating participation in screening programs for HCV infection. This program 
promoted screening by using leaflets outlining HCV infection, its risk factors, and the importance of 
screening, and used individually tailored pre- and post-test counseling that was adapted to individual 
knowledge and cultural understandings where appropriate (111). Although the uptake of screening 
in that study was relatively low (20.5%), the prevalence was relatively high (19.7%), especially 
considering the fact that no prescreening risk selection was used.
Other clinics (n=7)
Program characteristics: In total, seven screening programs for HCV infection were integrated in 
other clinics or services. These programs varied widely, from screening patients at an emergency 
health unit in France (112) to screening couples that wish to get married in Saudi Arabia (113). Two 
programs targeted MSM; one in an outreach service for HIV point-of-care testing in the UK (115), 
and another in a community care facility in the USA (116). The study in the USA reported the use 
of media activities to attract participants, wherein MSM were recruited through advertisements as 
well as by referral of medical staff (116). Two of the seven studies used a prescreening selection; 
a program at an emergency health unit only screened those with a reported risk factor (112), and 
in France, only those with elevated ALT levels as determined during routine medical check-up 
were screened for HCV (112). None of the programs reported the use of psychosocial theory or 
knowledge about determinants facilitating participation in screening programs, and none reported 
about the possibility of anonymous screening, or a comparison group for evaluation purposes. The 
one study reporting about participants’ costs for screening mentioned that it was free (116). With 
respect to screening procedures, all studies used venipuncture for specimen collection. Four of the 
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seven programs also screened for other diseases (mainly HBV infection). 
Program outcomes: In total, the seven programs screened 78,377 individuals (range: 55-74,662), 
and identified 397 HCV-infected individuals (range: 1-250). The screening uptake was reported 
in three out of seven programs, varying from 66.2% to 77.6%. The prevalence of HCV infection 
varied from 0.3% in a mandatory premarital screening program in Saudi Arabia (113) to 11.5% in a 
program for MSM (116). None of the programs reported an opt-out strategy, and one reported that 
screening was mandatory but did not report the screening uptake (113). Only three studies reported 
the proportion of viremic patients, varying from 50% to 73%. Only one study reported the number 
of patients that started treatment, which was zero (112). 
Discussion
This systematic review describes characteristics and outcomes of screening programs for HCV 
infection in the general population, and includes 67 programs. In total, 24 of them were exclusively 
set up, whereas 41 were integrated in already existing health care facilities (not aimed at risk groups 
for HCV infection), and two programs used both an integrated and nonintegrated approach. We 
identified only four screening programs in countries of intermediate to high prevalence of HCV 
infection, and all were nonintegrated screening programs. Altogether, the programs that were 
published identified only approximately 25,700 HCV-infected individuals, a tip of the iceberg 
considering that HCV infection affects an estimated 130-170 million individuals worldwide (120), 
of which the majority is considered to be undiagnosed. Clearly, more-effective, large-scale, and 
structural screening and referral programs are needed to address the HCV-related burden of disease 
in an era of potent therapy for HCV infection.
The programs were highly heterogenic in their organization, recruitment, and screening procedure, 
and the vast majority did not use a comparison group to assess the effectiveness of their screening 
program. Hence, we cannot draw firm conclusions as to which screening program strategy, or which 
program characteristic (e.g., free-of-cost vs. low-cost screening, anonymous vs. nonanonymous 
screening, use of particular media to promote screening, opt-in vs. opt-out screening) is more 
effective than another in attracting or motivating individuals for screening or in attracting those at 
higher risk for HCV infection. Screening programs that compare different recruitment and screening 
strategies are needed to gain insight into effectiveness of strategies and program characteristics. 
In addition, many studies did not report program characteristics (e.g., the laboratory tests that were 
used). The same was true for screening uptake and follow-up data, and even if reported, there was 
not much consistency (e.g., some reported the SVR rate among those who completed treatment, 
whereas others reported that treatment was ‘rather successful’). The underreporting and the lack of 
uniformity of data reporting greatly hinder the comparison of screening programs. Data reporting 
standards (see parameters in Box 2) are needed to be able to compare screening program characteristics 
and outcomes in order to find out which factors are effective. 
With respect to publication bias, programs that were successful in identifying HCV-infected 
individuals may have been more likely to be published. However, we did identify several programs 
in which none individuals were diagnosed (54;70). Furthermore, as identification of HCV-infected 
individuals serves a clinical goal and not necessarily a scientific goal, not all screening efforts have 
been evaluated or published. Our search identified several announcements of screening activities for 
HCV infection (e.g., 121-126) or cost-effectiveness evaluations of screening activities (127) that did 
not provide any further information about the screening program and/or outcomes. Therefore, there 
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may be more screening programs for HCV infection than those described in this review.
In general, we noticed relatively high prevalence rates in programs that used a prescreening selection 
based on risk factors for HCV infection (especially in programs that used elevated ALT or a history 
of IDU as indications for screening for HCV infection) or migrant status, in programs that were 
carried out in countries or regions of intermediate to high prevalence of HCV infection, and in 
programs in psychiatric clinics. Also, relatively high prevalence rates were found in nonintegrated 
programs in low-prevalence countries that targeted the general population (see row 1-7 of Table 1a), 
even without a prescreening risk assessment. These programs screened a self-referred population, 
and may have attracted those at risk of HCV infection in the general population (e.g., those with 
a history of IDU), and therefore observed prevalence rates are higher than those in the general 
population. For the study by Hayashi et al (61), screening was performed in a specific region in 
Japan with a presumably high prevalence of HCV infection, explaining the very high prevalence that 
was found. In most studies, a history of IDU was the main risk factor among the identified HCV-
infected individuals. In general, low prevalence rates were found in programs that targeted health 
care workers, and in programs that were carried out in antenatal clinics. Programs in STD and GP 
clinics that did not use a prescreening risk selection also found relatively low prevalence rates.
Only one study reported that the promotion of the screening program was based on theoretical 
insights or knowledge about determinants facilitating participation in screening programs. None 
of the studies reported the use of simple tools that may increase the screening uptake, such as 
reminder messages (128;129), or support with planning of when and how to get screened (i.e., 
creating implementation intentions (130)). In many studies, and especially those describing 
nonintegrated programs, the uptake of screening was not reported. Only a few studies reported that 
individuals could be screened anonymously; in the nonintegrated programs, only those targeted at 
health care workers organized the screening in a way that people could stay anonymous. The fact 
that HCV infection might be associated with drug use may pose a barrier for individuals and health 
care providers when deciding for or against screening. Hence, anonymous screening may increase 
screening uptake, especially among those at high risk of infection. 
Surprisingly, none of the programs reported the use of the Internet to attract or inform individuals 
about screening (data not reported). Even programs that were carried out in recent years when Internet 
use in high-income countries was widespread did not report the use of this medium. Since Internet 
use in most high-income countries is relatively common, and the Internet is a relatively anonymous 
medium, it may fit into screening programs for HCV infection very well. Two programs that were 
from 2011 and 2012, and therefore not included in this review, used an Internet-based hepatitis 
C risk-assessment questionnaire and an Internet referral service for blood testing for those at risk 
of HCV infection (131;132). These programs concluded that such a Web-based and anonymous 
questionnaire might be useful to detect undiagnosed HCV infections. 
We found that integrated screening programs in general screened a larger number of individuals 
than did nonintegrated screening programs in countries of low prevalence of HCV infection. 
Integrated screening programs have three advantages in that they do not have to attract their target 
population for screening, and they can use a facility that is familiar to the public. In addition, they 
can facilitate continuous screening and follow-up of individuals at relatively low cost, whereas 
nonintegrated programs offer screening usually for a limited period. On the other hand, integrated 
screening programs only reach those who have a reason to visit such facilities (unless media 
campaigns have been used to attract more people), whereas nonintegrated programs may attract a 
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different risk population that otherwise would not be screened and do not perceive themselves at 
risk for HCV infection (i.e., the hidden population). We believe that both approaches are useful and 
complementary. In addition, since nonintegrated screening in general is more complex to organize, it 
may be efficient to screen for other diseases (e.g., HBV infection) simultaneously, when risk groups 
overlap (e.g., in migrant populations).
We identified several studies that did not confirm anti-HCV antibody test results. Many of the 
identified programs targeted asymptomatic individuals in the general population with a relatively 
low prevalence. In such populations, unconfirmed anti-HCV antibody test results may include 35% 
(range: 15%–60%) false-positive test results (133). Hence, the program outcomes that are reported 
may include a substantial degree of uncertainty, and should be interpreted with care. We like to 
emphasize that screening programs for HCV infection should use screening methods that are in line 
with recommendations for confirmation testing of all anti-HCV screening-test positive results (133), 
and describe the tests that were used when publishing the results of their screening projects. 
Our review describes several screening programs, but it cannot determine the efficiency and 
effectiveness of these screening programs in preventing future HCV-related morbidity and mortality. 
Measuring these effects of screening programs for HCV infection is a challenge because randomized, 
controlled trials or comparison groups and decades of follow-up time are required. As an alternative 
method, mathematical modelling studies might be useful. In addition, the efficiency and effectiveness 
of screening depends not only on the number of individuals screened and the number of individuals 
identified, but also on the uptake and outcomes of therapy and other preventive measures (e.g., 
lowering alcohol intake) that may follow from diagnosis. Efficiency relates to the number needed to 
be screened to identify a treatable case of HCV infection. Surprisingly, most studies did not report 
such data, and merely mentioned that HCV-infected individuals were notified of their test result and 
referred for clinical care. Following Wilson and Jungners third screening principle (134), facilities 
for diagnosis and treatment should be available. This means that the screening program itself is 
as important as the efforts that are undertaken to bring identified patients into care and have them 
benefit from preventive measures and/or treatment. Hence, evaluation reports of screening programs 
should include clinical follow-up and systematically report outcomes.
A recent systematic review by Jones et al. on the effectiveness and cost-effectiveness of interventions 
aimed at raising awareness of and/or increasing engagement in case finding and testing with high-
risk groups for HCV and HBV infection and practitioners included only programs with a comparison 
group (e.g., randomized controlled trials, pre- and postintervention data, repeated cross-sectional 
studies) (135). About half of the studies (12/25) included in that review were aimed at high-risk 
groups for HCV infection that are relatively easy to target, such as current IDU and incarcerated 
individuals, whereas our review includes studies that aimed to identify the hidden population of 
HCV-infected individuals. Jones et al. identified drug services and primary care as settings in which 
interventions could effectively increase screening uptake. They also found that DBS testing in 
addition to venipuncture might increase screening uptake in drugs services or prisons. In our review, 
a few studies reported the use of home collection tests, DBS, or oral fluid tests, but these studies 
did not demonstrate high screening uptake. Further insight into the effect of alternative noninvasive 
testing procedures on screening uptake is needed. As in our review, Jones et al. concluded that 
improvement of health outcomes following diagnosis for those identified with CHC deserves careful 
attention. 
In conclusion, HCV infection has serious health implications and, at the start of the era of potent 
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therapy for CHC, screening programs are not yet reaching all potentially infected individuals 
worldwide. Therefore more effective programs are urgently needed. This review identified 67 
screening programs that targeted risk groups for HCV infection that are hidden in the general 
population. Relatively high prevalence rates of HCV infection were found in programs that used a 
prescreening selection based on a risk profile or migrant status, in programs that were carried out 
in intermediate to high prevalence countries or regions, and in programs in psychiatric clinics. In 
general, low prevalence rates were found in programs that targeted health care workers and pregnant 
women. The reported use of motivational communication based on theory and/or determinants 
facilitating screening, and tools to increase screening uptake were virtually absent. Comparison 
of the screening programs was strongly hindered by the lack of reported data on screening uptake, 
program characteristics, the type of diagnostic tests used, and clinical outcomes. In addition, only a 
few programs used a comparison group to evaluate program effectiveness. 
We suggest that screening programs should be theory-based and provide tools to increase screening 
uptake. For populations with low prevalence of HCV infection, the use of prescreening selection 
criteria should be considered to increase efficiency. In addition, to be able to assess screening 
program effectiveness, programs using a comparison group are needed. To improve comparability of 
screening programs and outcomes, it is necessary for all programs to systematically report program 
characteristics, screening uptake, the type of diagnostic tests that were used, as well as clinical 
outcomes. 
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st
in
g
 s
it
es
; 
d
ru
g
 t
re
a
tm
en
t 
fa
ci
li
ti
es
, 
co
rr
ec
-
ti
o
n
s 
fa
ci
li
ti
es
, 
fi
el
d
 v
is
it
/ 
o
u
tr
ea
ch
 s
it
es
 
(e
.g
.,
 b
a
rs
, 
ad
u
lt
 
b
o
o
ks
to
re
s,
 
h
o
m
el
es
s 
sh
el
te
rs
),
 S
T
D
 
cl
in
ic
s,
 f
am
il
y 
p
la
n
n
in
g
 c
li
n
ic
, 
p
ri
m
a
ry
 h
e
al
th
 
ca
re
 f
ac
il
it
y 
 
6
 y
e
ar
s 
S
T
D
, 
H
IV
 
Y
es
: 
ID
U
, 
sh
ar
in
g
 e
q
u
ip
m
en
t 
u
se
d
 t
o
 s
n
o
rt
 d
ru
g
s;
 h
av
in
g
 
re
ce
iv
ed
 a
 t
at
to
o
 o
r 
p
ie
rc
in
g
 
u
n
d
e
r 
u
n
sa
n
it
ar
y 
co
n
d
it
io
n
s;
 
h
av
in
g
 5
0
 o
r 
m
o
re
 l
if
et
im
e 
se
x 
p
ar
tn
er
s;
 e
xc
h
an
g
in
g
 s
ex
 
fo
r 
m
o
n
e
y;
 h
av
in
g
 s
e
x 
w
it
h
 
an
 H
C
V
-p
o
si
ti
v
e 
p
er
so
n
; 
p
eo
p
le
 w
it
h
 s
o
m
e 
m
ed
ic
al
 
ex
p
o
su
re
s 
an
d
 o
cc
u
p
a
ti
o
n
s 
 
N
o
 
S
cr
. 
u
p
ta
ke
: 
N
R
 
 Pr
ev
al
en
ce
: 
2
3
.2
%
 
(8
9
6
4
/3
8
7
1
7
; 
9
5
%
 C
I:
 2
2
.7
-
2
3
.6
) 
*
*
*
 
Li
st
ed
 r
is
k 
fa
ct
o
rs
: 
- 
H
is
to
ry
 o
f 
ID
U
 (
m
ai
n
 r
is
k 
fa
ct
o
r)
 
- 
R
is
ky
 t
at
to
o
/p
ie
rc
in
g
 
- 
R
is
ky
 s
e
x 
 
- 
B
lo
o
d
 o
r 
m
ed
ic
al
 
ex
p
o
su
re
 
- 
S
h
ar
in
g
 s
n
o
rt
in
g
 
eq
u
ip
m
en
t 
- 
O
cc
u
p
a
ti
o
n
al
 e
xp
o
su
re
 
 
Po
st
-t
e
st
 c
o
u
n
se
li
n
g
 a
n
d
 r
ef
e
rr
al
 
to
 p
u
b
li
c 
an
d
 p
ri
va
te
 p
ro
vi
d
er
s 
in
 t
h
e 
lo
ca
l 
co
m
m
u
n
it
y 
w
as
 
o
ff
er
ed
. 
 
5
0
.3
%
 o
f 
7
7
6
 s
u
b
st
a
n
ce
 a
b
u
se
 
re
fe
rr
al
s,
 2
2
.4
%
 o
f 
4
4
1
0
 
m
e
d
ic
al
 e
v
al
u
a
ti
o
n
 r
ef
e
rr
al
s,
 
an
d
 1
7
.4
%
 o
f 
2
2
9
9
 v
ac
ci
n
a
ti
o
n
 
re
fe
rr
al
s 
w
er
e 
co
n
fi
rm
ed
. 
 O
u
tc
o
m
es
: 
R
N
A
 r
a
te
: 
 
N
R
 
S
ta
rt
 t
re
at
m
en
t:
 
N
R
 
S
V
R
: 
 
N
R
 
G
u
n
n
, 
R
A
, 
2
0
0
1
 (
8
7
) 
1
9
9
8
 
S
T
D
 c
li
n
ic
 
cl
ie
n
ts
 
U
S
A
 (
1
.9
%
):
 
S
an
 D
ie
g
o
 
S
T
D
 c
li
n
ic
 
6
 w
ee
ks
 
H
B
V
 
N
o
 
N
o
 
S
cr
. 
u
p
ta
ke
: 
8
2
.4
%
 
(6
1
8
/7
5
0
) 
 Pr
ev
al
en
ce
: 
3
.4
%
 (
2
1
/6
1
8
; 
9
5
%
 C
I:
 2
.2
-
5
.1
) 
*
*
 
 
Li
st
ed
 r
is
k 
fa
ct
o
rs
: 
- 
H
is
to
ry
 o
f 
ID
U
 
- 
A
m
o
n
g
 n
o
n
-I
D
U
: 
ag
e 
≥
3
0
 y
rs
 
H
C
V
-p
o
si
ti
v
e 
p
e
rs
o
n
s 
w
e
re
 
g
iv
en
 i
n
fo
rm
at
io
n
 a
b
o
u
t 
th
e 
p
re
v
en
ti
o
n
 o
f 
H
C
V
 t
ra
n
sm
is
si
o
n
 
an
d
 a
 l
is
t 
o
f 
fa
ci
lit
ie
s 
w
h
er
e 
th
e
y 
m
ig
h
t 
o
b
ta
in
 a
 m
ed
ic
al
 
ev
al
u
a
ti
o
n
. 
A
p
p
r.
 8
 m
o
n
th
s 
af
te
r 
th
e 
p
ro
je
ct
, 
1
4
/2
1
 c
li
en
ts
 w
e
re
 
co
n
ta
ct
ed
 o
f 
w
h
o
m
 6
 h
ad
 s
e
en
 a
 
p
h
ys
ic
ia
n
 f
o
r 
m
ed
ic
al
 
ev
al
u
a
ti
o
n
. 
 O
u
tc
o
m
es
: 
R
N
A
 r
a
te
: 
 
N
R
 
S
ta
rt
 t
re
at
m
en
t:
 
N
R
 
S
V
R
: 
 
N
R
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N
o
te
: 
C
I 
=
 c
o
n
fi
d
en
ce
 i
n
te
rv
al
; 
N
R
 =
 n
o
t 
re
p
o
rt
e
d
; 
S
T
D
 =
 s
ex
u
al
ly
 t
ra
n
sm
it
te
d
 d
is
ea
se
; 
B
B
V
 =
 b
lo
o
d
-b
o
rn
e 
vi
ru
s;
 I
D
U
 =
 i
n
je
ct
in
g
 d
ru
g
 u
se
; 
H
C
V
 =
 h
ep
a
ti
ti
s 
C
 v
ir
u
s;
 H
B
V
 =
 h
ep
a
ti
ti
s 
B
 v
ir
u
s;
 H
A
V
 =
 h
e
p
a
ti
ti
s 
A
 
vi
ru
s;
 H
IV
 =
 h
u
m
an
 i
m
m
u
n
o
d
ef
ic
ie
n
cy
 v
ir
u
s;
 M
S
M
 =
 m
en
 w
h
o
 h
av
e 
se
x 
w
it
h
 m
e
n
; 
S
V
R
 =
 s
u
st
ai
n
ed
 v
ir
o
lo
gi
ca
l 
re
sp
o
n
se
 
 *
 H
C
V
-a
n
ti
b
o
d
y 
p
re
v
al
en
ce
 i
s 
co
n
si
d
er
ed
 s
u
b
o
p
ti
m
al
 (
d
a
ta
 w
er
e 
co
ll
ec
te
d
 b
ef
o
re
 1
9
9
4
 w
h
en
 s
en
si
ti
vi
ty
/s
p
ec
if
ic
it
y 
o
f 
te
st
s 
w
as
 n
o
t 
o
p
ti
m
al
, 
o
r 
re
ac
ti
ve
 H
C
V
-a
n
ti
b
o
d
y 
te
st
 r
es
u
lt
s 
w
er
e 
n
o
t 
co
n
fi
rm
ed
 b
y 
im
m
u
n
o
b
lo
t)
. 
*
*
 T
h
e 
re
li
ab
il
it
y 
o
f 
th
e 
re
p
o
rt
ed
 H
C
V
-a
n
ti
b
o
d
y 
p
re
v
al
en
ce
 i
s 
u
n
d
ec
id
ed
 (
d
at
a 
w
e
re
 c
o
ll
ec
te
d
 a
ft
e
r 
1
9
9
3
, 
b
u
t 
th
e 
d
ia
g
n
o
st
ic
 t
es
ts
 a
re
 u
n
sp
ec
if
ie
d
, 
o
r 
o
th
er
 t
h
an
 d
e
sc
ri
b
e
d
 b
el
o
w
, 
o
r 
d
ri
ed
 b
lo
o
d
 s
p
o
ts
 o
r 
o
ra
l 
fl
ui
d
 
sa
m
p
le
s 
w
er
e 
u
se
d
).
 
*
*
*
 H
C
V
-a
n
ti
b
o
d
y 
p
re
v
al
en
ce
 i
s 
co
n
si
d
er
ed
 v
al
id
; 
d
at
a 
w
er
e 
co
ll
ec
te
d
 a
ft
er
 1
9
9
3
, 
a
n
d
 r
e
ac
ti
ve
 H
C
V
-a
n
ti
b
o
d
y 
te
st
 r
es
u
lt
s 
w
er
e 
co
n
fi
rm
ed
 b
y 
se
co
n
d
 o
r 
h
ig
h
er
 g
en
e
ra
ti
o
n
 i
m
m
u
n
o
b
lo
t 
as
sa
ys
 f
ro
m
 O
rt
h
o
, 
C
h
ir
o
n
, 
N
o
v
ar
ti
s 
(R
IB
A
),
 I
n
n
o
g
en
et
ic
s 
(L
ia
T
e
k)
, 
P
as
te
u
r 
(D
E
C
IS
C
A
N
 H
C
V
),
 G
en
el
ab
s 
D
ia
g
n
o
st
ic
s 
(H
C
V
 B
LO
T
),
 o
r 
M
ik
ro
g
en
 (
re
co
m
B
lo
t 
H
C
V
 I
g
G
 2
.0
).
 
 
a
 H
is
to
ry
 o
f 
ID
U
, 
b
o
d
y 
p
ie
rc
in
g
/t
a
tt
o
o
in
g
 i
n
 u
n
sa
n
it
a
ry
 c
o
n
d
it
io
n
s,
 t
ra
n
sf
u
si
o
n
 r
ec
ip
ie
n
ts
 b
ef
o
re
 1
9
8
7
, 
n
e
ed
le
st
ic
k 
in
ju
ry
, 
h
e
m
o
d
ia
ly
si
s 
p
a
ti
en
ts
, 
th
o
se
 b
o
rn
 t
o
 m
o
th
er
s 
w
it
h
 d
o
cu
m
e
n
te
d
 H
C
V
 i
n
fe
ct
io
n
, 
in
d
iv
id
u
al
s 
w
h
o
 r
ep
o
rt
ed
 e
v
er
 h
av
in
g
 b
ee
n
 t
o
ld
 t
h
at
 t
h
ey
 w
er
e 
in
fe
ct
ed
 w
it
h
 H
C
V
 y
e
t 
la
ck
ed
 s
u
p
p
o
rt
in
g
 d
o
cu
m
en
ta
ti
o
n
. 
 
 
E
ll
ks
, 
R
, 
2
0
1
0
 (
8
8
) 
2
0
0
8
 
V
is
it
o
rs
 o
f 
se
x
u
al
 a
n
d
 
re
p
ro
d
u
ct
iv
e 
h
e
al
th
 
se
rv
ic
e
 
U
K
 (
1
.1
%
):
 
C
re
w
e
 
S
T
D
 a
n
d
 
re
p
ro
d
u
ct
iv
e 
H
e
al
th
 S
er
vi
ce
 
(i
n
te
g
ra
te
d
 
se
rv
ic
e)
 
1
 y
e
ar
 
H
IV
, 
sy
p
h
il
is
, 
H
B
V
  
N
o
  
N
o
 
S
cr
. 
u
p
ta
ke
: 
N
R
 
 Pr
ev
al
en
ce
: 
0
.1
%
 (
8
/5
4
6
8
; 
9
5
%
 C
I:
 0
.1
-
0
.3
) 
*
*
 
Li
st
ed
 r
is
k 
fa
ct
o
rs
: 
- 
H
is
to
ry
 o
f 
ID
U
  
- 
M
S
M
 w
h
o
 s
n
o
rt
ed
 d
ru
g
s 
 
- 
b
o
rn
 o
u
ts
id
e 
th
e 
U
K
 
- 
H
IV
 i
n
fe
ct
io
n
 
T
h
er
e 
w
er
e 
fo
ll
o
w
-u
p
 
ap
p
o
in
tm
e
n
ts
 f
o
r 
th
o
se
 w
h
o
 
te
st
ed
 p
o
si
ti
ve
. 
 O
u
tc
o
m
es
: 
R
N
A
 r
a
te
: 
 
N
R
 
S
ta
rt
 t
re
at
m
en
t:
 
N
R
 
S
V
R
: 
 
N
R
 
 
T
w
ee
d
, 
E
, 
2
0
1
0
 (
8
9
) 
2
0
0
2
-
2
0
0
7
 
V
is
it
o
rs
 o
f 
S
T
D
 a
n
d
 
co
n
tr
ac
ep
ti
o
n
 a
n
d
 s
ex
u
al
 
h
e
al
th
 
cl
in
ic
s,
 a
n
d
 
sp
ec
ia
li
st
 
H
IV
 s
er
vi
ce
s 
U
K
 (
1
.1
%
):
 
T
h
ro
u
g
h
o
u
t 
th
e 
co
u
n
tr
y
 
S
T
D
 c
li
n
ic
s,
 
co
n
tr
ac
ep
ti
o
n
 
an
d
 s
ex
u
al
 
h
e
al
th
 c
li
n
ic
s,
 
sp
ec
ia
li
st
 H
IV
 
se
rv
ic
es
 
6
 y
e
ar
s 
Li
ke
ly
 S
T
D
/H
IV
 
N
o
 
N
R
 
S
cr
. 
u
p
ta
ke
: 
es
ti
m
a
te
d
 a
t 
1
4
.0
%
 
 Pr
ev
al
en
ce
: 
 
3
.2
%
 (
2
8
5
 
8
/9
0
4
2
4
; 
9
5
%
C
I:
 3
.0
4
-
3
.2
7
) 
*
*
 
M
u
lt
iv
ar
ia
b
le
 r
eg
r.
 
an
al
ys
is
: 
- 
M
al
e 
se
x
 
- 
A
g
e 
3
5
+
 
- 
H
is
to
ry
 o
f 
ID
U
 
T
h
o
se
 w
h
o
 t
es
te
d
 p
o
si
ti
ve
 w
er
e 
fo
llo
w
ed
-u
p
 w
it
h
 c
li
ni
ci
an
s 
(n
o
 
d
at
a 
re
p
o
rt
ed
).
 
O
f 
th
e 
an
ti
H
C
V
 p
o
si
ti
ve
 
in
d
iv
id
u
al
s,
 6
0
.1
%
 (
1
7
1
9
/2
8
5
8
) 
w
er
e 
te
st
ed
 f
o
r 
H
C
V
 R
N
A
. 
 
 O
u
tc
o
m
es
: 
R
N
A
 r
a
te
: 
 
6
9
.2
%
 (
1
1
9
1
/1
7
1
9
) 
S
ta
rt
 t
re
at
m
en
t:
 
N
R
 
S
V
R
: 
 
N
R
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T
a
b
le
 2
b
. 
I
n
te
g
ra
te
d
 s
c
re
e
n
in
g
 p
ro
g
ra
m
s
 a
t 
g
e
n
e
ra
l 
p
ra
c
ti
ti
o
n
e
r 
(
G
P
)
 c
li
n
ic
s
 
 P
ro
g
ra
m
 c
h
a
ra
c
te
ri
s
ti
c
s
 
P
ro
g
ra
m
 o
u
tc
o
m
e
s
 
F
ir
s
t 
a
u
th
o
r,
 
y
e
a
r 
o
f 
p
u
b
li
c
a
ti
o
n
 
 
C
a
le
n
d
a
r 
y
e
a
r 
o
f 
d
a
ta
 
c
o
ll
e
c
ti
o
n
 
P
o
p
u
la
ti
o
n
 
 
C
o
u
n
tr
y
 a
n
d
 
H
C
V
 
p
re
v
a
le
n
c
e
 
a
c
c
o
rd
in
g
 t
o
 
C
D
C
 (
1
)
 
S
e
tt
in
g
 o
f 
s
c
re
e
n
in
g
 
D
u
ra
ti
o
n
 o
f 
s
c
re
e
n
in
g
 
p
r
o
g
ra
m
 
O
th
e
r
 
te
s
ts
 
P
re
-
s
c
re
e
n
in
g
 s
e
le
c
ti
o
n
 
M
e
d
ia
 
a
c
ti
v
it
ie
s
 
S
c
re
e
n
in
g
 
u
p
ta
k
e
 a
n
d
 
a
n
ti
-H
C
V
 
p
re
v
a
le
n
c
e
 
(
9
5
%
 C
I
)
  
R
is
k
 p
r
o
fi
le
 o
f 
id
e
n
ti
fi
e
d
 
H
C
V
 c
a
s
e
s
 /
 R
is
k
 f
a
c
to
rs
 
a
s
s
o
c
ia
te
d
 w
it
h
 H
C
V
 
 
F
o
ll
o
w
-u
p
 o
f 
H
C
V
-i
n
fe
c
te
d
 
in
d
iv
id
u
a
ls
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
o
n
n
e
t,
 E
, 
2
0
0
0
 (
9
0
) 
1
9
9
7
-1
9
9
8
 
Pa
ti
en
t 
o
f 
G
P 
cl
in
ic
s,
 h
ea
lt
h
 
ce
n
tr
es
, 
o
cc
u
p
a
ti
o
n
al
 
p
h
ys
ic
ia
n
s,
 
p
ri
so
n
 h
ea
lt
h
 
se
rv
ic
e,
 
p
u
b
li
c 
la
b
o
ra
to
ri
es
  
Fr
an
ce
 (
1
.1
%
):
 
Le
 D
o
u
b
s 
G
P 
cl
in
ic
s,
 h
ea
lt
h
 
ce
n
tr
e,
 
o
cc
u
p
a
ti
o
n
al
 
p
h
ys
ic
ia
n
s,
 
p
ri
so
n
 h
ea
lt
h
 
se
rv
ic
e,
 p
u
b
li
c 
la
b
o
ra
to
ri
es
 
1
 y
e
ar
 
N
o
n
e
 
Y
es
, 
n
o
 p
re
vi
o
u
s 
p
o
si
ti
ve
 
H
C
V
 s
er
o
lo
g
y,
 a
n
d
 a
t 
le
a
st
 
h
av
in
g
 o
n
e 
ri
sk
 f
ac
to
r:
 
tr
an
sf
u
si
o
n
 b
ef
o
re
 1
9
9
1
, 
(e
x-
)I
D
U
, 
(e
x-
)s
n
o
rt
in
g
 c
o
ca
in
e,
 
ta
tt
o
o
, 
H
C
V
 d
ia
g
n
o
si
s 
in
 
li
vi
n
g
 e
n
vi
ro
n
m
e
n
t 
 
Y
es
 
S
cr
. 
u
p
ta
ke
: 
8
2
.5
%
 
(7
8
2
/9
4
8
) 
 Pr
ev
al
en
ce
: 
4
.0
%
 (
3
1
/7
8
2
; 
9
5
%
 C
I:
 2
.8
-
5
.6
) 
*
 
M
u
lt
iv
ar
ia
b
le
 r
eg
r.
 
an
al
ys
is
: 
- 
A
g
e 
3
0
+
 
- 
D
ru
g
 u
se
 
 
7
0
.9
%
 (
2
2
/3
1
) 
a
tt
e
n
d
ed
 t
h
e 
h
ep
at
o
lo
g
is
t 
fo
r 
H
C
V
 R
N
A
 
te
st
in
g
. 
O
f 
th
o
se
 w
h
o
 t
es
te
d
 
H
C
V
 R
N
A
 p
o
si
ti
ve
, 
1
0
 h
a
d
 
el
ev
at
ed
 A
LA
T
 o
f 
w
h
ic
h
 8
 h
ad
 a
 
b
io
p
sy
. 
B
as
ed
 o
n
 t
h
e 
re
su
lt
s,
 5
 
w
er
e 
in
d
ic
a
te
d
 f
o
r 
tr
ea
tm
e
n
t 
(n
o
 r
es
u
lt
s 
re
p
o
rt
ed
).
 
 O
u
tc
o
m
es
: 
R
N
A
 r
a
te
: 
 
8
6
.4
%
 
(1
9
/2
2
)
 
S
ta
rt
 t
re
at
m
en
t:
 
N
R
 
S
V
R
: 
 
N
R
 
 
A
n
d
e
rs
o
n
, 
E
M
, 
2
0
0
9
 
(9
1
) 
2
0
0
3
-2
0
0
4
 
G
P 
p
a
ti
en
ts
 
ag
ed
 3
0
-5
4
 
yr
s 
S
co
tl
an
d
 
(1
.1
%
):
 s
o
ci
o
-
ec
o
n
o
m
ic
al
ly
 
d
ep
ri
v
ed
 a
re
a 
o
f 
G
la
sg
o
w
  
G
P 
cl
in
ic
s 
(i
n
te
rv
en
ti
o
n
 
cl
in
ic
 a
n
d
 
co
m
p
ar
is
o
n
 
cl
in
ic
) 
6
 m
o
n
th
s 
N
o
n
e
 
N
o
; 
in
 i
n
te
rv
en
ti
o
n
 p
ra
ct
ic
e 
al
l 
in
di
vi
d
u
al
s 
ag
ed
 3
0
-5
4
 y
rs
 
w
h
o
 a
tt
e
n
d
e
d
 n
o
n
-u
rg
en
t 
ap
p
o
in
tm
e
n
ts
 w
er
e 
o
ff
er
ed
 
H
C
V
 s
cr
e
en
in
g
. 
 In
 c
o
m
p
ar
is
o
n
 p
ra
ct
ic
e,
 n
o
 
in
te
rv
e
n
ti
o
n
 w
as
 c
ar
ri
ed
 o
u
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Many individuals with hepatitis C virus (HCV) infection 
are undiagnosed. This study evaluates a risk assess-
ment questionnaire, developed for use online to target 
blood-screening for HCV. Two hundred and eighty-
nine patients with known HCV status completed a 
written questionnaire on prominent HCV risk factors. 
Questionnaires generated advice to seek testing if at 
least one risk factor was reported. Agreement of the 
testing advice with the HCV status of respondents was 
evaluated. Subsequently, we validated our question-
naire among 985 patients of an outpatient clinic for 
sexually transmitted infections. The post-test-prob-
ability-of-disease (PTPD) and diagnostic gain (PTPD 
minus prior probability of disease) were calculated. 
The questionnaire’s sensitivity and specificity were 
84.6% and 63.8%, respectively, and higher in the STI 
clinic patients. The PTPD of positive testing advice 
was 72.5% given HCV prevalence of 53.0%, yielding 
a diagnostic gain of 19.5%. Applying the estimated 
prevalence in the general Dutch population (0.1-0.4%), 
and the anticipated prevalence in the online project 
(1.0-6.0%), yielded diagnostic gains of 0.13-0.53% and 
1.3-7.0%, respectively. We conclude that our question-
naire succeeded in selecting at-risk individuals as its 
testing advice agreed well with the HCV status. We 
suggest that the questionnaire be used online as a 
selection tool for HCV blood-screening in the general 
population.
Introduction
Hepatitis C virus (HCV) infection, first identified in 
1989, is caused by a bloodborne virus and affects an 
estimated 120 million individuals worldwide [1]. Almost 
75% of HCV infections become chronic [2]. 
Twenty to 30 years after infection, chronic HCV leads to 
liver cirrhosis in 20%-30% of patients, 2%-5% of whom 
each year will progress to liver failure or liver carci-
noma [3]. Since the onset of the infection itself and 
the development of cirrhosis in chronically infected 
patients are usually asymptomatic [3,4], many cases 
are undetected. Earlier diagnosis of HCV enables 
patients to start timely treatment, adopt a healthy life-
style (e.g., avoiding alcohol [5]), and prevent possible 
transmission to others. Treatment options for HCV have 
improved substantially since 2001 [5,6], and the Dutch 
Health Council has recommended that more educa-
tion and tracing be focused on groups at risk for HCV 
infection [7]. In most western European countries, the 
prevalence of HCV infection is low, estimated at 0.1%-
0.4% in the Netherlands [8], 0.8% in France [9], and 
0.6%-1.1% in the UK [10]. For low-prevalence countries, 
it is worth considering whether selective screening 
(i.e., establishing individual risk for HCV infection as 
a condition for screening) may be more cost-effective 
than mass screening (i.e. every inhabitant is advised 
to test for HCV) [11,12]. Therefore, as a pilot project in 
the Netherlands, an HCV internet programme was set 
up to identify HCV-infected individuals in the general 
population by testing individuals at risk for HCV. The 
programme’s strategy consists of a public media cam-
paign to refer individuals from the general population 
who are potentially at risk of HCV, to an online inter-
active risk assessment questionnaire at www.heptest.
nl. The questionnaire determines whether or not indi-
viduals are at risk for HCV and offers an opportunity for 
anonymous blood testing, free of charge. 
This study describes the development and evaluation 
of the HCV risk assessment questionnaire before its 
use online. We determined the questionnaire’s dis-
criminative value for diagnosing HCV. Furthermore, we 
evaluated its relevance in clinical practice. This paper 
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discusses implications for use of the questionnaire 
online.
Methods
Development of the HCV risk 
assessment questionnaire
The questionnaire was developed in three stages. 
Firstly, the content was developed. Secondly, the ques-
tions were formulated and tested on members of the 
public for comprehensibility. This resulted in a core 
questionnaire, which was sent out to patients for the 
evaluation study. Meanwhile, however, new data on 
risk factors had become available. Thirdly, therefore, 
an extended questionnaire was developed. The fol-
lowing paragraphs describe these three stages in the 
developmental process.
Content
Development of the core questionnaire was based on a 
literature review of risk factors for HCV, followed by a 
meeting of experts, in which the risk factors from the 
literature were discussed for inclusion in the question-
naire. The expert group consisted of eight health care 
professionals (professor in hepatology, professor in 
epidemiology and prevention of infectious diseases, 
senior epidemiologist, two medical doctors who spe-
cialised in infectious diseases and public health, coor-
dinator of the National Hepatitis Centre, senior social 
psychologist specialising in online research, health 
communication expert). The expert group decided to 
include risk factors/groups either if the expected prev-
alence in the specific group was considered to be high 
(e.g. injecting drug users (IDUs)) or if not informing a 
specific group was considered to be unethical (e.g. indi-
viduals who were administered blood products before 
1992 as these individuals have never been informed in 
the Netherlands and have the right to know about their 
risk). Some risk factors described in literature (e.g. 
dental care [13]) were not included, or included only 
when they occurred in countries with a medium to high 
Table 1
Risk factors/behaviours included in the core and extended risk assessment questionnaires; associated HCV prevalences 
(where known), HCV risk questionnaire evaluation study, the Netherlands, 2006-2007
Risk factor HCV prevalence
IDU Occasional users: 1.5%-14.1% [14]Frequent users: 31%-98% [15]
Being born in a HCV-endemic country 
HCV endemic countries: Egypt (18%), Bolivia (11%), Rwanda (17%), 
Burundi (11%), Cameroon (13%), Guinea (11%), Mongolia (11%) 
[16]
Having received blood (products) before 1992 0.02%-0.2% [8]
HCV-infected mother Mother HIV-neg: ~4%  Mother HIV-pos: ~20% [17] 
Mother is/was IDU Prevalence may be slightly lower than the above (4%-20%) as the HCV prevalence among IDU is high but not 100%
Living together for >1 year and sharing bathroom items with HCV-infected 
individuals 0%-11% [15]
Living together for >1 year and sharing bathroom items with IDU Prevalence may be slightly lower than the above (0%-11%), as the HCV prevalence among IDU is high but not 100%
Needlestick injury: needle exposed to high-risk person (IDU, haemophiliac, 
dialysis patient, HCV-infected individual)
Prevalence unknown. Transmission rate with HCV-contaminated 
needle: 1%-10% [18,19]
Needlestick injury in HCV-endemic country Prevalence data of HCV-endemic countries: see above. Transmis-sion rate with HCV-contaminated needle: 1%-10% [18,19]
Haemophilia patient ~70% [20,21]
Haemodialysis patient 2.6%-22.9% [22]
Organ recipient Prevalence unknown
Having received blood (products) in medium/high risk country a Prevalence unknown
Exposure of healthcare workers to blood/tissue in medium/high risk country a Prevalence unknown
Surgical/dental procedure in medium/high risk country a Prevalence unknown
Ritual intervention such as circumcision or scarification in medium/high risk 
country a Prevalence unknown
Tattoo in medium/high risk country a Prevalence unknown
Body-piercing in medium/high risk country a Prevalence unknown
HCV risk factors added in the extended HCV risk assessment questionnaire:
HIV-positive status 33% [23]
NIDU ≥ 3 times a week for ≥3 months 2.3%-35.3% [24]
CDC: United States Centers for Disease Control and Prevention; HCV: Hepatitis C virus; HDI: Human development index; HIV: Human 
immunodeficiency virus; IDU: Injecting drug user; NIDU: Non-injecting illicit drug use; WHO World Health Organization.
a Indicated as risk for HCV infection if happened in countries with low or medium HDI or with an estimated HCV prevalence >2% according to 
either country-specific estimates of the WHO [16] or regional estimates of the CDC [1].
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prevalence of HCV infection, as including these risks 
would be tantamount to advising almost everyone to 
be tested for HCV, yielding low discriminative power 
to the questionnaire. The experts reached consensus 
for all risk factors. The upper panel of table 1 shows 
the risk factors selected for inclusion in the core ques-
tionnaire, and the prevalence of HCV infection asso-
ciated with each risk factor. For study purposes, we 
also included questions on demographics (age, sex, 
educational level) and whether or not individuals were 
infected with hepatitis B virus (HBV).
Pre-testing
To improve its comprehensibility, the core question-
naire was pre-tested on 20 people (11 male) recruited 
at a popular Amsterdam street market that attracts a 
demographically diverse population and at the liver 
outpatient clinic of the Academic Medical Center of 
Amsterdam. All questions were read by the partici-
pants, and comprehension was examined by asking 
them to comment if they did not fully understand any 
detail. If concepts thought likely to be difficult were not 
queried by a participant, the interviewer asked him/her 
to describe their meaning. Terminology found difficult 
to comprehend was altered according to suggestions 
by participants. After pre-testing, the core question-
naire was ready for evaluation.
Development of the extended HCV 
risk assessment questionnaire
After the initial development of the core questionnaire, 
data were published that indicated a relatively high 
prevalence of HCV infection in non-injecting illicit drug 
users (NIDU) and HIV-infected patients [25,26]. We 
therefore extended the core questionnaire with these 
two risk factors. Furthermore, in this extended ques-
tionnaire, we asked patients how they thought they 
had become infected, seeking risks for HCV infection 
that were not covered by the core questionnaire. The 
lower panel of table 1 shows the risk factors that were 
added in the extended questionnaire.
Evaluation study
To evaluate both the core and the extended question-
naire, individuals whose HCV infection status was 
known (i.e. liver disease patients) were approached and 
asked to fill out the questionnaire. Firstly, the sensitiv-
ity and specificity of both the core and the extended 
questionnaire were determined. Secondly, clinical rel-
evance was evaluated by determining the diagnostic 
gain (i.e. the improvement in knowledge/certainty as 
to whether or not an individual was infected with HCV, 
resulting from the use of the questionnaire). Thirdly, 
a validation study was performed using data from 
patients attending a clinic for sexually transmitted 
infections (STI). 
Recruitment of the liver disease patients
Between October 2006 and October 2007, Dutch 
speaking patients suffering from liver-related dis-
eases (such as HCV or HBV infection) were recruited at 
various locations. These people were selected because 
they were presumed to have been tested for HCV and to 
know their HCV status. 
From October 2006 to June 2007 the core question-
naire was distributed at two liver outpatient clinics in 
Amsterdam, and was handed out during the National 
Hepatitis Week’s patient symposium 2007. From July 
to October 2007 the extended questionnaire was sent 
to 459 members of the Dutch liver patient organisa-
tion (Nederlandse Leverpatiëntenvereniging), with an 
explanation about the evaluation study and a request 
to cooperate by filling out and returning the question-
naires by post. 
Validation study in STI clinic patients
In order to validate the questionnaire in a population 
more representative of the general Dutch population 
with respect to liver disease prevalence, data from an 
anonymous survey conducted from April to May 2007 
among 985 patients at the outpatient clinic for STI of 
the Public Health Service of Amsterdam were used ret-
rospectively. This survey collected detailed data about 
sexual risk behaviour and risk factors for HCV and 
blood tests for HIV, HCV, and other STI. HCV antibody 
screening was performed by means of a third-genera-
tion commercial microparticle EIA system (AxSym HCV 
version 3.0), and positive test results were confirmed 
by Immunoblot (Chiron RIBA HCV 3.0 SIA). The preva-
lence of HCV infection among the STI clinic patients 
was 1.0%. The data collected on HCV risk factors were 
used to assess whether an individual would have been 
advised to test for HCV according to the extended risk 
assessment questionnaire.
Statistical methods
All participants who reported at least one risk factor 
were advised to be tested for HCV infection (‘posi-
tive testing advice’; PTA), and those who reported no 
risk factors were advised that testing was unneces-
sary (‘negative testing advice’; NTA). Where answers 
to questions were missing or inconclusive (i.e., the 
answer ‘don’t know’), we assumed that the risk was 
not present. Differences in risk factor prevalence 
between the HCV-positive and the HCV-negative group 
were tested using Pearson chi-square test or, when 
numbers were small, Fisher’s Exact two-tailed test. For 
testing differences in age, the Mann-Whitney-U test 
was used. We calculated Likelihood Ratio-based 95% 
confidence intervals (CI) for sensitivity and specificity. 
To examine whether sensitivity and specificity differed 
with sex and age, we performed stratified sensitivity 
and specificity analyses for sex and age (≤50 and >50 
years, cut-off based on median age). Furthermore, we 
performed two multivariate logistic regression analy-
ses, separately for HCV positives and for HCV nega-
tives/unknown, with sex and age (continuous variable) 
as predictors of testing advice (outcome variable).
The sensitivity of the core and extended question-
naires – i.e., the percentage of HCV-positive patients 
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being correctly identified as HCV-positive – was calcu-
lated as True PTA/(True PTA+False NTA). The specificity 
– i.e. the percentage of HCV-negative patients being 
correctly identified as HCV negative – was calculated 
as True NTA/(True NTA+False PTA). 
For the validation study, we calculated sensitivity 
and specificity of the extended questionnaire in the 
STI clinic patients. Some minor risk details had not 
been questioned in the STI clinic survey (e.g. living 
together for >1 year and sharing bathroom items with 
HCV-infected individuals or IDU). Data from the liver 
disease patients were restricted to the same risk fac-
tors to calculate a comparable sensitivity and specifi-
city. Differences between sensitivity and specificity 
from liver disease patients and STI clinic patients were 
evaluated using Newcombe’s method 10 for independ-
ent proportions [27].
Sensitivity and specificity represent the diagnostic 
accuracy of a screening questionnaire, but they do not 
reflect the individual likelihood of disease associated 
with a certain questionnaire result and are therefore 
less useful in clinical practice. The clinical relevance 
of the questionnaire was assessed by calculating the 
post-test probability of disease (PTPD; i.e. the likeli-
hood of being HCV-positive when given a positive or 
negative HCV testing advice [28]) using the formulas: 
As the PTPD depends largely on the pre-test probabil-
ity of disease (i.e. the HCV prevalence in the popula-
tion), Fagan’s nomogram [29] was used to visualise the 
diagnostic gain after a PTA. This graphical calculation 
of Bayes’ theorem describes how the result of a test 
(positive or negative) changes the perception of dis-
ease probability by combining the pre-test probability 
of disease with the likelihood ratio of the test (which 
is calculated from sensitivity and specificity) [28]. 
Fagan’s nomogram converts pre-test probabilities into 
pre-test odds, then multiplies the odds by the likeli-
hood ratios and converts post-test odds back to post-
test probabilities. The PTPD was plotted for a range of 
HCV prevalences, including the prevalence in the liver 
disease patients, the estimated prevalence for the gen-
eral Dutch population, and the prevalence expected to 
be revealed by the HCV internet programme. 
We used SPSS for Windows (SPSS version 15.0, SPSS 
Inc., Chicago) and R (R version 2.7.1, libraries Epi and 
Binom; The R Foundation for Statistical Computing) to 
perform our statistical analyses.
Results
At the liver outpatient clinics, 99 patients filled out 
the core questionnaires anonymously while waiting 
for their consultation. In addition, 20 visitors at the 
National Hepatitis Week’s patient symposium 2007 
took part. Data on non-response for these two groups 
were not collected. Of the 459 members of the Dutch 
Liver Patient Organisation to whom the extended ques-
tionnaire was sent, 249 (54%) responded; 72 returned 
blank questionnaires, (some said they had not been 
tested for HCV and therefore could not participate; 
some did not want to); and 177 were willing to cooper-
ate, yielding a response rate of 39% (177/459). In total, 
296 patients took part: 99 and 20 filled out the core 
questionnaire (total 119), and 177 responded to the 
extended questionnaire.
One hundred and thirty-eight of the 296 participants 
(47%) reported that they were HCV-positive, 132 (45%) 
said they were HCV-negative, and 19 (6%) were una-
ware of their HCV status. An additional 7 (2%) did not 
give their HCV status and were therefore excluded, 
leaving 289 liver disease patients. Those unaware of 
their HCV status were assumed to be HCV-negative.
Table 2 shows characteristics and HCV risk factors of 
the liver disease patients by HCV status. As expected, 
prevalence of IDU, having received blood products 
before 1992, living together for >1 year and sharing 
bathroom items with HCV-infected individuals or IDU, 
having experienced a needlestick injury from a needle 
exposed to a high risk person, and non-injecting illicit 
drug use on regular basis were significantly higher 
among HCV-positives than among HCV-negatives. 
Being an organ recipient achieved borderline signifi-
cance in the opposite direction (p=0.05). Prevalence of 
other risk factors did not differ significantly between 
HCV-positives and HCV-negatives, but the numbers 
of individuals with these exposures were often very 
small. 
Sensitivity and specificity 
Table 3 shows the sensitivity and specificity of both 
the core and extended HCV risk assessment question-
naires. Based upon the risk factors in the core ques-
tionnaire, 114 of 138 HCV-positive participants were 
identified as being at risk of HCV infection (PTA given), 
yielding a sensitivity of 82.6% (95% CI: 75.7 to 88.3). 
Of 151 HCV-negative participants, 96 were identified as 
not being at risk of HCV infection (NTA given), yielding 
a specificity of 63.6% (95% CI: 55.7 to 71.0). Stratified 
analyses and logistic regression analyses with sex and 
age as covariates and HCV testing advice (yes/no) as 
outcome variable, did not show significant differences 
in sensitivity or specificity by sex or age (data not 
shown).
The stability of our results was evaluated by excluding 
all cases (n=155) with missing values or uncertainties 
as to any risks or HCV status, yielding sensitivity of 
85.9% (95% CI: 76.1 to 93.0) and specificity of 64.3% 
(95% CI: 52.7 to 74.9) (n=134, data not shown).
Finally, sensitivity and specificity were calculated for 
the extended questionnaire (including all risk factors 
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listed in table 1), yielding sensitivity and specificity 
of 84.6% (95% CI: 76.3 to 91.0) and 63.8% (95% CI: 
52.9 to 73.7), respectively (n=171). With exclusion of all 
cases (n=86) with missing values to or uncertainties as 
to risks or HCV status, sensitivity was 89.4% (95% CI: 
78.5 to 96.1) and specificity was 73.7% (95% CI: 58.4 to 
85.8) (n=85, data not shown). 
Table 2
Study population characteristics and identified HCV risk factors, HCV risk questionnaire evaluation study, the Netherlands, 
2006-2007 (n=289)
Study population characteristics
Total
number (%)
n=289
HCV-
positive
number (%)
n=138
HCV-
negative/unknown
number (%)
n=151
p-value
Sex
Male
Female
Unknown (missing)
146 (51)
140 (48)
3 (1)
69 (50)
68 (49)
1 (1)
77 (51)
72 (48)
2 (1)
0.82
Educational level *
Low
Low-medium
Medium-high
High
Unknown (missing)
22 (8)
 82 (28)
81 (28)
96 (33)
8 (3)
5 (4)
42 (30)
35 (25)
52 (38)
4 (3)
17 (11)
40 (26)
46 (30)
44 (29)
4 (3)
0.04
Median age in years* 50(IQR=43-60)
53
(IQR=47-60)
47
(IQR=36-59) <0.01
Born in the Netherlands * 201 (70) 105 (76) 96 (64) 0.02
Hepatitis B infection * 106 (37) 32 (23) 74 (49) <0.01
HCV risk factors Risk factor prevalence in study population
IDU * 50 (17) 50 (36) 0 <0.01
Being born in a HCV-endemic country 1 (0.3) 1 (0.7) 0 0.48
Having received blood (products) before 1992 * 81 (28) 67 (49) 14 (9) <0.01
HCV-infected mother 5 (2) 2 (1) 3 (2) 1.00
Mother is/was IDU 1 (0.3) 1 (0.7) 0 0.48
Living together for >1 year and sharing bathroom 
items with HCV-infected individuals * 20 (7) 14 (10) 6 (4) 0.04
Living together for >1 year and sharing bathroom 
items with IDU * 22 (8) 20 (14) 2 (1) <0.01
Needlestick injury with needle exposed to high 
risk person (IDU, haemophiliac, dialysis patient, 
HCV-infected individual) *
23 (8) 21 (15) 2 (1) <0.01
Needlestick injury in HCV-endemic country 1 (0.3) 1 (0.7) 0 0.48
Haemophilia patient 7 (2) 6 (4) 1 (0.7) 0.12
Haemodialysis patient 6 (2) 1 (0.7) 5 (3) 0.22
Organ recipient * 13 (4) 3 (2) 10 (7) 0.05
Having received blood (product) in medium/high 
risk country a 0 0 0
Exposure of healthcare worker to blood/tissue in 
medium/high risk countrya 6 (2) 2 (1) 4 (3) 0.69
Surgical/dental procedure in medium/high risk 
countrya 15 (5) 7 (5) 8 (5) 0.93
Ritual intervention such as circumcision or scari-
fication in medium/high risk countrya 15 (5) 4 (3) 11 (7) 0.09
Tattoo in medium/high risk country a 6 (2) 2 (1) 4 (3) 0.69
Body-piercing in medium/high risk countrya 3 (1) 1 (0.7) 2 (1) 1.00
HCV risk factors added in the extended HCV risk 
assessment questionnaire
total
(n=171)
HCV positive
(n=91)
HCV negative/unknown
(n=80) 
HIV-positive status 5 (3) 2 (2) 3 (4) 0.67
NIDU ≥ 3 times a week for ≥3 months * 31 (18) 30 (33) 1 (1) <0.01
CDC: United States Centers for Disease Control and Prevention; HCV: Hepatitis C virus; HDI: Human development index; HIV: Human 
immunodeficiency virus; IDU: Injecting drug user; IQR: Interquartile range; NIDU: Non-injecting illicit drug use; WHO: World Health 
Organization.
a  Indicated as risk for HCV infection if happened in country with low or medium HDI or with an estimated HCV prevalence > 2% according to 
either WHO country-specific estimates [16] or CDC  regional estimates [1].
* p<0.05.
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In the extended questionnaire, HCV-positive patients 
were asked to describe their perceived route of infec-
tion. Fourteen HCV-positive participants (15.4%) had 
reported no risks and were therefore assigned to 
NTA. Nine of these 14 did not know how they acquired 
HCV; four presumed they had been infected due to: 
Table 3
Relation between HCV risk questionnaire’s advice and HCV status for core (n=289) and extended (n=171) versions of the 
questionnaire, HCV risk questionnaire evaluation study, the Netherlands, 2006-2007
Core questionnaire Extended questionnaire
HCV-positive HCV-negative Total HCV-positive HCV-negative Total
Positive testing advice 114 (82.6%a) 55 (36.4%) 169 77 (84.6%a) 29 (36.3%) 106
Negative testing advice 24 (17.4%) 96 (63.6%b) 120 14 (15.4%) 51 (63.8%b)  65
Total 138 151 289 91 80 171
HCV: Hepatitis C virus.
a Sensitivity.
b Specificity.
Figure 
Calculation of post-test probability of HCV, given positive testing advice, for liver disease patients and the general Dutch 
population and the HCV prevalence range expected in the HCV internet programme, HCV risk questionnaire evaluation 
study, the Netherlands, 2006-2007
HCV: Hepatitis C virus
Liver disease patients HCV prevalence 53.9%
General Dutch population HCV prevalence 0.1%-0.4%
HCV prevalence range expected in the HCV internet
programme, 1% - 6%
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dentistry, vaccination during military service, health 
care work without gloves, and travel vaccination in the 
mid 1970s. One HCV infection was officially recognised 
as occupational, resulting from police work related to 
traffic accidents. 
Questionnaire validation
The sensitivity of the extended risk assessment ques-
tionnaire in the STI clinic patients was 90.0% (95% CI: 
62.8 to 99.4) and its specificity 86.6% (95% CI: 84.3 
to 88.6) (n=985). Sensitivity and specificity in the liver 
disease patients, ignoring risks about which the STI 
clinic patients were not asked, were 81.3% (95% CI: 
72.5 to 88.4) and 77.5% (95% CI: 67.6 to 85.7) (n=171). 
The difference in sensitivity (8.7%) was not significant 
(p=0.69), but the specificity was significantly higher 
for the STI clinic patients (difference=9.1%, p=0.03). 
Post-test probability of disease
The post-test probability of disease (PTPD) was calcu-
lated using sensitivity and specificity of the extended 
HCV risk assessment questionnaire in the liver disease 
patients. Fagan’s nomogram (figure) shows the PTPD of 
a PTA and gives a precise view of diagnostic gain, spe-
cifically for low-prevalence populations. The line that 
starts at the left y-axis shows the pre-test probability 
of disease (i.e. the HCV prevalence), crosses the likeli-
hood ratio for PTA (+LR, i.e. sensitivity/(1–specificity)), 
then points to the post-test probability of disease at 
the right y-axis. The diagnostic gain is the difference 
between the chance of disease for an individual before 
filling out the questionnaire (i.e. the prevalence) and 
the chance of disease for an individual after being 
assigned to PTA according to the questionnaire (i.e. the 
PTPD).  For example, the diagnostic gain after PTA in 
the liver disease patients with a prevalence of 53.0% 
(n=171) is 19.5% (72.5% minus 53.0%), as shown by the 
striped line.
For the estimated prevalence in the general Dutch pop-
ulation (0.1%-0.4%[8]), the PTPD of a PTA is 0.23% to 
0.93% (see dotted lines). The diagnostic gain varies 
from 0.13% (0.23% minus 0.1%) to 0.53% (0.93% minus 
0.4%). In the HCV Internet programme, the media cam-
paign, targeted at the general population, addresses 
risk factors for HCV and aims to refer those potentially 
at risk to the questionnaire. Therefore, we anticipate a 
prevalence of 1.0% to 6.0% in the population filling out 
the online questionnaire, yielding a PTPD of a PTA of 
2.3% to 13.0% (vertically hatched area), which would 
lead to a diagnostic gain of 1.3% to 7.0%.
Discussion
Sensitivity was relatively high in this study. The HCV 
risk assessment questionnaire identified 84.3% of 
the HCV-infected individuals, and almost 90% when 
patients with missing values were excluded from 
analyses. In the STI clinic patients both sensitivity 
and specificity reached almost 90%. The fact that the 
risk assessment was based on self-reported risk fac-
tors, relying on the participant’s memory instead of 
biological markers, strengthened the findings. Of the 
14 HCV-infected individuals not identified by the ques-
tionnaire, only one mentioned a confirmed transmis-
sion route (police work related to traffic accidents). The 
others either did not know the route or mentioned vari-
ous possibilities, such as dentistry, vaccinations, and 
health care work without gloves. Although all these 
possibilities include blood-blood contact and therefore 
could be sources of HCV infection, their probability of 
transmitting infection in low prevalence areas is likely 
to be very low. Furthermore, adding such risk factors 
to the questionnaire would decrease its discrimina-
tive value as it would lead to almost everyone in the 
Netherlands (or other low prevalence areas) being 
advised to seek testing.
The extended questionnaire performed better than 
the core questionnaire. It includes HIV as a risk fac-
tor for HCV. Recently, outbreaks of sexually acquired 
HCV infection have been reported among HIV-infected 
men who have sex with men [25]. Based largely on 
case studies, sexually-acquired HCV infection has 
been associated with HIV infection, the presence of 
ulcerative sexually transmitted diseases (STD), sexual 
practices that cause mucosal damage, and sex under 
the influence of drugs [25]. As the prevalence of HCV 
infection among HIV-infected individuals is high, partly 
because of shared bloodborne routes, and HCV/HIV co-
infection accelerates HCV disease progression [30;31], 
HIV infection should be included in a HCV risk assess-
ment questionnaire.
A few other studies have used or evaluated a risk 
assessment questionnaire for HCV infection [32-35]. 
For example, Lapane et al. found sensitivity and spe-
cificity of 69% and 74%, respectively, for risk fac-
tor based screening using a questionnaire including 
socially intrusive questions (e.g. IDU). Using this 
model, the costs per case detected were lower than 
when a questionnaire was used omitting socially 
intrusive questions, or when screening was based on 
elevated alanine transaminase levels [32]. However 
not all studies evaluated sensitivity, specificity, and 
feasibility in clinical practice. The feasibility of a pre-
screening selection questionnaire, as opposed to mass 
screening, requires a balance between sensitivity and 
specificity, to ensure validity of the advice, diagnostic 
value, and cost-effectiveness of the selection method. 
The diagnostic value is largely dependent upon the 
disease prevalence. When the estimated prevalence in 
the general Dutch population (0.1%-0.4%) was used as 
a pre-test probability of disease, PTPD after PTA more 
than doubled but still remained small. This means 
that a large proportion of those who receive PTA will 
test HCV-negative, because of the relatively low risk 
of HCV infection associated with risk factors such as 
having received a blood transfusion. Nevertheless, 
false NTA is more problematic than false PTA because 
of the potentially severe long-term consequences of 
HCV infection. On the other hand, a large proportion 
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of HCV-negative individuals receive NTA and avoid the 
invasive and costly blood-screening procedure. 
The following scenario illustrates the diagnostic value 
of the risk assessment questionnaire. If there is a pop-
ulation of 100,000 individuals, 2,000 of whom have 
HCV infection (prevalence 2.0%) and the aim is to trace 
them, one could simply test everyone, yielding one 
infected individual per 50 tested. Using a pre-screen-
ing selection questionnaire, however, 37,266 (84.6% 
of 2,000 HCV-infected plus 36.3% of 98,000 HCV-
negative) individuals would be tested for HCV antibod-
ies to trace 1,692 infected individuals, yielding a ratio 
of 1:22 instead of 1:50. Three hundred and eight (15.4% 
of 2,000) HCV-infected individuals would not be tested 
and therefore not traced, but 62,524 (63.8% of 98,000) 
HCV-negative individuals would not have to undergo 
testing. As the validation study showed a higher spe-
cificity in non-liver disease patients, the number of 
screened HCV-negative individuals may decrease when 
the questionnaire is applied to the general population.
Online use of the risk assessment questionnaire in the 
HCV internet programme appears feasible, and may be 
more cost-effective than other screening strategies, 
such as mass screening. Firstly, as the internet pro-
gramme’s public media campaign and website infor-
mation will address risk factors (e.g. receiving a blood 
transfusion), the online questionnaire will be likely to 
attract groups at increased risk of HCV infection in 
the general population, leading to a higher PTPD after 
PTA. Secondly, the possible anxiety of HCV-negative 
participants who are concerned about their potential 
risk of HCV infection could be reduced by incorporat-
ing an internet-mediated, low-threshold, anonymous 
blood testing procedure (i.e. a service in which indi-
viduals print their laboratory forms from the website, 
visit a laboratory for blood sampling, and obtain their 
blood test results online). Thirdly, internet-mediated 
blood testing may reduce health care costs (e.g. GP 
consultations).  
The internet may provide easy availability and ano-
nymity, but certain factors must be considered when 
using the internet for offering an HCV risk assess-
ment. Firstly, although internet uptake is high in the 
Netherlands, not all individuals have access to it or 
possess sufficient literacy or skills to use it. Secondly, 
it is a challenge to attract individuals to a website. 
Developing an HCV screening programme through the 
internet without marketing it properly would probably 
fail to identify HCV-infected individuals.
Our study has several limitations. We used self-
reported HCV status of the liver disease patients to cal-
culate sensitivity and specificity. Although unlikely in 
this population, it could be that some patients did not 
report their true HCV status. We did not collect data 
on non-response for the liver disease patients at the 
hospitals and at the symposium and were thus unable 
to evaluate whether selection bias had occurred. Our 
validation study made use of previously collected sur-
vey data. We cannot exclude the possibility that indi-
viduals who fill out a risk assessment questionnaire 
knowing its purpose (like the liver disease patients in 
our study) recall relevant information differently from 
those who take part in a survey without knowing why 
the data are being collected. A potential difference 
might result in an under- or overestimation of the sen-
sitivity and specificity in our validation study. In gen-
eral, we do not know whether our study population is 
representative for the population as a whole.
In conclusion, although our study population might not 
be representative for the population as a whole, the 
questionnaire’s validity is high, as the testing advice 
agrees well with the HCV status in this study. The diag-
nostic gain, however, depends largely on HCV preva-
lence and is therefore lower when the questionnaire is 
used in low-prevalence populations.
We encourage the use of our questionnaire, especially 
in European countries where the prevalence is some-
what higher than in the Netherlands. A future study 
should assess the cost-effectiveness of a risk-based 
screening strategy in internet-based and alternative 
programmes compared with other strategies, such 
as mass screening or screening of easy-to-target-risk 
groups only (e.g. drug users who participate in care 
programmes). The cost-effectiveness analysis should 
take into account not only the prevention of future 
health care costs of identified HCV-infected individu-
als but also the health care costs associated with HCV-
infected individuals who would not be detected using 
one of these screening strategies.
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Using Mass Media and the Internet As Tools
to Diagnose Hepatitis C Infections in the
General Population
Freke R. Zuure, MSc, Udi Davidovich, PhD, Roel A. Coutinho, MD, PhD, Gerjo Kok, PhD,
Christian J.P.A. Hoebe, MD, PhD, Anneke van den Hoek, MD, PhD,
Peter L.M. Jansen, MD, PhD, Paula van Leeuwen-Gilbert, BE, Nicole C. Verheuvel, MSc,
Christine J. Weegink, MD, PhD, Maria Prins, PhD
Background: Many individuals with hepatitis C virus (HCV) infection are undiagnosed.
Purpose: This study describes the development and the use and outcomes of a mass media
campaign, combined with an Internet risk assessment and an Internet-mediated blood-testing
procedure for HCV to identify individuals infected with HCV in the general population.
Methods: From April 2007 to December 2008, individuals in HCV risk groups were referred to an
online, previously validated risk-assessment questionnaire at www.heptest.nl. Individuals at risk could
download a referral letter for a free, anonymousHCVblood test in anonclinical setting.Test results could
be obtained online, 1 week later, using a personal log-in code. Anti-HCV-positive participants were
requested to visit the PublicHealth Service for confırmation andRNA testing. ChronicallyHCV-infected
individuals were referred for treatment. Data were analyzed in 2009–2010.
Results: The website attracted 40,902 visitors. Of the 9653 who completed the questionnaire, 2553
were at risk for HCV (26.4%). Main reported risk factors were a blood transfusion prior to 1992 and
noninjecting drug use. Of the 1480 eligible for the blood test, 420 opted for testing (28%). HCV
antibodies were detected in 3.6% (n15, 95% CI2.1%, 5.7%); of the 12 with a chronic HCV
infection, six began treatment.
Conclusions: Internet-mediated risk-based testing for HCV has proved to be a feasible and effec-
tive strategy to identify undiagnosed HCV infection in the general population. All HCV-infected
individuals belonged to hard-to-reach populations. Test uptake was 28%, which is high for an online
project that includes blood testing. Because Internet-mediated testing is low-cost, this strategy holds
promise for future screening.
(Am J Prev Med 2011;40(3):345–352) © 2011 American Journal of Preventive Medicine
Introduction
Hepatitis C virus (HCV) infection, caused by ablood-borne virus and fırst identifıed in 1989, isa major public health problem. Worldwide an
estimated 123million individuals areHCV antibody pos-
itive,1 approximately 75% of whom are chronically in-
fected and at risk for the development of cirrhosis, liver
cancer, and death.2,3 In chronically infected patients, the
onset of HCV itself and the development of cirrhosis are
usually asymptomatic.2,4 Therefore, many infections re-
main undetected or are diagnosed late. On the basis of
mathematical modeling, the HCV-related morbidity and
mortality rates in high-income countries are expected to
at least double in the next 2 decades.5,6 Because successful
combination therapy forHCVbecamewidely available in
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20017–11 and an era of new therapeutic options is ex-
pected shortly,12,13 the challenge now is to identify as
many HCV-infected individuals as possible.
One option to meet this goal is a mass HCV screening
program. Such a screening program in low-prevalence
countries, however, is not considered cost effective.14 As
a result, mainly groups at high risk for HCV, such as
current injecting drug users (IDUs),15,16 and hemophili-
acs,17,18 have been targeted. In addition, as HCV spread
among individuals who received contaminated blood
products before the introduction of the fırst HCV anti-
body test in 1991, various high-income countries intro-
duced look-back programs in which recipients of blood
from HCV-infected donors were notifıed and encour-
aged to be tested.19,20 The costs, however, were high, and
the yield low.21,22
Attempts to identify HCV-infected individuals from
multiple risk groups in the general population are scarce.
A few studies have evaluated screening tools for deter-
mining risk of HCV (e.g., establishing individual risk for
HCV infection as a condition for screening) to support
effıcient screening in healthcare facilities.23–25 Such selec-
tive screening is promising and more affordable than
mass screening,26,27 but the use of these tools will not
reach the pool of undiagnosed HCV-infected individuals
who do not visit such facilities.
Therefore, wider distribution of screening tools for
HCV risk is desirable. Use of the Internet has the poten-
tial to reach many individuals beyond the setting of
healthcare facilities. For example, several studies have
reported successful use of the Internet with screening
programs for depression28 and for syphilis in men who
have sex with men.29 In the Netherlands, because of the
low HCV prevalence (estimated at 0.1%–0.4%30,31) and
thewidespread use of the Internet, HCV screening via the
Internet could be feasible and effective. Therefore, a pilot
project was developed and launched in two regions in the
Netherlands. The project combined a mass media infor-
mation campaign onHCV in the general populationwith
an online risk-assessment tool and free blood-testing
procedure for HCV. This paper describes the project and
evaluates its usage, determinants of usage, and clinical
outcomes.
Methods
Campaign Design
The project aimed to test inhabitants of Amsterdam (population
size, 1,497,278) and South Limburg (population size, 608,885), the
Netherlands, who were at risk for HCV. From April 2007 to De-
cember 2008, a limited, regional mass media campaign (e.g., with
regional TV commercials, advertisements, and online banners)
was run by the Public Health Services of Amsterdam and South
Limburg. The campaign communicated risk factors for acquiring
HCV, the fact that one can be infected without experiencing symp-
toms, the potential severe long-term health outcomes of chronic
HCV, and the availability of treatment. The campaign aimed to
motivate individuals to assess their risk forHCVusing the project’s
website and then to be tested.
Risk-Assessment Procedure
The project website, accessible at www.heptest.nl and available in
Dutch, English, French, Spanish, Turkish, and Arabic, contained
information and a link to a questionnaire assessing HCV risk
through structured multiple-choice questions that addressed the
prominent risk factors for infection (Table 1). Risk factors were
included if the expected prevalence in the specifıc group was consid-
ered to be high (on the basis of a theoretically plausible transmission
risk, or epidemiologic data), or if not informing a specifıc group was
considered to be unethical (e.g., individuals who were administered
bloodproductsbefore1992since theyhaveneverbeen informed in the
Table 1. HCV risk factors of individuals living in
Amsterdam or South Limburg who were offered the
blood-testing procedure, n (%)
Reported HCV risk N1480
Having received blood (products) prior to 1992 628 (42.4)
Non-injecting illicit drug use for 3 times a
week during a period of 3 months
342 (23.1)
Medical/dental surgery in medium- to high-risk
countriesa
209 (14.1)
Living together for 1 year and sharing
bathroom items with HCV-infected
individuals or IDU
164 (11.1)
Ritual intervention such as a circumcision or
scarification in medium- to high-risk
countriesa
141 (9.5)
Tattoo in medium- to high-risk countriesa 134 (9.1)
Former IDU 62 (4.2)
Needle-stick injury with needle of high-risk
people (IDU, hemophiliacs, dialysis patients,
HCV-infected individuals)
41 (2.8)
Exposure of healthcare workers to
blood/tissue in medium- to high- risk
countriesa
41 (2.8)
HCV-infected mother 40 (2.7)
Body-piercing in medium- to high-risk
countriesa
36 (2.4)
Being born in a HCV-endemic country 28 (1.9)
Having received blood (products) in medium-
to high-risk countriesa
14 (0.9)
Mother is/was IDU 12 (0.8)
Needle-stick injury in HCV-endemic countries 6 (0.4)
aIndicated as risk for HCV infection if in countries with low or medium
Human Development Index (HDI) or with an estimated HCV preva-
lence 2% according to either country-specific estimates of the
WHO34 or regional estimates of the CDC1
HCV, hepatitis C virus; IDU, injecting drug user
Chapter 3
84
Netherlands). In addition, to exclude individuals already diagnosed
withHCVinfection fromthe testing, data regarding results of possible
previous HCV tests were collected. In addition, questions were in-
cluded to inform uninsured individuals about their need for health
insurance to receive HCV treatment in the Netherlands.
Individuals who reported at least one risk factor for HCV were
advised to have a blood test. Individuals in the risk groups that are
regularly tested for HCV in the pilot regions (i.e., those receiving
hemodialysis or organ transplant, hemophiliacs, HIV-infected in-
dividuals, and active IDUs participating in drug-user healthcare
programs) were advised to visit their general practitioner or spe-
cialist for testing and were discouraged from using the Internet-
mediated testing procedure. All other individuals living in the pilot
regionswhowere at risk forHCVwere offered the free, anonymous
HCVblood test, whereas those living outside the pilot regions were
advised to visit their general practitioner for testing. The diagnostic
accuracy of the risk-assessment questionnaire was previously ex-
amined, yielding a sensitivity of 84.6% and specifıcity of 63.8%.32
Blood Test
The project’s website provided a referral letter to a testing labora-
tory, along with instructions and addresses of the participating
laboratories. All but one of the laboratories were walk-in laborato-
ries, mainly used by primary care professionals as referral facilities.
Each referral letter carried a unique identifying code generated by
the computer. Participants could print, download, or send the
referral letter to an e-mail address. They also could opt to receive
either an e-mail or short message service (SMS) reminder, sub-
scribe to an alert service, or both. Those who chose a form of
reminder received a message to be tested 5 days later.
After the participants presented the referral letter to the labora-
tory, they had their blood drawn for serologic testing by a third-
generation commercial microparticle enzyme immunoassay
(MEIA) system (AxSymHCV, version 3.0; Abbott). The test results
were uploaded online, where participants could obtain their results
using their unique identifying code. Those subscribed to the alert
service received an automated message when their results were
uploaded. Individuals who tested positive were informed about a
potential HCV infection and were requested to visit the Public
Health Service again for HCV antibody, recombinant immunoblot
assay, and HCV RNA testing (AxSym HCV, version 3.0; Chiron
RIBA HCV 3.0 SIA, Ortho-Clinical Diagnostics; Cobas Amplicor,
Roche, respectively). Participantswhowere found to be chronically
infected with HCV were referred to a hepatologist. Informed con-
sent was obtained for notifying the participant’s general practitio-
ner and for future HCV clinical data collection. The medical ethics
committee of the Academic Medical Center, Amsterdam, decided
that the project did not require IRB approval.
Measures
Website usage and user characteristics. Website visitors
were counted via the total number of website hits. The chosen
website language and the Internet provider (IP) address (i.e., a code
identifying a specifıc computer on the Internet) were recorded.
Further, the questionnaire included data on sociodemographics
(age, gender, educational level), postal codes, and whether individ-
uals who completed the questionnaire intended to assess their risk
for HCV or just out of curiosity. The last is also referred to as a
“seriousness check,”33 enabling the exclusion of nonintentional
website users (e.g., other researchers who wanted to just review the
questionnaire) from the evaluation analyses. In the analyses, those
individuals were excluded, as well as those who previously tested
positive for HCV and risk groups who were presumed to have
already undergone testing and were therefore discouraged from
using the questionnaire andblood-testing procedure. The collected
data were used to assess the proportion and characteristics of
website users at risk for HCV, as well as determinants for risk of
HCV.
Use of hepatitis C virus blood test. Among those individu-
als determined to be at risk for HCV, the proportion that under-
went the blood test was assessed, with the subsequent results. Of
those who tested positive, the proportion that visited the Public
Health Service for follow-up testing was assessed. To examine
determinants of blood testing, data were used from the question-
naire and the subscriptions to the reminder service.
Clinical outcomes. The number of individuals identifıed as
HCV-antibody-positive, and the proportion of chronically in-
fected (HCV–RNA positive) individuals were measured, and data
were collected on treatment and outcomes.
Statistical Analyses
Descriptive analyses were used to assess the characteristics of the
website users. With logistic regression analyses, determinants of
being at risk for HCV and determinants of using the HCV blood
test among those eligible for testing were examined. Variables
evaluated in the analyses included sociodemographics andwhether
an individual had health insurance. Age was categorized based on
quartiles. Educational level was divided into four categories (low:
primary school; low-medium: lower secondary school; medium-
high: senior secondary school/vocational school; high: higher vo-
cational education/University/PhD). In the second analysis, the
proximity of the nearest laboratory (celestial latitude based on
midpoints of postal-code areas categorized by quartiles), reminder-
service subscription, and specifıc HCV risks were also evaluated.
Participants who reported more than one HCV risk were allocated
to the group that included the most likely risk factor for HCV. The
results in Table 2 are presented according to this hierarchy.
Variables with a p-value of 0.10 in univariate analyses were
entered in the multivariate logistic regression model. A stepwise
backward selection procedure was used. A p-value of0.05 was
considered signifıcant. In sensitivity analyses, potential dupli-
cate cases, which were defıned as participants who reported the
same gender, date of birth, postal code, country of birth, and the
same IP address, were included only once at their last participa-
tion date.
SPSS for Windows, version 17.0, and Stata statistical package,
version 9.1, were used for statistical analyses. Data were collected
from March 2007 to December 2008, and the analyses were per-
formed in 2009 and 2010.
Results
Website Usage
From March 2007 to December 2008, the website at-
tracted 40,902 visitors (Figure 1). Of that number,
38.5% started the risk-assessment questionnaire and
completed the seriousness check. According to that
check, 15.7% did not intend to determine their risk for
Risk-based and Internet-based screening for hepatitis C
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HCV and were excluded from further analyses. Of the
remainder, 12.1% left the website before completing
the questionnaire’s section on demographics; 87.9%
completed the demographics and began the questions
regarding risk factors for HCV.
Of the 10,507 who began the risk factor section of the
questionnaire, 0.7% indicated that they had tested posi-
tive for HCV before, and 2.7% belonged to the specifıc
risk groups presumed to have received previous testing
for HCV. These individuals were discouraged from fur-
Table 2. Univariate and multivariate logistic regression analyses of factors associated with HCV testing among
participants at risk for HCV (N1480)
Characteristics HCV tested (%)
Univariate
Multivariate
OR (95% CI) p-value
Adjusted OR
(95% CI) p-value
Age (years)
32
32–45
46–54
54
Missing
55/392 (14.0)
91/373 (24.4)
127/363 (35.0)
146/345 (42.3)
1/7 (14.3)
1
2.0 (1.4, 2.9)
3.3 (2.3, 4.7)
4.5 (3.1, 6.4)
—
0.001
1
1.5 (1.02, 2.3)
2.6 (1.7, 3.8)
3.4 (2.3, 5.2)
—
0.001
Gender
Male
Female
156/659 (23.7)
264/821 (32.2)
1
1.5 (1.2, 1.9)
0.001
—
—
Educational level
Low
Low-medium
Medium-high
High
No answer
48/180 (26.7)
113/463 (24.4)
164/499 (32.9)
46/143 (32.2)
49/195 (25.1)
1
0.9 (0.6, 1.3)
1.3 (0.9, 2.0)
1.3 (0.8, 2.1)
0.9 (0.6, 1.5)
0.023
1
1.1 (0.7, 1.7)
1.9 (1.2, 2.9)
1.8 (1.0, 3.0)
1.2 (0.7, 2.1)
0.003
Country of birth
Netherlands
Elsewhere
327/1155 (28.3)
93/325 (28.6)
1
1.0 (0.8, 1.3)
—
—
Region of residence
Amsterdam
South Limburg
Unknown whether in Amsterdam or South
Limburg
262/993 (26.4)
158/477 (33.1)
0/10 (0)
—
1
1.4 (1.1, 1.8)
—
—
0.008
1
1.4 (1.01, 1.9)
—
—
0.046
Proximity of the nearest laboratory (km)
1.17
1.17–2.19
2.20–6.08
6.08
Unknown (incomplete postal code)
106/319 (33.2)
113/384 (29.4)
109/364 (29.9)
89/362 (24.6)
3/51 (5.9)
1
0.8 (0.6, 1.2)
0.9 (0.6, 1.2)
0.7 (0.5, 0.9)
0.1 (0.0, 0.4)
0.003
1
0.9 (0.6, 1.3)
0.7 (0.5, 1.0)
0.5 (0.4, 0.8)
0.2 (0.1, 0.8)
0.003
Health insurance
Insured
No/unknown about insurance
404/1440 (28.1)
16/40 (40.0)
1
1.7 (0.9, 3.3)
0.102
1
2.4 (1.1, 5.2)
0.028
Request for e-mail/SMS reminder
No
Yes
352/1342 (26.2)
68/138 (49.3)
1
2.7 (1.9, 3.9)
0.001
1
2.8 (1.9, 4.1)
0.001
HCV risk group
Blood transfusion prior to 1992
Having lived together with HCV-infected/IDU
and having shared bathroom attributes
Mother HCV-infected/IDU
Needle-stick injury
Risky event in medium-/high-risk country
NIDU on a regular basis
HCV endemic country of birth
Former IDU
204/545 (37.4)
27/92 (29.3)
10/29 (34.5)
6/23 (26.1)
103/396 (26.0)
34/306 (11.1)
12/27 (44.4)
24/62 (38.7)
—
1
0.7 (0.4, 1.1)
0.9 (0.4, 1.9)
0.6 (0.2, 1.5)
0.6 (0.4, 0.8)
0.2 (0.1, 0.3)
1.3 (0.6, 2.9)
1.1 (0.6, 1.8)
—
0.001
1
0.8 (0.5, 1.4)
1.3 (0.6, 3.1)
0.7 (0.3, 2.0)
0.9 (0.6, 1.2)
0.3 (0.2, 0.5)
1.8 (0.8, 4.4)
1.1 (0.6, 2.0)
—
0.001
Note: ORs in the multivariate model are adjusted for all factors for which adjusted ORs are shown: age; educational level; region of residence;
proximity of the nearest laboratory; health insurance; request for e-mail/SMS reminder; HCV risk group.
HCV, hepatitis C virus; IDU, injecting drug user; NIDU, non-injecting drug user; SMS, short message service
Chapter 3
86
ther participation, referred to their specialist, and ex-
cluded from additional analyses.
Of the remaining 10,148, only 4.9% left the website
before completing all questions, whereas 95.1% com-
pleted the questionnaire, 5368 of whom were living
within the referral regions for the blood test. Of those,
51.5% were female. The median age was 38 years (inter-
quartile range [IQR]26–50 years). The education le-
vel varied from low (10.2%) to low-medium (30.3%);
medium-high (38.5%); and high (9.5%); whereas 11.6%
refused to answer this question.Most individuals (86.6%)
were born in the Netherlands; 5.4% were born in another
Western country, and 8.0% were of non-Western origin.
Only 1.3% used a version of the questionnaire in a lan-
guage other than Dutch, and 27.6% appeared to be at risk
for HCV. In multivariate analyses, being at risk for HCV
was associated with female gender (OR1.3, 95%
CI1.2, 1.5); having a low-medium (OR1.2, 95%
CI1.1, 1.4) or unknown educational level (OR1.3,
95% CI1.04, 1.6) compared with a medium-high edu-
cational level; older age (OR1.3, 95% CI1.1, 1.6, for
those aged 27–38 years; OR2.3, 95% CI1.9, 2.7, for
those aged 39–50 years; OR3.0, 95% CI2.5, 3.6,
for those aged 50 years; all compared with those
aged 27 years); being born outside the Netherlands
(OR2.5, 95%CI2.1, 3.0); and not having health insur-
ance (OR1.8, 95%CI1.2, 2.8) (data not shown). In the
sensitivity analysis, excluding potential duplicate partici-
pants (n172), results were comparable.
Hepatitis C Virus Blood Testing and Its
Determinants
The blood test was offered to those at risk living within
the referral regions. Table 1 shows an overview of the
reported HCV risks of these individuals. Of the 1480
participants, 19.7% reportedmore than one risk factor. In
total, 28.4% opted for testing. The median time between
website visit and their testing was 5 days (IQR2–10),
and most individuals were tested within 3 weeks after
their website visit.
Table 2 shows the results of univariate andmultivariate
analyses of determinants of HCV testing. In the sensitiv-
ity analysis, excluding potential duplicate participants
(n70), results were comparable.
Figure 1. Overview of the Internet procedure, usage, and clinical
outcomes
A’dam, Amsterdam; GP, general practitioner; HCV, hepatitis C virus;
RIBA, ribavirin; S-L, South Limburg; SMS, short message service
26.4% (2,553 / 9,653) 
at risk of HCV
40,902 website visitors
38.5% (15,734/40,902) started questionnaire’s 
section on demographics
95.1% (9,653/10,148) completed the risk 
assessment questionnaire
Amsterdam
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25.0% 
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1,480 were offered blood testing
4,5% (19/420) tested HCV ab positive
87.9% (10,507/11,957) completed questions 
on demographics and started the 
questionnaire’s section on HCV risks
According to the ‘seriousness 
check’, 15.7% (3,777/15,734) 
did not visit the website for 
HCV risk determination. They 
are excluded from analyses.
3.4% (359/10,507) were 
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because of their condition or 
HCV positive status
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GP for HCV 
testing
1/19
went to GP for 
confirmation testing
18/19
were tested at Public Health Service 
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first test)
17/18 HCV ab positive
28.4% (420/1,480) printed the referral 
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testing
Public Health Service received blood 
test results and made them available 
online
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 reminder message for 
testing was sent by 
email/SMS to those 
subscribed
5 days
message about 
obtaining results was 
sent by email/SMS to 
those subscribed
95.5% (401/420) obtained test result 
online
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14/17 RIBA 
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3/15 RNA 
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Unknown 
A’dam or S-L
41.7% 
(10/24)
3/12
sustained 
virological 
resonse
3/12
under 
treatment
4/12
awaiting 
treatment
2/12
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follow-up
12.1% (1,450/11,957) left the 
website before completing the 
section on demographics
4.9% (495/10,148) left the 
website before completing the 
questionnaire’s section on 
HCV risks
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Clinical Outcomes
Of the 420 who tested, only 4.5% did not obtain their test
results from the website (all tested negative for HCV
antibody), and 4.5% (95%CI2.8%, 6.8%) tested positive
for HCV antibody. All but one individual visited the
Public Health Service for confırmation testing; that per-
son stated he preferred to visit his general practitioner for
that testing. In the analysis, that personwas considered to
be positive for HCV antibody. Twelve individuals were
chronically infected with HCV, of whom 11 reported
former injecting drug use (IDU), and one reported a
blood transfusion prior to 1992. The lower portion of
Figure 1 shows an overview of the clinical outcomes of
these individuals.
Discussion
To our knowledge, this is the fırst time a public HCV
information campaign targeting the general population
has been launched combined with risk-based blood
screening for HCV via the Internet.
This study shows that the online process of assessing
risk, arranging a blood test, and obtaining the results is
feasible. The blood-test uptake of 28% is high; a similar,
successful online method of testing for syphilis yielded a
test uptake of 10%.29 Further, almost all of those who
were tested for HCV through the project obtained their
results online, and all individuals with positive results
went to their general practitioner or PublicHealth Service
for confırmation testing.
The project’s strategy succeeded in identifying HCV-
infected individuals in the general population, resulting
in aHCVprevalence of 3.6%,which is nine to 36 times the
estimated prevalence in the general Dutch population
(0.1%–0.4%30). Most of those identifıed with chronic
HCV infection were former IDUs not taking part in the
present healthcare services for IDUs. Hence, it is unlikely
that they would have been identifıed without the current
project. Considering the high prevalence in this group,
interventions are needed to both reach and inform for-
mer IDUs, as well as to motivate them to be tested.
The volume of the project’s reach was limited; in a
period of 21 months, it attracted 1480 individuals at risk
for HCV living in the pilot regions. This small number is
attributed to the restricted reach of a regional media
campaign. Toward the end of the project, a 1-day national
media event was arranged, and an immediate peak in
exposure and testing was observed, far exceeding all
peaks during the regional campaign (data not shown).
Therefore, in future similar efforts, it is recommended
that nationalmedia be used to achieve themaximal expo-
sure needed to reach hidden populations for HCV. Fur-
ther, the proportion of non-Westernmigrants participat-
ing in the project (8.0%) was lower than expected, based
on the proportion of those living in the pilot regions
(12.7%; Statistics Netherlands, 2009). Given the impor-
tance of reaching these groups because of their presum-
ably higher risk for HCV, an additional, more-direct ap-
proach is suggested, such as through organized outreach
activities supported by community leaders.
Regarding determinants ofHCV testing, individuals of
older age, of higher educational level, and with residence
in a less urbanized region were more likely to be tested.
Older age and higher educational level have been associ-
ated previously, but not consistently, with screening up-
take for various diseases.35 The higher uptake of HCV
screening in less-urbanized South Limburg compared to
Amsterdam is also observed in the age-corrected uptakes
for cancer screening in these regions.36 Explanations
might include small regional differences in the media
campaign, or a potential perception of a higher level of
authority of the local Public Health Service.
Further, not having health insurance was associated
with being tested. In theNetherlands, individualswithout
a residence permit are uninsured; hence, they do not have
access to regular health care. Because HCV testing in the
online project was not restricted to those having health
insurance, it may have created a specifıc health gain for
the uninsured group that otherwise might not have been
feasible.
Also, NIDUs were less likely to test compared with the
other risk groups. Because the reported HCV prevalence
in NIDUs varies between 2.3% and 35.3%,37 it is sug-
gested that future screening programs make more effort
to motivate this group for testing. The geographic dis-
tance to the testing location was found to be associated
with testing, indicating that screening projects should
minimize the travel distance to the laboratory, for exam-
ple, by organizing a mobile testing unit. Also, reminder
messages were found to stimulate testing behavior. As
shown in other studies,38,39 reminder messages can be an
effective and relatively easily implemented strategy to
increase test uptake in screening projects, especially with
computer-based methods.
Regarding study limitations, the analyses are based on
the individuals who responded to the campaign and used
the website and thus do not give insight into the total
population at risk of HCV in the study regions. This
limits the generalizability of the fındings. In addition, the
reach of the media campaign was not measured. Further,
it is unknown whether participants at risk who were not
tested through the project decided to be tested elsewhere.
If participants have been tested elsewhere, the impact of
the program has been underestimated.
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Conclusion
The online approach proved to be feasible and effective in
identifying undiagnosedHCV-infected individuals in the
general population. Itmay be used for screening for other
diseases, recognizing that its impact can be increasedwith
a more extensive mass media campaign combined with
direct outreach approaches for immigrant risk groups.
Online testing offers many advantages, such as low cost
and anonymity. It should be complementary to regular
screening options, especially in countries with high prev-
alence of Internet use. Proximate testing locations and
reminder messages are important in enhancing the effec-
tiveness of screening projects that involve collection of
body specimens.
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advice to test for hepatitis C via an internet-
mediated blood screening service: a qualitative
study
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Abstract
Background: Hepatitis C virus (HCV) is mainly transmitted by exposure to infected blood, and can lead to liver cirrhosis
and liver cancer. Since the onset of HCV and the development of liver cirrhosis usually are asymptomatic, many HCV-
infected individuals are still undiagnosed. To identify individuals infected with HCV in the general population, a low
threshold, internet-mediated blood testing service was set up. We performed a qualitative study examining reasons for
compliance and noncompliance with advice to test for HCV via the online blood testing service.
Methods: Semistructured telephone interviews were conducted with 33 website visitors who had been advised to
test for HCV (18 testers, 15 non-testers). Transcribed interviews were analyzed qualitatively and interpreted using
psychosocial theories of health behavior.
Results: Reasons for testing pertaining to the online service were: the testing procedure is autonomous, personalized
test advice is provided online, reminder emails are sent, and there is an online planning tool. Reasons for testing not
specific to the online service were: knowing one’s status can prevent liver disease and further transmission of HCV, HCV
is curable, testing can provide reassurance, physical complaints are present, and there is liver disease in one’s social
environment. Service-related reasons for not testing pertained to inconvenient testing facilities, a lack of commitment
due to the low threshold character of the service, computer/printing problems, and incorrectly interpreting an online
planning tool. The reasons for not testing that are not specific to the online service were: the belief that personal risk is
low, the absence of symptoms, low perceived urgency for testing and treatment, fear of the consequences of a positive
test result, avoiding threatening information, and a discouraging social environment.
Conclusions: Features specific to the online service played a significant role in motivation to test for HCV above
and beyond the more conventional perceived health benefits of HCV testing. However, some online specific
features were considered problematic and need to be adapted. Methods and strategies for dealing with these
impeding factors and for improving compliance with testing via the online service are outlined.
Background
Hepatitis C virus (HCV) infection, caused by a blood-
borne virus and first identified in 1989, is a major public
health problem. Worldwide an estimated 123 million
individuals are HCV antibody positive, [1] approximately
75% of whom are chronically infected and at risk for the
development of cirrhosis, liver cancer, and death [2,3].
In chronically infected patients, the onset of HCV itself
and the development of cirrhosis are usually asympto-
matic [2,4]. Therefore, many infections remain unde-
tected or are diagnosed late. On the basis of
mathematical modeling, the HCV-related morbidity and
mortality rates in high-income countries are expected to
at least double in the next 2 decades [5,6]. Because suc-
cessful combination therapy for HCV became widely
available in 2001 [7-11] and an era of new therapeutic
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options is expected shortly [12,13], the challenge now is
to identify as many HCV-infected individuals as possi-
ble. Consequently, the Public Health Services of Amster-
dam and South Limburg introduced the Hepatitis C
Internet Project, a pilot study aimed at identifying
undiagnosed HCV-infected individuals in the general
population.
In the Netherlands, the estimated HCV prevalence is
low (0.1-0.4% [14]). Therefore, the strategy used in the
Hepatitis C Internet Project consisted of a public media
campaign that addressed HCV risk factors and referred
risk groups to an online HCV risk assessment question-
naire at http://www.heptest.nl[15]. Individuals who vis-
ited the website and were identified by the
questionnaire as at risk were advised to get tested for
HCV and were immediately offered the opportunity to
arrange, online, a free and anonymous HCV blood test.
The website also provided information about HCV risks
that was tailored to the individual’s risk profile and
emphasized the severity of HCV infection, its often
asymptomatic onset, and the benefits of treatment. It
also explained the testing procedures, stating that the
blood test procedure included an initial HCV antibody
test, a follow-up test for those who tested positive, and
a direct referral to the hospital for those infected with
HCV. Individuals could arrange the blood test them-
selves by printing out a laboratory form that contained a
personal identification code with which participants
could anonymously obtain their test result online seven
days after testing. The form also included addresses and
opening hours of the participating low threshold test
locations. In order to increase the test uptake, indivi-
duals were offered an online planning tool for testing
where they could specify the date, time, and location
upon which they would have their blood drawn for the
HCV test. The tool explicitly mentioned that it did not
result in an actual appointment with the laboratory and
that individuals later could decide to take their test at a
different date, time, or location. The tool was considered
advantageous because, according to the theory of Imple-
mentation Intentions [16], detailed planning of when
and how to execute an intended action facilitates the
actual performance of the behavior. In addition, indivi-
duals could subscribe to an email and/or a mobile
phone Short Message Service (SMS) reminder system if
they wanted to receive a reminder message for blood
testing five days after they completed the risk assess-
ment questionnaire.
While 28% (n = 420) of the individuals who completed
the risk assessment questionnaire and were found to be
at risk for HCV infection (n = 1,480) complied with the
test advice and were tested for HCV, a substantial pro-
portion (72%) failed to visit the test locations. Because
the online testing service is new, it is unclear which
service-related factors promoted or impeded website
visitors’ decision to test for HCV. Understanding why
some complied with the advice to test through the
online service and others did not is vital to not only the
further implementation of this service but also to the
improvement of HCV testing campaigns in general.
Therefore, this study investigated reasons for compli-
ance and noncompliance with the HCV test advice
obtained through the online risk screening tool and
focused particularly on the role of the online blood test-
ing procedures in that process. A descriptive qualitative
design was used to be able to explore and understand
the participants’ views and motives with regard to HCV
testing.
Theoretical background
The health belief model [17,18], the theory of planned
behavior [19], and the extended parallel process model
[20] were used as theoretical bases for the interpretation
of the findings. The health belief model focuses on per-
ceived severity of and vulnerability to a disease (per-
ceived threat), perceived barriers to and benefits of
executing the behavior (expectations regarding the out-
comes of the positive health behavior), perceived self
efficacy (the degree to which one perceives oneself cap-
able of executing the health behavior), and cues to
action (stimuli which trigger the cognitive processes that
lead to the health behavior). Applied to the context of
HCV screening, the likelihood of HCV testing increases
when perceived threat of HCV is high, perceived bar-
riers of testing are low, perceived benefits of testing are
high, self efficacy for testing is high, and relevant cues
for action are present.
The theory of planned behavior suggests that behavior
is determined by more than just health beliefs. Accord-
ing to the theory of planned behavior, attitudes (perso-
nal evaluations of the behavior based on behavioral
beliefs), subjective norms (perceptions of other people’s
evaluations of the behavior based on normative beliefs),
and behavioral control (perceived control over the
execution of the behavior based on control beliefs; simi-
lar to self-efficacy) determine the intention to engage in
a behavior. Behavioral intention is presumed to best pre-
dict behavior. However, actual behavioral control (e.g.
lack of control due to environmental factors) can also
directly influence behavior. Applied to the context of
HCV screening, the likelihood of HCV testing increases
when attitudes towards testing are positive, when sub-
jective norms favor HCV testing, and when perceived
behavioral control is high.
The extended parallel process model also focuses on
health beliefs but is more specific than the health belief
model with regard to the role of emotion in responses
to a perceived health threat. According to the extended
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parallel process model, health threats can cause indivi-
duals to engage in either danger control or fear control
processes. Danger control is aimed at reducing the
health threat through cognitively processed adaptive
responses (e.g. seeking testing and treatment), whereas
fear control is aimed at reducing unpleasant feeling
related to the health threat. Fear control often results in
maladaptive responses such as message avoidance and
defensive reactions (e.g. denial of risk). Whether indivi-
duals engage in danger or fear control processes
depends on the degree to which threat, self efficacy, and
response efficacy (the extent to which the recommended
behavior is expected to effectively reduce the threat) are
perceived to be present [20]. Medium to high perceived
threat combined with high perceived efficacy will most
likely result in danger control responses while high per-
ceived threat combined with low perceived efficacy will
most likely lead to fear control responses. In a study
conducted with men who have sex with men (MSM) by
Mikolajczak et al. [21], men at risk for HIV mentioned
both the fear of testing HIV-positive and a low per-
ceived risk of HIV infection as reasons for not testing,
thus implying that cognitive dissonance reduction takes
place. Applied to the context of HCV screening, the
extended parallel process model would suggest that the
likelihood of HCV testing is greatest when individuals
perceive the threat of HCV as moderate to high and
possess high levels of perceived self efficacy and
response efficacy.
Methods
Recruitment and Sample
Because the Hepatitis C Internet Project was anon-
ymous, only individuals who had subscribed to the
reminder service could be contacted for participation in
this study. To note, those who subscribed to the service
were informed that they could receive an email invita-
tion for participation in a study. Recruitment took place
among these individuals between May and July 2007
and between May and July 2008 (n = 97). The invitation
sent by email briefly explained the study procedures and
indicated that the aim of the study was to improve the
project by hearing the opinions of participants. The invi-
tation was sent at least three weeks after the potential
participant’s website visit, in order to provide the parti-
cipant with sufficient time to be tested, but no later
than three months, in order to reduce potential recall
bias. If individuals did not reply to the email invitation
within two weeks, an email reminder was sent. Recruit-
ment of participants continued until data saturation [22]
was reached, i.e. until no new reasons for compliance or
noncompliance emerged from three consecutive inter-
views. In total, 33 interviews were conducted. Informa-
tion regarding demographics (sex, level of education,
and country of birth) and HCV risk factors were
obtained from the online risk assessment questionnaire
data. Age was asked during the interview.
Procedure
Semistructured interviews were chosen as they allow
flexibility, facilitate empathy, enable the interview to
explore new topics, and tend to produce rich data [23].
Interviews were conducted in Dutch by telephone. Tele-
phone interviews were considered the most ideal choice
as they lower possible barriers to participation (e.g. tra-
velling to the Public Health Service) and enhance anon-
ymity. Two female researchers conducted interviews of
approximately 15 minutes each. Every interview com-
menced by explaining the purpose of the interview fol-
lowed by an oral informed consent. The following topics
were then addressed: motives for visiting http://www.
heptest.nl and filling out the risk assessment question-
naire; feelings about the outcome of the risk assessment;
personal perception of risk for HCV infection (this topic
was added after the first two interviews); and the rea-
sons for compliance or noncompliance with the advice
to test for HCV. The central topic of the interview con-
cerned why participants used or did not use the pro-
ject’s testing service. Follow-up probes (e.g., “Could you
explain this further?”) were applied to motivate partici-
pants to provide a detailed rationale for their test deci-
sion. All interviews were audio-taped and transcribed
verbatim (quotes are translated). Participants were pro-
vided with a gift certificate as reward for their
participation.
Analyses
The transcribed interviews were entered into a database
for coding and content analysis using qualitative data
analysis software (MAXqda 2007). The data analysis
team consisted of four researchers from different disci-
plines (communication science, biomedical science, psy-
chology, and anthropology). The data analysis consisted
of two phases; in the first phase the data were analysed
in an inductive manner, not informed by the theoretical
frameworks. In the second phase, the results of the first
phase were interpreted using the theoretical frameworks.
A detailed description of the two phases follows below.
Phase 1: After conducting the first two interviews, two
researchers independently coded those interviews. In
order to stay as close as possible to the phenomenon
described by the participants, coding was inductive and
open, not yet classified or interpreted through the theo-
retical frameworks, and an unrestricted number of facets
were expressed in preliminary code names. A discussion
meeting with the data analysis team then took place to
ensure that all relevant content was incorporated in
codes. Furthermore, based on the first two interviews,
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the team discussed whether additions were needed to
the initial interview schedule. Thereafter, two additional
interviews were conducted and discussed. This iterative
process of interviewing alternated with open coding and
a team discussion comprised three rounds. Thereafter,
when all 33 transcripts were coded, the team reached
consensus on the final code names. The codes had to be
concise and self-explaining. If multiple codes were
found that refer to a similar principle (e.g., the codes:
‘inconvenient opening hours of the laboratories’, ‘no
evening opening hours’, and ‘needing an appointment
for a specific time to be tested at the closest laboratory’),
codes were merged together (in this example into
‘inconvenient test facilities’), reducing the number of
codes. Consequently, the first author then reread the
coded segments of the 33 transcripts to confirm that all
coded segments fitted in the final code names.
Phase 2: Focusing on the research question, the team
then grouped the relevant codes into categories based
on the theoretical background of the health belief
model, the theory of planned behavior, and the extended
parallel process model. Each category was based on at
least one code.
Ethical framework
Prior to the interviews, participants were informed
about the purpose of the interview and the fact that
they could withdraw from participation whenever they
wished (also after finishing the interview), by emailing
the researcher that had contacted them via email pre-
viously (none of the participants withdrew). Oral
informed consent for audio taping the interview was
requested before the interview started. To maximize
confidentiality, potential personal identifiers were
deleted from the transcripts, and only the involved
researchers had access to the interview transcripts. The
study was approved by the Ethical Committee Psychol-
ogy of the School of Psychology and Neuroscience,
Maastricht University.
Results
Sample characteristics
Most participants (91%; 30/33) were born in the Nether-
lands and female (79%; 26/33). Median age at the time
of the interview was 49 years (IQR = 41-62 years). Edu-
cational level varied from low (22%) to moderate (19%)
to high (59%). Of the 33 participants, 18 (55%) had
complied with the test advice and had used the project’s
testing service. One of these 18 had tested positive for
HCV. The participants belonged to various HCV risk
groups. The most frequently reported risk was having
had a blood transfusion before 1992 (n = 16), followed
by having the skin pierced in countries with medium to
high HCV prevalence (n = 13). Other reported risks
were former injecting drug use (n = 2), frequent use of
non-injection illicit drugs (i.e., cocaine, heroine, amphe-
tamine, LSD, GHB and/or poppers; n = 1) and living
together and sharing bathroom attributes with HCV
positive individuals or drug users (n = 4). Three partici-
pants had multiple HCV risks.
Reasons for testing related to the online testing
procedures
From the interviews with participants that had been com-
pliant with the advice to test (N = 18), we identified five
reasons for testing that related directly to the online test-
ing procedure (see upper right section of Figure 1). The
first reason was that the online testing service allowed
individuals access to a test without having to discuss or
explain their desire to be tested for HCV with their gen-
eral practitioner (GP). This reason was labeled ‘to avoid
the GP’ and is illustrated by the following quotes:
“At that time [years ago], I thought about testing but
I didn’t do it. [...] The reason is that, back then, you
had to visit the GP - it was the standard procedure -
and you’d have to tell him or her why you want a
test [...] and, with this offer, you can remain anon-
ymous but still get tested.” (tester [T]-8)
“I have a lot of health problems. Visits to the GP are
time-consuming and, above all, you don’t want to be
thought of as a whiner. [...] Everytime you have
something, you kind of start to dislike to yourself
and, by bringing it up with the GP, it’s like you are
again make a big deal out of things.” (T-9)
The second reason for compliance pertaining to the
testing service was that the online service enabled users
to become well-informed about HCV and the testing
procedures without time pressure and at their own pace.
The fact that participants ‘could obtain information
independently’ enabled them to deliberate about whether
or not they should test for HCV:
“Well, after doing the risk test and being told that I
need to test, then you can search for information your-
self and find out what it all means, you know? Then
you are not blindly having your blood drawn while you
actually know nothing. You can immediately search on
the internet. You can look up why or how and what...
Then I think, ‘It’s not so scary, I’ll do it’” (T-1).
The third reason was that there was ‘personalized test
advice’. The tailored feedback on risk factors provided
motivation to test, as illustrated by the following quote:
“Well it [the personal advice] is so clear that you feel
compelled to follow the advice you receive” (T-8).
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The fourth reason was that participants had been
reminded to get tested. ‘Receiving a reminder e-mail/
sms message’ alerted individuals to the test advice and
promoted testing, as illustrated by the following the
quote:
“Well, actually, I think if I didn’t get that reminder
of yours, it would have ended up in the back of my
mind, like something I would have to do some time.
[...] Without the reminder, I probably wouldn’t have
gotten tested.” (T-12)
The final reason for compliance related to the online
service was the availability of the online planning tool.
The ‘use of the online planning tool’ stimulated partici-
pants to test:
“I think it’s a helpful tool. They ask you what date
you want to go. I thought, ‘Hey, that’s good. I’ll just
pick that date. I’ll do it. I’ll just put it in my day-
planner and I’ll do it’” (T-7).
Reasons for testing unrelated to the online testing service
We identified ten reasons for testing that were unrelated
to the online testing service (see upper left section of
Figure 1). First, participants mentioned health gain from
early detection of HCV. This was labeled as ‘preventing
liver disease’ and is illustrated by the following quote:
“These diseases always start small. They are invisible
and, later on, they develop further and, at a certain
point, you’re too late for treatment. You know, it
gives you problems. If you find it at an early stage,
you may be able to cure or treat it.” (T-4)
Secondly, participants reported testing because the
undetected virus could spread to other people. This rea-
son was labeled as ‘preventing further transmission’ and
is illustrated by the following quote:
“I thought, ‘Well, for goodness’ sake, let me get the
test.’ [...] also because I could infect others with it”
(T-7).
Figure 1 Reasons for compliance (+) and noncompliance (-) with online advice to test for HCV. The left section of the figure presents the
reasons related to HCV testing in general whereas the right section presents reasons specific to testing via the online blood testing service.
Note. HCV = hepatitis C virus
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A third reason for testing was labeled ‘curability of
HCV’. This reason focused on the fact that there are
treatment options for HCV when diagnosed. One parti-
cipant said,
“I also read that there are medications and stuff
available, so I thought ooohkay. [...] I thought, ‘Well,
this is not very scary, I will do it.’ You get me?” (T-
1).
Another participant stated, “I heard that if you have
it, it can be effectively treated, at least if you’ve
detected it at an early stage. That’s why I reacted
immediately” (T-6).
Furthermore, some participants expressed that caring
for one’s own health and body was imperative. ‘Taking
responsibility for one’s health’ was thus one of the rea-
sons to test for HCV:
“Look, when I hear about something like this, I take
action immediately. It is my body and I believe that
we should care for our bodies. And when you are
offered something like this, well, then you should do
it” (T-18).
Some participants mentioned that they got tested
because they wanted to know their HCV status. They
were not scared of the test results but reported that
they were ‘seeking reassurance’:
“I wasn’t afraid that something was wrong but, yes, I
wanted to be sure.” (T-5); and “I have other things, I
mean unpleasant things [medical conditions] so I
liked being able to exclude something” (T-9).
Several participants had incorrect perceptions regard-
ing HCV risks. They had experienced certain events that
they considered to pose a risk. Although these events
posed no actual risk, they did increase perceived risk
and motivated individuals to test. We labeled this reason
as ‘imaginary risks’:
“I’ve had numerous medical examinations and much
more. I’ve had a stroke, three TIAs. [...] I used to go
for walk in wooded areas and I’ve been bitten by
ticks [...] so I thought, “Oh, oh maybe it [being HCV
positive] could be because of all that.” (T-2)
Also, some participants reported testing because they
were ‘experiencing general physical complaints’. One
participant said the following:
“It said that you could be carrier for a long time and
that it won’t manifest itself - only maybe in a much
later stage - that it can take years. And yes, well
maybe it’s because lately I have had a lot of com-
plaints that I never had before. I thought well, ‘For
goodness’ sake, let me get the test.’” (T-7)
In addition, knowing people with liver-related diseases
was mentioned as a reason for testing. This was labeled
as ‘liver-related disease in the social environment’ and is
illustrated by the following quote:
“At this time, I have acquaintances who are dying
because of their liver. So I think the liver is very
important” (T-18).
Another reason for testing was based on the principle
of finishing what you started and was labeled as ‘gaining
a sense of accomplishment’:
“Well, I tested because I think, ‘Well, I want to
know, finish this, just do it.’” (T-17).
“There was no specific, no special reason, just to
have it done” (T-11).
Finally, some participants tested in the interest of
science or in the interest of the organization facilitating
the testing. This reason was labeled ‘feeling morally
obliged to complete participation in the study’ and is
illustrated by the following quotes:
“If everyone starts but, for whatever reason, doesn’t
finish, that doesn’t bring any good to science or
[knowledge] dissemination or anyone. So I thought,
‘Let me be the person who does do it.’” (T-12).
“I found it nice to know that people are doing this
[providing HCV testing]. It gives you the sense that
you also need to reciprocate so it won’t be one-
sided” (T-17).
Reasons for not testing related to the online testing
procedures
From the interviews with participants who did not com-
ply with the test advice, we identified four reasons for
not testing related to the online testing service (see
lower right section of Figure 1). The first reason
reported was that specific features of the laboratories (e.
g. opening hours) hindered them from getting tested.
This reason was labeled as ‘inconvenient testing facilities’
and is illustrated by the following quotes:
“The laboratory which is closest to me is open until,
I believe, half past one or half past two [...] and it
didn’t get to the point that I thought, “Let’s go out
of bed early to get the test.” (non-tester [NT]-15).
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“The one that is closest to me - there you can only
test by appointment and then I thought, ‘Well, I
may be in another area someday where there is a lab
that doesn’t work with appointments and then I’ll
just walk in to have blood drawn.’ That’s just more
convenient.” (NT-6).
Second, the test procedures did not engage partici-
pants to commit to taking the test immediately but
rather allowed for testing until the end of the year. The
testing procedure had therefore an optional, facultative
character. This reason was labeled as ‘lack of obligatory
procedures for testing’ and is illustrated by the following
quotes:
“Because I am a diabetic, I have to get blood drawn
pretty often, and I thought ‘Well, this can wait a lit-
tle while.’ I will certainly do it in time, before
December. And that’s the deadline you determined”
(NT-9).
“I think, for these kind of things, I kind of really
need to be ordered to come. It should say, ‘Well, on
this day at that particular time, you should be there.’
Then I would probably free up time for it” (NT-7).
Third, some participants reported ‘computer/printing
problems’ as a reason for not testing:
“I went to print the form to have the test and my
printer broke. It didn’t work anymore and I don’t
have a new printer yet” (NT-11).
“My computer broke down and then I actually didn’t
end up doing anything with it” (NT-12).
Finally, we found that incorrectly thinking that the
online planning tool was a real appointment planner
caused uncertainty as to whether the test could still be
taken when the planned appointment was skipped. In
this situation, we found ‘incorrectly interpreting the
online planning tool ’ to be a reason for not getting
tested:
“Well, I skipped the appointment and I didn’t know
whether I could go another time so I thought, ‘Well,
then I need to visit my own GP’” (NT-5).
Reasons for not testing unrelated to the online testing
service
We identified eight reasons for not testing that were
unrelated to the online testing service (see lower left
section of Figure 1). First, despite the results of their
online risk assessment, some participants felt they were
not at risk or downplayed their reported personal risk
for HCV. This reason was labeled as a ‘downplaying per-
sonal risk’:
“Actually, I naturally assumed that when you receive
blood in the hospital, it’s fine” (NT-16).
“I got a tattoo in South Africa but, from what I can
remember about that tattoo shop, it was hygienic
and they always used new needles. At the time, I
never had the sense and today I still don’t have the
sense that I got something, hepatitis C or maybe
something else that you can get from unhygienic tat-
tooing.” (NT-15)
Second, some participants perceived the likelihood of
being HCV-infected as low because they did not have
HCV-related symptoms. The ‘absence of HCV symptoms
as an indication of HCV-negative status’ is illustrated by
the following quote:
“Otherwise I would be completely yellow now. In
any event, I don’t have any symptoms” (NT-10).
Third, some participants mentioned that there was no
immediate need to test as they were not suffering from
physical distress that disrupted their daily lives. This
reason for not testing does not reflect the perception
that one is not at risk but rather it reflects a perceived
lack of immediate need to test that is rooted in the per-
ception that the potential HCV infection is not a handi-
cap to the participant’s daily functioning. The argument
‘low perceived urgency for testing due to the absence of
physical complaints’ is illustrated by the following quote:
“I don’t have any physical complaints now, regard-
less of whether or not I have it. There’s no emer-
gency. [...] And because now I have little, actually,
no complaints, it is not on the top of my priority
list. It is not something I really have to do.” (NT-15).
We also found that some participants perceived that
there was little to be gained from diagnosing and treat-
ing a long-term persisting infection now instead of later,
and therefore postponed testing. The ‘low perceived
urgency for HCV treatment’ is illustrated by the follow-
ing:
“It is not something that is life-threatening. It is not
like if I don’t get treated within a month, I will be
dead by next month. You know, because it is such a
long time ago” (NT-8).
Furthermore, some participants reported rejecting the
test advice in order to prevent emotional worries about
being infected. This was labeled as ‘avoiding threatening
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information’ and is illustrated as follows:
“I always think that you shouldn’t always take every-
thing to heart because, if you do, you’ll feel it your-
self too. I always try to be very straight in that.
When I have a headache, I don’t think, ‘Well then, I
will probably also have this and that.’ [...] It [not
seeking testing] is because of that. We shouldn’t take
everything to heart.” (T-11).
In addition, ‘fearing the negative consequences of a
positive test result’ and the corresponding uncertainty
regarding the chain of events following a positive test
result was also an impediment to testing:
“Is taking the medication hard? Are you stuck with it
for the rest of your life? What is it? What are the
risks? I don’t have a clue. And imagine that the test
result is positive. Then you think, “What am I get-
ting myself into?” (NT-6).
“It is just like [...] pretending it isn’t there [...] bury-
ing your head in the sand. [...] I just have to, how
can I say it, I have to get the courage to take that
step. [...] Yes, because imagine that it is not good,
you would have never taken that into account.”
(NT-9).
Some participants mentioned ‘discouraging individuals
in the social environment’ as a reason for not testing, as
illustrated by the following:
“I didn’t go and get the test yet because my husband
says, ‘Well, you don’t have to do it.’ [...] My children
also took a look at the laboratory form and ques-
tioned whether it was necessary. [...] Actually, in the
beginning, I thought I’d go to the Public Health Ser-
vice and because other people saw it [the form] and
said to me, ‘Oh, you don’t need to do it,’ that’s why
I haven’t done it yet.” (NT-13).
Also, ‘competing events’ were found to impede testing
for HCV, as illustrated by the following quote:
“Unexpectedly, my father had surgery so I am always
at the hospital and I haven’t been able to do any-
thing for myself. So I haven’t tested yet because of
these private matters.” (NT-8).
Finally, some participants ‘thought they had already
been tested for HCV elsewhere’ and therefore did not get
tested again:
“Yes, I wanted to do the test but my GP had already
sent me for extensive blood work because, lately, I
haven’t been feeling well. Then it turned out that
my blood had been tested for almost everything and
the results showed that my blood was okay.” (NT-3)
Reasons for intention to test among noncompliant
participants
Without explicit solicitation, the majority (11/15) of the
participants who did not comply with the test advice
expressed the intention to get tested in the future. One
reason was the ‘ease of testing’:
“Actually I assume that I’m not infected. That’s what
plays a role but, because it is that easy, I think, ‘Well
let’s then do it just to be sure’” (NT-6).
Another reason is the ‘anonymity of the testing service’
as illustrated by the following quote:
“Where I live - a small village - if you got to the
local care unit where blood is drawn, you see all
sorts of people you know. If you sit there, then
you’re either pregnant or you have some scary dis-
ease. Well for me, I don’t like that, so I’d prefer to
go to Amsterdam.” (NT-5).
Both of the above-mentioned reasons for intention to
test are comparable to reasons for testing mentioned by
the compliant participants.
Participants with the intention to test also mentioned
reasons related to the benefits of testing. Again, these
were identical to those mentioned by the compliant par-
ticipants. These were ‘preventing of liver disease’: “I
think everything is okay but there is a chance that I
have it. So then maybe it is just better to know and
maybe go through nasty treatment for a while so that I
don’t have complaints later on.” (NT-15); ‘curability of
HCV’: “Well if you read that if you’re infected, it is pos-
sible to get treated, then I think, ‘Well, maybe I should
find that out’” (NT-6); ‘seeking reassurance’: “Yes, I
intend to test just to know for sure that it’s not there”
(NT-13); and ‘preventing the further transmission of
HVC’: “Yes, well, I have four children so [...] I have
another responsibility too. If I were to get sick then I
could also infect my children” (NT-5).
Discussion
The purpose of this study was to gain a better under-
standing of, firstly, why some people who receive online
advice to test for HCV comply with that advice while
others do not and, secondly, the role of the online test-
ing procedures in compliance and noncompliance with
testing advice. Here, we discuss our findings in relation
to existing theory. We suggest methods and strategies to
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improve not only our online HCV screening project but
also other comparable projects that use online tools or
aim to encourage individuals to test for HCV.
We found that the autonomous nature of the testing
procedure (i.e. with this procedure, it is possible to
obtain information independently and to get the test
without having to discuss it with a GP) motivated indivi-
duals to go for testing. From the theoretical perspective
of the theory of planned behavior, the autonomous nat-
ure of the service increases perceived behavioral control
over the testing procedure as it removes constraining
conditions (e.g. having to discuss testing with a GP).
The autonomous nature of the service clearly illustrates
the added value of internet-based screening projects
complementary to existing prevention and screening
options. In future screening projects, the autonomous
nature of the testing procedure should to serve as the
strongest selling-point in communication about the
service.
Furthermore, we found that getting an HCV test was
also motivated by the fact that knowing one’s HCV sta-
tus can provide reassurance for those who test negative,
and can prevent liver disease and inhibit the further
transmission of HCV through the initiation of treatment
and precautionary measures for those who test positive.
Also, knowing that HCV is curable promotes testing.
From the perspective of the health belief model, these
reasons reflect the expected benefits of testing that can
be obtained from either a positive test result followed by
treatment and preventive measures or a negative test
result (reassurance). We suggest that screening projects
communicate not only the physical gains of testing posi-
tive but also the emotional benefits that testing negative
can potentially offer to especially individuals in low pre-
valence populations.
As expected, high perceived severity of HCV and high
perceived vulnerability to HCV motivated individuals to
seek testing. High perceived severity was based on
experiences with liver disease in the social environment,
where seeing significant others suffer from liver disease
increased the will to prevent the disease. High perceived
vulnerability was mainly based on the personal test
advice that was tailored to the individual’s risk profile.
The positive effect of tailored health information on
screening uptake has been demonstrated previously. For
example, Skinner et al. found that among groups with
low adherence to breast cancer screening (African
American and low-income women), a mammography
recommendation letter that was tailored to women’s
specific health belief model perceptions resulted in a
higher mammography adherence at follow-up compared
to those who received a nontailored version of the letter
[24]. Both perceived vulnerability and severity fit the
health belief model, in which especially high perceived
vulnerability is an important predictor of performing a
desired health behavior [17]. Among the participants in
our study, however, sometimes strong feelings of vulner-
ability were based on previously experiences or events
that do not carry any risk for acquiring HCV or on phy-
sical complaints unrelated to HCV. For these indivi-
duals, the project’s threatening information likely
created excessive worry that, in turn, motivated testing.
Although it was the project’s aim to motivate individuals
at risk for HCV to seek testing, this finding indicated
that presenting threatening information may also moti-
vate the ‘worried well’ to seek testing. We suggest that
HCV screening campaigns increase the perceived rele-
vance of testing for those at risk while also seeking to
mitigate the worried well response. This could be done
by presenting information about potential personal risk
for HCV together with information about the issues that
might cause individuals to needlessly worry about HCV
(e.g. risks related to other less severe infections).
Furthermore, we found that some individuals got
tested to gain a sense of accomplishment and a sense of
personal gratification from getting the test that could be
interpreted as an anticipated positive emotional reaction.
Others claimed to have a moral obligation to complete
their participation in the study, which appears to be a
form of altruism. Other studies have shown that altru-
ism can indeed motivate participation in research and
other projects [e.g. [25]]. Screening projects could use
the argument of anticipated gratification in persuasive
communication that seeks to enhance compliance with
test procedures (e.g. in a reminder message).
Reminder messages and the online planning tool were
indicated by some users as facilitative of testing. Remin-
der messages can be described best as cues to action.
They help individuals to recall their initial motivation
and rationale to test. The effect of reminders has been
demonstrated previously, for example by Sequist et al
[26], who showed that colorectal cancer screening rates
were higher for patients who received mailings com-
pared with those who did not, and DeFrank et al [27],
who showed that reminders were effective in promoting
repeat mammography adherence. In our project, we
used relatively simple reminder messages that simply
stated that individuals should seek testing. The impact
of these reminders could likely be improved by includ-
ing messages that play into the established reasons for
testing (e.g. the benefits of testing or the anticipated
gratification of finishing the testing procedure).
The online planning tool that was offered to indivi-
duals after their online risk assessment supported indivi-
duals to set their testing goal and to plan each step
toward that goal. This module assisted in closing the
gap between intention and behavior and its effect has
previously been demonstrated [28]. However, in our
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study, some individuals did not go for testing because
they mistook the online planning tool to be a real
appointment planner and, once the planned appoint-
ment was missed, they felt uncomfortable making a new
appointment. Alternatively, they thought that they could
only test at their initially chosen location and time. We
suggest that future online planning tools include a
clearer explanation of its self-regulating nature in order
to prevent the incorrect perception that the planning
tool is a real appointment planner. It would also be
advantageous to inform those who miss their planned
test date that it is possible to get the test at another
moment in time. In addition, online planning tools
could incorporate email or SMS reminder messages
that, for example, a day prior to the planned appoint-
ment, send a reminder message in which the personal
goal (i.e. getting tested at a particular date, location, and
time) is reiterated.
With respect to the reported reasons for not using the
online HCV testing service, we found that the lack of
obligatory procedures for testing and inconvenient test-
ing facilities impeded testing. Although these aspects
reflect the autonomous nature of the testing service,
which did motivate most individuals to seek testing,
some found these very same features to be barriers to
their use of the service. Individuals had to plan the
HCV testing appointment themselves and the online
service did not incorporate any procedures that produce
high commitment for testing (e.g. scheduling real
appointments). Moreover, the online testing procedure
unintentionally offered a cue for procrastination as it
explicitly indicated a lenient deadline for testing (i.e. a
maximum of 12 months). We suggest that online
screening projects in the future provide individuals with
a clearly defined and relatively tight deadline for testing.
We recommend a period of one month as the evalua-
tion study of the HCV internet project (data not pub-
lished) showed that most individuals were tested within
two weeks.
Furthermore, we found that low perceived urgency for
testing and treatment impeded testing for HCV. From
the perspective of the health belief model, this reason
reflects low perceived severity of HCV infection which
can lead to procrastination in testing. Although it is true
that, in most cases, HCV is not an acute life-threatening
disease that demands immediate treatment, individuals
cannot precisely know the degree to which their (poten-
tial) infection has progressed. We thus suggest that
future HCV screening projects emphasize this and seek
to deter the notion that HCV treatment can be easily
postponed. This could be done by outlining both the
negative consequences of postponing an HCV test and
the benefits of immediate testing and subsequent
treatment.
Additional reasons for noncompliance with HCV test
advice were that no symptoms were present and that the
risk was downplayed. These reflect low perceived vulner-
ability of HCV infection. The absence of symptoms as an
indication that no infection has occurred might be based
on a false belief that all HCV infections are accompanied
by physical symptoms. Interestingly, the information pro-
vided by the testing service did indicate that the majority
of HCV infections are asymptomatic. The fact that indivi-
duals mentioned these reasons for not testing despite the
provision of appropriate information and personalized
advice to seek testing may reflect unrealistic optimism,
which is an optimistic bias regarding personal vulnerabil-
ity to a health threat ["It won’t happen to me"; [29]].
With this in mind, we suggest the use of scenario-based
risk information that addresses doubts about personal
risks and the consequences of downplaying of risk. For
example, future efforts to promote compliance with test
advice could use the story of a HCV-infected peer who
was diagnosed late because he did not experience any
symptoms and thought that his chance of having
acquired HCV was small.
Although low perceived severity and vulnerability
(representing low perceived threat) can lead to procras-
tination or noncompliance with testing advice, we
should be careful with respect to increasing perceived
threat as we found that some individuals showed testing
avoidance because of a high perceived threat. For these
individuals, avoidance of threatening information and
fear of the consequences of a possible positive test result
impeded testing. As such, the advice to seek testing may
have resulted in a fear control reaction as described by
the extended parallel process model. According to this
model, high perceived threat in combination with low
perceived efficacy for testing can lead to maladaptive
responses such as denial of the message and message
avoidance. Therefore, screening projects should not only
seek to address personal risk and increase the perceived
health threat of HCV; they should also endeavor to
increase individuals’ perceived response and self efficacy
for managing a possible infection. In our project, we
informed individuals about the blood testing procedure
but we did not specifically mention the face-to-face
post-test counseling session with a trained professional
that always follows a positive test result. We, therefore,
recommend that screening projects provide more detail
on the procedures that follow a positive test result.
Online screening projects could also incorporate oppor-
tunities for an immediate online post-test counseling
session (e.g. via webcam) in addition to face-to-face
counseling. Furthermore, they could include an online
module that teaches individuals the necessary skills to
overcome their fear of a positive test result by, for
example, arranging support from family members.
Chapter 3
102
Some participants indicated that individuals in their
direct social environment discouraged them from testing
for HCV. According to the theory of planned behavior,
a strong negative subjective norm (i.e. others’ beliefs
regarding testing plus the motivation to comply with the
beliefs of others) can influence testing behavior. In order
to overcome social pressure not to test, screening pro-
jects can offer skill-building tools that help individuals
to negotiate or withstand discouragement from their
environment. Scenarios that offer counterarguments
against a discouraging partner or demonstrate how to
surpass social pressure and maintain the original testing
intention would be beneficial in this regard.
Some participants reported a malfunctioning compu-
ter or printer as a barrier to testing. In our project, indi-
viduals could have their laboratory form emailed to
them or they could download it onto their computer
but we did not actively offer individuals a solution to
printing problems. This technical problem could be
overcome in future screening projects by offering to
send the laboratory form by post or by having the
laboratory forms emailed to mobile phones or to the
laboratories directly.
Finally, competing events impeded testing. Most of the
reported competing events were very serious (e.g. hospi-
talization of a family member). Consequently, the low
prioritization of HCV testing by these participants
seems reasonable. Given this finding, we suggest that
future HCV screening projects incorporate a multiple
reminder system in which individuals are reminded of
testing not only a couple of days after their risk assess-
ment, as in our project, but also a couple of weeks later.
Although our study focused on reasons for compliance
and noncompliance with advice to test for HCV, some
noncompliant participants mentioned that they still
intended to test. These participants provided similar rea-
sons for testing as the advice-compliant participants.
This suggests that the reasons for testing and the rea-
sons for not testing may have played a role in both tes-
ters’ and non-testers’ decision-making. It would be
interesting to further investigate what discriminates
individuals who eventually test from those who do not.
It could be that testers encountered the impeding fac-
tors to a lower extent or that they overcame these fac-
tors better than non-testers. Quantitative studies in the
future could provide further insight regarding the pre-
sence and strength of the various reasons among both
groups and their relation to testing.
To our knowledge, this is the first study to explore
reasons for compliance and noncompliance with an
HCV test advice in the general population. Previous stu-
dies have been conducted among drug users [30-32]. In
these studies, some of the reasons for testing or not
testing for HCV were similar to those identified by our
study. For example, these studies also found that a moti-
vating factor is that the test enables avoidance of the GP
and an impeding factor is low perceived risk of being
infected. However, the drug users in these studies rarely
mentioned reasons for testing related to health benefits.
They also mentioned many dissimilar reasons for non-
compliance such as fear of needles, perceived lack of
confidentiality regarding test results, and fear of discri-
mination and stigmatization. This seems to suggest that
HCV testing projects targeting active drug users should
have a different focus (e.g. focus on issues relevant to
drug users’ lifestyles and competing problems) than
HCV testing projects targeting the general population.
Our study has a number of limitations. First, the parti-
cipants were individuals who had responded to a HCV
campaign, completed the online risk assessment ques-
tionnaire, and left their email address. Individuals who
did not respond to the campaign or who left the website
before completing the risk assessment questionnaire
were not invited to participate. This could generate a
selection bias whereby our study sample includes rela-
tively more individuals who were informed and com-
mitted to the service. Also, women and individuals of
Dutch origin dominated the study sample and not all
risk groups for HCV were represented (e.g. individuals
born to an HCV-positive mother). Future research
should focus on the reasons for (non-)participation of
these groups.
Conclusions
This study has shown that our online screening cam-
paign motivated individuals to test because the testing
service is autonomous, because tailored risk information
is provided, because a reminder message service is in
place, and because there is an online planning tool.
Furthermore, our study elicited a number of feasible
intervention targets to improve the uptake of HCV test-
ing in general. We suggest that HCV screening projects
include a deadline for testing and anticipate the
responses of individuals with low perceived risk for
HCV by, for example, raising awareness of personal risk
and outlining the consequences of not testing. Also,
projects could communicate the emotional benefits of
testing negative in addition to the physical gains of test-
ing positive. Furthermore, projects could provide addi-
tional insight regarding the procedures that follow a
positive test result. We propose that organizing an effec-
tive low threshold HCV testing procedure for the gen-
eral population could not have been successful without
the internet. Given its tailoring capabilities, flexibility,
and the relatively low costs, the internet is a promising
tool not only for arranging HCV testing but also for
motivating individuals to get tested by providing them
with advice based on a personal risk profile. In addition,
Risk-based and Internet-based screening for hepatitis C
3
103
we believe that the anonymous character of the internet
and subsequent testing procedures are especially helpful
for addressing stigmatized diseases like HCV.
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Abstract 
Background: Egypt has high prevalence of hepatitis C virus (HCV) infection and intermediate 
prevalence of hepatitis B virus (HBV) infection; however, infection prevalence among Egyptian 
migrants is unknown. Considering the asymptomatic onset and development of disease in 
chronically-infected patients, many may remain undiagnosed.
Aims: To evaluate a screening programme designed to identify undetected HCV and HBV infections 
among first-generation Egyptian migrants in Amsterdam, the Netherlands. 
Methods: In 2009 and 2010, viral hepatitis educational and screening sessions were established at 
Egyptian meeting places. Data regarding demographics and risk factors for HCV infection were 
collected. Chronically infected participants were referred and followed up. Phylogenetic analyses 
were used to ascertain the geographic origin of infections.
Results: Eleven of 465 (2.4%; 95%CI=1.3-4.2%) migrants had anti-HCV antibodies; 10/11 were 
HCV RNA positive. All had HCV genotype 4a infection, and strains were typical of those of Egypt 
and the Middle East. Older age and exposure to parenteral antischistosomal therapy (PAT) were 
significantly associated with HCV infection. Anti-HBc prevalence was 16.8% (95%CI=13.7-20.4%); 
HBsAg prevalence was 1.1% (95%CI=0.5-2.5%). All had HBV genotype D infection, typical of 
those of the Middle East. Most (9/10 HCV; 3/5 HBV) chronic infections were newly diagnosed; four 
of the HCV-infected individuals started treatment. 
Conclusions: Anti-HCV and HBsAg infection prevalence among Egyptian migrants was lower 
compared with the general Egyptian population, but higher than the general population of Western 
countries. Phylogenetic analyses suggest that all infections were from the region of origin. Screening 
programmes for HCV infection should target first-generation Egyptian migrants, especially those of 
older age and those who received PAT, and include screening for HBV infection. 
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Introduction
Infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) affect an estimated 2 billion (1) 
and 123 million (2) people worldwide, respectively. The majority of HCV infections and the minority 
of HBV infections progress to chronic infection, placing the patient at risk for the development 
of cirrhosis, liver cancer, and death. Three quarters of liver cancers worldwide are attributed to 
chronic HBV and HCV infections (3). Because of their asymptomatic course, chronic HBV and HCV 
infections often go undetected and infection may be identified long after exposure.
The country with the highest estimated prevalence of HCV infection worldwide is Egypt. Because of 
the use of contaminated injection material in large-scale parenteral antischistosomal therapy (PAT) 
campaigns from the 1920s to the 1980s, nearly 15% of the general Egyptian population has been 
infected (4). In contrast, in the general population of the United States and many Western European 
countries, the HCV antibody prevalence, even in urban areas with a diverse population, is estimated 
below 2% (5-8). The use of contaminated injection material in PAT campaigns probably also lead to 
an increase in the reservoir for HBV infection in the general Egyptian population (9), and the HBsAg 
prevalence has been estimated at 2 to 7% (10).
Starting in the 1960s, political, economic, and social developments led Egyptians to migrate to the 
Arab Gulf, Europe, and North America. According to Egyptian government statistics, 2.7 million 
Egyptians live abroad; 1.9 million in the Arab Gulf, 430 thousand in North America, and nearly 
400 thousand in Western Europe (11). Little is known, however, about the prevalence of HCV and 
HBV infections among Egyptian migrants living in high-income countries. Considering the fact 
that the PAT campaigns started long before the 1960s and subsequent migration, an appreciable 
number of Egyptian migrants may be infected with HCV. Many who have been infected may remain 
undiagnosed, since the onset of HCV infection and disease progression often are asymptomatic. 
Treatment options for chronic HCV infection have improved substantially over recent years (12). 
Thus, the identification of HCV- and HBV-infected Egyptian migrants can significantly improve 
prognosis, reduce disease morbidity and mortality, and prevent further transmission. 
In 2009 and 2010, a community-based screening programme for first-generation Egyptian migrants 
was established in Amsterdam, the Netherlands, to identify those who were infected with HCV, to 
refer them for care, and to investigate the prevalence and determinants of HCV infection. Since 
treatment options for chronic HBV infection have improved (13), and Egyptians are at increased risk, 
the programme also included screening for HBV infection. Phylogenetic analyses were used to 
investigate the origin of HCV and HBV infections in Egyptian migrants. The study results aimed to 
inform future screening policies for HCV and HBV infections in migrants.
Materials and methods
Recruitment
An estimated 20,000 Egyptians have migrated to the Netherlands (14), of whom approximately 3,200 
are 18 years of age and older and live in the region of Amsterdam (15). In 2009, we searched the internet 
for Egyptian organizations in the greater Amsterdam area, and contacted all identified organizations: 
a Coptic church, two Islamic mosques, an Egyptian women’s empowerment organization, an 
Egyptian trade organization, a weekend school for Islamic Egyptians, and an Egyptian supermarket. 
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From September 2009 until September 2010, with the support of key figures within these organizations 
(e.g., the imam, priest, chairperson, owner of the supermarket), we organized 11 viral hepatitis 
educational and screening sessions, usually planned after regular meetings of each organization. The 
key figures distributed invitations for the sessions to their members/customers using our promotion 
flyers. We distributed approximately 1500 flyers to the community organizations. These flyers 
informed about transmission routes and risk factors for hepatitis A (HAV), B and C infections, 
vaccination against HBV infection, the consequences of unrecognized HBV and HCV infections, the 
fact that screening was free of cost during this campaign for those born in Egypt, and the availability 
of treatment. For customers of the Egyptian supermarket, the session was organized at the local 
public health service. Egyptians who were unable to attend a session were invited to visit the Public 
Health Service of Amsterdam for screening by appointment. The medical ethics committee of the 
Academic Medical Center, Amsterdam, decided that the project did not require IRB approval.
Screening procedure
The educational sessions were held in standard Arabic by Arab educators who were trained on the 
subject of viral hepatitis. They addressed the risk, transmission routes, prevention, consequences, 
and treatment options for chronic HBV and HCV infections. After the session, all adults (18 years 
and older) were offered screening for HBV and HCV infections. Those who opted for screening 
were given an information package, available in Dutch and Arabic, including information on the 
project, an informed consent, and a questionnaire on risk factors for HCV infection. Filling out 
the questionnaire was optional. After reading the information and filling out the forms, trained 
healthcare workers performed venipuncture to collect blood. Blood specimens were transported to 
and processed in the laboratory of the Public Health Service of Amsterdam.
Laboratory testing
HCV serological testing was done by third-generation commercial microparticle EIA system 
(AxSym HCV version 3.0; Abbott) and confirmed by recombinant immunoblot assay (Chiron RIBA 
HCV 3.0 SIA, Ortho-Clinical Diagnostics). Samples positive for anti-HCV were further tested for 
HCV RNA by transcription-mediated amplification (TMA; Versant®, Siemens). For HBV, the blood 
samples were first tested for anti-HBc using microparticle enzyme immunoassay (AxSYM CORE 
TM, Abbott). When positive or indeterminate, HBsAg was determined (AxSYM HBsAg version 
2.0, Abbott, confirmed with a neutralization test [miniVidas, Biomerieux]).
Sequencing and phylogenetic analyses 
HCV RNA and HBV DNA in the samples that tested positive for HCV RNA and HBsAg, respectively, 
was isolated, amplified, and sequenced, using an in-house PCR as described previously (16;17). HCV 
and HBV sequence data have been deposited in the GenBank sequence database under accession 
numbers JN564679-JN564688, and JX489382-JX489386, respectively. The viral genotypes for 
HCV and HBV infection were determined after phylogenetic analysis of the sequences obtained, 
along with established GenBank reference sequences (18). 
Phylogenetic comparisons for the HCV and HBV sequences was made as previously described 
by Van de Laar et al. (19) and  Van Houdt et al. (17), respectively. The HCV sequences of Egyptian 
migrants from this study were compared to those obtained from HCV genotype 4-infected patients 
previously diagnosed in the Netherlands including Egyptian migrants and injecting drug users (19-21), 
as well as to sequences from HCV genotype 4-infected drug users and patients originating from the 
Middle East that were obtained from the Los Alamos database (22). The HBV sequences of Egyptian 
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migrants from this study were compared to those obtained from drug users, men who have sex with 
men, and reported cases of acute HBV infection including migrants from the Middle East who were 
diagnosed in the Netherlands (17;23;24).
Follow-up procedure
Participants who tested negative or had cleared their infection received their test results within 3 
weeks by postal mail. Those found to be chronically infected with HBV and/or HCV were sent a 
letter requesting them to call the Public Health Service so that they could be orally informed of their 
test results. Those chronically infected with HCV were invited for a consultation with a visiting 
hepatologist at the Public Health Service of Amsterdam, at which the test results and possible 
treatment options were discussed, and referral to a hospital was arranged. Those chronically infected 
with HBV were referred to their general practitioner (GP) for further diagnostics. In addition, in 
accordance with the Dutch Public Health Act, the department of infectious diseases of the public 
health service in a patient’s home town was notified, a contact tracing procedure was initiated, and 
susceptible contacts were vaccinated. Participants who tested anti-HBc negative were advised to 
get vaccinated against HBV  infection when travelling to Egypt. The GPs of all participants were 
informed about the test results. 
Measures
Questionnaire  
The questionnaire that was given to those who opted for screening consisted of questions addressing 
the following risk factors for HCV infection: schistosomiasis treatment with injections and/or pills; 
blood transfusions; surgical operations; injections; dental surgery; hemophilia; hemodialysis; organ 
donors; hospitalizations; circumcision; hijamas (i.e., a traditional Arab treatment, in which blood 
is drawn by vacuum from a small skin incision); acupuncture treatment; needle stick incidents; 
non-injection drug use; injection drug use; tattoos; piercings; and whether participants had family 
members with HCV infection. For all risk factors except having HCV-infected family members, 
we asked the calendar year and country in which the risk factor occurred. Furthermore, the 
questionnaire also collected data on sociodemographics (age, gender, educational level, marital 
status, profession), migration history (country of birth, country of birth of both parents, former place 
of residence in Egypt, total length of stay in Egypt, calendar year of migration to the Netherlands), 
vaccination against HBV infection, and any previous test results for HBV and HCV infection. Data 
regarding religious background were collected to be able to characterize the study population and 
assess whether the population would be representative for the population of Egypt. The religious 
background was assumed afterwards on the basis of the location of recruitment (i.e., those who were 
screened at mosques or weekend school were considered Islamic; those who were screened at the 
Coptic church were considered Christian. Those who were screened at the Public Health Service 
were asked to state their religion. A native Arabic medical student translated the Arabic answers on 
open questions from the questionnaires.
Clinical outcomes
At least one year after data collection, we evaluated whether or not participants with a chronic HBV 
or HCV infection were followed-up in care. With informed consent from these patients, clinical 
follow-up data were collected from the GP or hepatologist: the outcomes of ultrasound, fibroscan 
and/or liver biopsy (if performed); and treatment eligibility, initiation, and outcomes. Outcomes of 
fibroscan and/or liver biopsy were reported using the METAVIR system for fibrosis assessment (F0: 
no fibrosis, F1: portal fibrosis without septa, F2: few septa, F3: numerous septa without cirrhosis, 
F4: cirrhosis) (25). 
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In addition, participants were asked to complete a short questionnaire that evaluated prevention 
measures that resulted from diagnosis: reduction/cessation of alcohol intake; and knowledge of 
transmission routes and precautionary measures against further transmission.
Statistical analyses
Descriptive analyses were used to describe the characteristics of the participants. Prevalence of 
anti-HBc, HBsAg, anti-HCV and HCV RNA and corresponding 95% confidence intervals (CI) were 
calculated. Participants with indeterminate HCV antibody test results (EIA and RIBA indeterminate) 
who were HCV RNA negative were considered HCV antibody-negative. CI around prevalence 
were calculated via the Wilson method, using the binom package in the R statistical computing 
environment (26;27). Using logistic regression analyses, we examined determinants of testing anti-
HCV positive. Variables evaluated included socio-demographic variables, and the previously 
mentioned risk factors. Former place of residence in Egypt was categorized in geographic regions 
following Frank et al (9). The region of longest residence was chosen if a participant had lived in 
more than one region. Variables with a p-value of ≤0.10 in univariate analyses were considered for 
entry in the multivariable logistic regression model. A stepwise backward selection procedure was 
used in the multivariable logistic regression model. A p-value of ≤0.05 was considered statistically 
significant. Odds ratios (OR) and CI in a table with one zero cell count were calculated via penalized 
logistic regression using the logistf package in R (27;28). Otherwise, logistic regression in SPSS for 
Windows (SPSS version 17.0, SPSS Inc., Chicago) was used. 
Results
Characteristics of participants
In total, 527 individuals were screened of which 465 were born in Egypt (see Figure 1). Those who 
were not born in Egypt (n=47; most were born in the Netherlands) and those for whom the country 
of birth was unknown (n=15) were excluded from the analyses. All of the 62 excluded individuals 
tested anti-HCV negative; six were anti-HBc positive, and all were HBsAg negative.
Of the 465 first-generation Egyptian migrants, median age was 43 years (IQR=36–49 years), and 
57.4% (267/465) were male. The majority (58.3%, 271/465) was highly educated. Most participants 
were assumed Christian (69.2%, 322/465) and 30.8% (143/465) were assumed Muslim. The median 
year of migration to the Netherlands was 1995 (IQR=1988-2001); the median number of years 
in which participants had lived in Egypt was 25 (IQR=22-28 years). Most participants originated 
from Cairo (34.8%; 162/465); 12.7% (59/465) originated from Alexandria; 12.7% (59/465) from 
lower Egypt; 14.2% (66/465) from middle Egypt; 10.1% (47/465) from upper Egypt, and for 15.5% 
(72/465) the region of origin was unknown.
Prevalence of HCV and HBV infections
Prevalence of anti-HCV was 2.4% (11/465; 95%CI=1.3-4.2%). HCV RNA was detected in 2.2% 
(10/465; 95%CI=1.2-3.9%), of whom one individual was already aware of his chronic infection. 
Anti-HBc prevalence was 16.8% (78/465; 95%CI=13.7-20.4%). Five participants were chronic 
HBV carriers (HBsAg positive; 5/465; 1.1% [95%CI=0.5-2.5%]), of which two were already aware 
of their infection. No participants were co-infected with HBV and HCV. Because of the small 
numbers, no analyses were performed to identify determinants of testing HBsAg positive. 
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Determinants of HCV infection
In univariate analyses, older age, being widowed or divorced, anti-HBc-positive status, and exposure 
to PAT were significantly associated with being anti-HCV-positive (see table 1a). In multivariable 
analysis, older age and exposure to PAT remained significantly associated with HCV. Those who were 
exposed to PAT were at increased risk for HCV infection (OR=9.2, 95%CI=2.5-32.5) compared with 
those not exposed, and those who were born before 1960 were at increased risk for HCV infection 
(OR=4.6, 95%CI=1.1-26.7) compared with those born in 1970 or later, whereas the OR was 1.2 
(95%CI=0.2-7.4) for those born between 1960 and 1969 (see table 1b).
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Figure 1. Overview of the recruitment procedures and clinical outcomes in a community-based screening programme for 
first-generation Egyptian migrants living in the region of Amsterdam in 2009-2010
±1500 flyers were 
sent to community 
organizations for 
further distribution
465/1500 (31.0%) 
persons born in 
Egypt were 
screened
62/1500 (4.1%) persons were 
screened but excluded from 
the analyses:
- 47 not born in Egypt
- 15 unknown country of birth
11/465 (2.4%) 
anti-HCV positive
10/465 (2.2%) HCV 
RNA positive
(9 newly diagnosed)
4/10 (40%) started 
tre tment
78/465 (16.8%) 
anti-HBc positive
5/465 (1.1%) HBsAg 
positive
(3 newly diagnosed)
2/4 (50%) 
treatment 
discontinued
1/4 (25%) 
treatment 
ongoing
1/4 (25%) 
SVR
4/10
Metavir 
F0-1 or 
“good”
1/10 
Metavir 
F2-3
2/10
Metavir 
unknown
2/10 
Metavir 
F4
1/10 
Metavir 
F3
2/3
not indicated 
for treatment
1/3
indicated for 
treatment
2/5 lost to
follow-up
1/3 (33%) started 
treatment
1/1 (100%) 
treatment 
discontinued
Chapter 4
114
Table 1a: Univariate logistic regression analyses of factors associated with testing hepatitis C 
virus (HCV) antibody positive among 465 Egyptian migrants participating in a community-
based screening programme in the region of Amsterdam, the Netherlands, 2009-2010.
HCV-antibody 
Negative (n=454)
N             (%)
HCV-antibody 
Positive (n=11)
    N (%)
Univariate
OR 
(95% CI)
Socio-demographic variables
Gender 
 Male
 Female
 Unknown (missing) 
259 (57.1)
194 (42.7)
    1 (0.2) 
8 (72.7)
3 (27.3)
0 
1
0.5 (0.1-1.9)
Education level
 Low 
 Medium
 High 
 Unknown (missing) 
  73 (16.1)
105  (23.1)
263  (57.9)
  13  (2.9) 
2 (18.2)
1 (9.1)
8 (72.7)
0 
1
0.35 (0.0-3.9)
1.11 (0.2-5.3)
Calendar year of birth
 ≥ 1970
 1960 - 1969
 < 1960
 Unknown 
199 (43.8)
179 (39.4)
  74  (16.3)
    2  (0.4) 
2 (18.2)
 (27.3)
6 (54.5)
0  
1**
1.6 (0.3-9.4)
7.0 (1.7-38.6)
Marital status
 Married or never married
 Widowed or divorced
 Unknown (missing) 
425 (93.6)
  28  (6.2)
    1 (0.2) 
8 (72.7)
3 (27.3)
0
1**
5.7 (1.4-22.6)
Region of origin in Egypt
 Alexandria
 Cairo
 Upper Egypt
 Middle Egypt
 Lower Egypt
 Unknown (missing) 
  57  (12.6)
159 (35.0)
  46  (10.1)
  65  (14.3)
  56  (12.3)
  71  (15.6)
2 (18.2)
3 (27.3
1 (9.1)
1 (9.1)
3 (27.3)
1 (9.1)
1
0.5 (0.09-3.3)
0.6 (0.05-7.0)
0.4 (0.04-5.0)
1.5 (0.2-9.5)
0.4 (0.04-4.5)
Living years in Egypt
 1-10 years
 11-20 years
 21-30 years
 More than 30 years
 Unknown (missing)
    6  (1.3)
  45  (9.9)
342  (75.3)
  53  (11.7)
    8  (1.8)
0
0
9 (81.8)
2 (18.2)
0
1
0.1 (0.0-27.5)
0.4 (0.0-48.3)
0.6 (0.0-87.4)
Calendar year of arrival in the 
Netherlands
 Before 1989
 1989-1995
 1996-2001
 2002 or later
 Unknown (missing)
110  (24.2)
118  (26.0)
112  (24.7)
104  (22.9)
  10  (2.2)
5 (45.5)
3 (27.3)
3 (27.3)
0
0
1
0.6 (0.1-2.3)
0.6 (0.1-2.4)
0.1 (0.0-0.9)
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Table 1a, continued 
Potential HCV risk factors 
HCV-antibody 
Negative (n=454)
    N (%)
HCV-antibody 
Positive (n=11)
    N (%)
Univariate
OR 
(95% CI)
Exposure to parenteral 
antischistosomal therapy (PAT) 
 No / Don’t know 
 Yes
 Unknown (missing)
419  (92.3)
  27  (5.9)
    8  (1.8)
6  (54.5)
5  (45.5)
0 
1 **
12.9 (3.7-43.3)
AntiHBc status
 Negative
 Positive 
380  (83.7)
  74  (16.3) 
7  (63.6)
4  (36.4)
1*
2.9 (0.8-10.3)
Injecting drug use (IDU)
 No
 Yes
 Unknown (missing)
421  (92.7)
    1  (0.2)
  32 (7.0)
11  (100)
0
0
1
12.2 (0.1-242.3)
0.6 (0.0-4.5)
HCV infected mother
 No 
 Yes
443  (97.6)
  11  (2.4)
11  (100)
0
1
1.7 (0.0-14.4)
HCV infection in social environment 
(not mother)
 No 
 Yes
326  (71.8)
128  (28.2) 
6 (54.5)
5  (45.5)
1
2.1 (0.6-7.1)
Blood transfusion
 No / Yes, not in Egypt a
 Yes, location Egypt
 Yes, location unknown
 Unknown (missing)
398  (87.7)
  11  (2.4)
  13  (2.9)
  32 (7.0) 
10  (90.9)
0
1  (9.1)
0
1
1.7 (0.0-14.3)
4.2 (0.4-20.2)
0.6 (0.0-4.7) 
Hospital operation
 No / Yes, not in Egypt a
 Yes, location Egypt
 Yes, location unknown
 Unknown (missing)
274  (60.4)
  84  (18.5)
  63  (13.9)
  33 (7.3)
7  (63.6)
2  (18.2)
2  (18.2)
0
1
1.1 (0.2-4.1)
1.4 (0.3-5.6)
0.5 (0.0-4.7)
Medical injections
 No / Yes, not in Egypt a
 Yes, location Egypt
 Yes, location unknown
 Unknown (missing)
172  (37.9)
109  (24.0)
112  (24.7)
  61 (13.4)
3  (27.3)
3 (27.3)
5 (45.5)
0
1
1.6 (0.3-7.6)
2.4 (0.6-10.6)
0.4 (0.0-4.2)
Dentist
 No / Yes, not in Egypt a
 Yes, location Egypt
 Yes, location unknown
 Unknown (missing)
239  (52.6)
  84  (18.5)
105  (23.1)
  26 (5.7)
4  (36.4)
5  (45.5)
2  (18.2)
0
1
3.5 (1.0-13.2)
1.3 (0.2-5.8)
1.0 (0.0-9.8)
Haemophilia treatment
 No 
 Yes, location Egypt
 Yes, location unknown
 Unknown (missing)
401  (88.3)
    1  (0.2)
    3  (0.7)
  49 (10.8)
10  (90.9)
0
0
1  (9.1)
1
12.7 (0.1-254.2)
5.5 (0.0-61.9)
1.2 (0.1-5.1)
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Table 1a, continued 
Potential HCV risk factors 
HCV-antibody 
Negative (n=454)
    N (%)
HCV-antibody 
Positive (n=11)
    N (%)
Univariate
OR 
(95% CI)
Haemodialysis
 No
 Yes, location Egypt
 Yes, location unknown
 Unknown (missing)
420  (92.5)
    0
    1  (0.2)
  33 (7.3)
11  (100)
0
0
0
1
12.2 (0.1-241.7)
0.5 (0.0-4.4) 
Hospitalization
 No / Yes, not in Egypt a
 Yes, location Egypt
 Yes, location unknown
 Unknown (missing)
317  (69.8)
  36  (7.9)
  63  (13.9)
  38 (8.4)
7  (63.6)
2  (18.2)
2  (18.2)
0
1
2.9 (0.5-11.4)
1.7 (0.3-6.4)
0.5 (0.0-4.7)
Circumcision
 No / Yes, not in Egypt a
 Yes, location Egypt
 Yes, location unknown
 Unknown (missing)
121  (26.7)
141  (31.1)
161  (35.5)
  31 (6.8)
3  (27.3)
5  (45.5)
3  (27.3)
0
1
1.3 (0.4-5.9)
0.8 (0.2-3.6)
0.6 (0.0-5.9)
Hijama
 No / Yes, not in Egypt a
 Yes, location Egypt
 Yes, location unknown
 Unknown (missing)
392  (86.3)
    5  (1.1)
    4  (0.9)
  53 (11.7)
11  (100)
0
0
0
1
3.1 (0.0-30.2)
3.8 (0.0-39.0)
0.3 (0.0-2.5)
Acupuncture 
 No / Yes, not in Egypt a
 Yes, location Egypt
 Yes, location unknown
 Unknown (missing)
401  (88.3)
    3  (0.7)
  13  (2.9)
  37 (8.1)
10  (90.9)
0
1  (9.1)
0
1
5.5 (0.0-61.9)
4.2 (0.4-20.3)
0.5 (0.0-4.1)
Needle stick injury
 No / Yes, not in Egypt a
 Yes, location Egypt
 Yes, location unknown
 Unknown (missing)
386  (85.0)
    6  (1.3)
  18  (4.0)
  44 (9.7)
11  (100)
0
0
0
1
2.6 (0.0-24.2)
0.9 (0.0-7.5)
0.4 (0.0-3.0)
Drugs usage
 No 
 Yes, location Egypt
 Yes, location unknown
 Unknown (missing)
415  (91.4)
    1  (0.2)
    7  (1.5)
  31 (6.8)
11  (100)
0
0
0
1
12.0 (0.1-238.8)
2.4 (0.0-22.0)
0.6 (0.0-4.6) 
Tattoo
 No / Yes, not in Egypt a
 Yes, location Egypt
 Yes, location unknown
 Unknown (missing)
284  (62.6)
  59  (13.0)
  78 (17.2)
  33 (7.3)
9  (81.8)
0
2  (18.2)
0
1
0.3 (0.0-2.0)
1.0 (0.2-3.5)
0.4 (0.0-3.7)
Piercing
 No 
 Yes, location Egypt
 Yes, location unknown
 Unknown (missing)
385  (84.8)
    3  (0.7)
    9  (2.0)
  57 (12.6)
11  (100)
0
0
0
1
4.8 (0.0-53.9)
1.8 (0.0-15.5)
0.3 (0.0-2.3)
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Table 1a, continued 
Potential HCV risk factors 
HCV-antibody 
Negative (n=454)
    N (%)
HCV-antibody 
Positive (n=11)
    N (%)
Univariate
OR 
(95% CI)
Other blood contact
 No / Yes, not in Egypt a
 Yes, location Egypt
 Yes, location unknown
 Unknown (missing)
376  (82.8)
    2  (0.4)
  10  (2.2)
  66 (14.5)
11  (100)
0
0
0
1
6.5 (0.0-86.8)
1.6 (0.0-13.5)
0.2 (0.0-1.9) 
Note. CI=confidence interval; *overall p-value ≤0.1 **overall p-value <0.05.
a Combined with the ‘no’-category because only a small number of individuals experienced these risk 
factors outside of Egypt. Of those who did, most experienced them in high-income countries (mostly 
the Netherlands); one person had medical injections in Libya, one person had dental treatment in 
Kuwait, and one in Jordan.
Table 1b: Multivariable logistic regression analysis of factors associated with testing hepatitis C virus (HCV) 
antibody positive among 465 Egyptian migrants participating in a community-based screening programme in 
the region of Amsterdam, the Netherlands, 2009-2010.
Multivariable 
Adjusted OR (95% CI)
Calendar year of birth
≥ 1970
1960 - 1969
< 1960
1**
1.2 (0.2-7.4)
4.6 (1.1-26.7)
Exposure to parenteral antischistosomal therapy (PAT) 
No / Don’t know
Yes
1**
9.2 (2.5-32.5)
Note. CI=confidence interval; **overall p-value <0.05
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Genotyping and phylogenetic analyses
Sequences of the HCV-NS5B fragment were successfully obtained from all 10 HCV RNA-
positive Egyptian migrants. All isolates were HCV genotype 4a. The obtained sequences, together 
with strains from other HCV genotype 4a -infected patients, were used for phylogenetic analysis. 
The analysis showed two epidemiological profiles. One profile consisted mainly of strains obtained 
from patients descending from Egypt and the Middle East; the other consisted of mainly Dutch 
IDU (the latter in bold; Figure 2). Although receiving little bootstrap support in this analysis, these 
two epidemiological profiles are considered to be distinct according to earlier detailed phylogenetic 
analysis, performed on combined NS5B fragments from HCV genotype 4-infected patients (20). 
Sequences obtained from our study participants (n=10) all fitted within the first epidemiological 
profile, indicating that they are likely to have been infected with HCV in Egypt.
Amplification and sequencing of the S-region succeeded in all five HBsAg positive Egyptian 
migrants. All isolates were HBV genotype D. Phylogenetic analysis showed a high degree of 
phylogenetic clustering with HBV strains obtained from patients originating from the Middle East, 
and the analysis proved there was no link to other risk groups, like men who have sex with men and 
drug users (figure not shown). 
Clinical outcomes
Seven out of ten HCV-infected participants gave informed consent for obtaining medical follow-
up data; three self-reported data. Of those five who were infected with HBV, three gave informed 
consent, and two were lost to follow-up. Table 2 shows an overview of the clinical follow-up data 
for both HCV- and HBV-infected participants. In total, four of the ten HCV-infected participants 
started treatment; two discontinued, for one treatment is ongoing, and one successfully completed 
12 months of treatment. However, follow-up was too short to determine sustained virologic response 
to treatment. For HBV infection, one of the three patients for whom data was available started 
treatment, but discontinued due to side effects.
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Figure 2. Neighbor-joining tree based on the Tamura-Nei substitution model with γ-distribution (α=0.40). Phylogenetic 
analysis included HCV NS5B sequences of first-generation Egyptian migrants (n=10) identified in a community-based 
screening programme in Amsterdam in 2009-2010, and previously identified cases with genotype 4a  HCV infection among 
various risk groups. Bootstrap values higher than 70 are shown (n=1000). Labels show the country of sampling, year of 
sampling, and GenBank accession number, or the study participation number (EG***). Black dots: study participants; open 
dots: previously diagnosed patients from Egypt; open squares: previously diagnosed patients from Iraq, Greece, Saudi-
Arabia; black triangles: injecting drug users.
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Discussion
This community-based screening programme in the Netherlands demonstrated that screening of 
first-generation Egyptian migrants results in the identification of previously undetected HCV and 
HBV infections. Exposure to PAT and older age were strongly associated with anti-HCV-positive 
status. Furthermore, phylogenetic analyses showed that all HCV and HBV infections clustered with 
strains originating from Egypt and the Middle East, suggesting that infections were acquired in 
Egypt before migration to the Netherlands. 
Although the anti-HCV and HBsAg prevalence among the Egyptian migrants (2.4% and 1.1%, 
respectively) is relatively high compared with the prevalence among the general Dutch population 
(0.3% (8) and 0.3-0.5%(29), respectively), it is much lower than the estimated prevalence in Egypt. 
This is in line with several studies in diverse migrant populations; lower prevalence than in the 
country of origin was found in a community-based screening programme for HCV and HBV 
infections among South Asian migrants in England (30), in a study among inhabitants of a multi-
ethnic neighbourhood in the Netherlands (31), and in a prevalence study for HCV infection including 
migrants from Morocco, Surinam and Turkey in the Netherlands (32). In a screening programme 
among first-generation Turkish migrants in the Netherlands, the HBsAg prevalence was in the lower 
range (3%) of the estimated prevalence in the general population in Turkey (2-8%) (33).
There are several potential explanations for the relatively low prevalence in comparison with the 
estimations from the country of origin. Migrants have a shorter exposure period to risk factors for 
viral hepatitis in the home country than those who remain. In our study, the median number of living 
years in Egypt was 25 years. In addition, migrants may represent a selected healthier group, often 
referred to as the ‘healthy migrant hypothesis’. Although migration is dependent on multiple factors, 
this may also account for our study population, as almost half of them originated from regions of 
relatively low prevalence of HCV infection (Cairo and Alexandria) (9). Another potential explanation 
has been described as the salmon bias hypothesis, according to which migrants who retire or suffer 
from disease are likely to return to their country of origin (34). Finally, the study design may also 
have influenced the prevalence findings, since a community-based screening does not attract those 
who are already aware of their infection. On the other hand, people with increased exposure to risk 
factors for HCV or HBV infection, and those experiencing physical symptoms may be more likely 
to participate.
Given the relatively high educational level, the majority originating from Cairo and Alexandria, 
and the high proportion of Copts (69.2%), our study population is not representative of the general 
Egyptian population. The key question is whether our results can be generalized to the Egyptian 
migrant population. According to Egyptian migrant statistics, the Egyptian migrant population is 
highly educated; 77% who migrate to the United States and other OECD (Organisation for Economic 
Cooperation and Development) countries have tertiary education (35). Furthermore, 37% of migrants 
from urban areas including Cairo and Alexandria moved to non-Arab countries compared with 
10% or less for other Egyptian regions (36), possibly explaining the greater proportion of migrants 
from Cairo and Alexandria in our study. Limited data are available on the proportion of Copts 
among Egyptians that migrated, but one report suggests that Egyptian migrants to Australia are 
mostly Copts (37). In addition, various websites (e.g., http://immigration-online.org/93-egyptian-
immigration.html) suggest that Copts make up a large proportion of Egyptian migrants to non-Arab 
countries. Altogether, our study population may be well representative of Egyptian migrants living 
in non-Arab, high-income countries.
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Our study showed that PAT exposure was strongly associated with anti-HCV-positive status, and 
those born before 1960 were at increased risk for HCV infection. The association between PAT 
and HCV infection has been described before (9). The fact that older age was associated with HCV 
infection can be explained by the fact that these older people have had more lifetime exposure to 
risks for acquiring HCV infection. In addition, the hygienic standards of their childhood health 
care were likely lower compared with those born later, facilitating transmission of HCV infection. 
We did not identify any iatrogenic risk factors other than PAT to be significantly associated with 
anti-HCV positive status. However, six participants had antibodies to HCV but were not exposed 
to PAT. Recent publications suggest that iatrogenic transmission of HCV still occurs in Egypt (38;39). 
In our study we found non-significant OR greater than 1 for some of the iatrogenic risk factors. The 
absence of statistically significant associations may be due to a lack of power.
Phylogenetic analysis suggests that the HBV infections that were identified in this study were 
acquired in Egypt. However, sexual transmission in the Netherlands from an Egypt-born partner 
is also a likely route for HBV transmission. We could not investigate this since data on sexual risk 
behaviour were not collected.
Community-based outreach screening can be an effective means of screening the Egyptian migrant 
population for HCV and HBV infection and for referral to care. We screened 14.5% (465/3,200) of 
first-generation Egyptian migrants aged 18 years or older living in the Amsterdam region, and we 
estimated the acceptance rate for screening at 31.0% (465/1500), assuming that each of the 1500 
distributed flyers could result in one participant. These figures may be underestimated since some 
Egyptians may have been screened already because HCV infection is a well-known problem in 
Egypt. In comparison, other community-based screening programmes for HCV and/or HBV infection 
targeting migrants in the Netherlands have demonstrated screening rates varying from 13.0% (40) to 
28.4% (41). The majority of the identified Egyptian patients in our study visited a GP or hepatologist. 
The total costs for the screening programme were estimated at €49,500, including staff, laboratory 
costs, and recruitment costs. Related to the outcomes, it represents €106 (€49,500/465) per screened 
Egyptian, €3300 (€49,500/15) per person identified with a chronic HBV or HCV infection and 
€4125 (€49,500/12) per person newly identified with a chronic HBV of HCV infection. Treatment 
success was limited. For HCV, only one person successfully completed treatment within the study 
period. Previous cost-effectiveness analyses evaluating screening for HCV infection in populations 
with a similar prevalence and similar screening uptake rates as in our study were favourable (42;43). 
However, Egyptians are predominantly infected with HCV genotype 4, which is a difficult to treat 
genotype. Therefore, a cost-effectiveness analysis of screening for HCV infection in the Egyptian 
population is needed to inform and underpin screening recommendations for this population. Such 
an analysis should include the scenario of simultaneous screening for HBV infection. Since the 
HBsAg prevalence in our population is relatively low (i.e., substantially lower [1.1%] than the 
lowest prevalence estimate that was used in a modelling study that showed that screening for 
HBV infection among migrants in the Netherlands is cost-effective [2.2%] (44)), screening for HBV 
infection only in first-generation Egyptian migrants may not be cost-effective compared with no 
screening. However, screening for HBV infection can be added at relatively low extra cost when 
screening for HCV infection is performed, and can result in identification of undetected chronic 
HBV infections, which in turn may lead to tracing of HBV-infected contacts, treatment if indicated, 
and prevention of further HBV transmission. In addition, since many people confuse HCV and HBV 
infections, a combined approach gives the opportunity to clarify transmission routes and prevention 
measures, and may increase the screening uptake. 
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In conclusion, the prevalence of HCV and HBV infections among Egyptian migrants in the region 
of Amsterdam is relatively low compared with the prevalence estimates in Egypt. However, first-
generation Egyptian migrants are still at substantial higher risk for HCV and HBV infections 
compared with the general population in Western countries. Therefore, we suggest that all first-
generation migrants from Egypt be considered for screening for HCV and HBV infections, especially 
those of older age and those exposed to PAT. Cost-effectiveness analyses are needed to inform future 
screening policies for this population. In addition, improvement in the treatment of chronic HCV 
genotype 4 infection is needed to prevent future morbidity and mortality related to HCV infection 
among Egyptians and other patients infected with this type.
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Hepatitis C virus (HCV) infection is a major public health problem with millions of individuals 
infected but yet to be diagnosed. Efforts in advancing therapeutic options for chronic HCV infection 
will only come to fruition when those infected are detected and able to access specialized health 
care. Low awareness for HCV infection among the general population and health care professionals 
is a huge problem for scaling up diagnosis and treatment of HCV-infected individuals. Increased 
awareness and effective screening strategies are needed to decrease future HCV-related morbidity 
and mortality. 
The studies presented in this thesis focus on the feasibility and effectiveness of various HCV 
screening strategies to identify the population of HCV-infected individuals hidden among the 
general population. This population that, amongst others, is comprised of first-generation migrants, 
individuals who received a blood transfusion before 1992, and individuals who experimented with 
injection drugs in the remote past, has been estimated to account for 66% of the total HCV-infected 
population in the Netherlands (1). We conducted a systematic review of the international literature 
(see chapter 2), and synthesized points for future consideration in new screening programs. An 
Internet-based HCV screening program, which incorporated findings from the systematic review, 
was developed, applied and evaluated (see chapter 3). The evaluation of that program resulted in the 
launch and evaluation of a different approach for the identification of undiagnosed HCV infections: 
A community-based screening program for HCV and hepatitis B virus (HBV) infection for first-
generation migrants from Egypt (see chapter 4). This chapter summarizes the main results of the 
studies presented in this thesis, and their implications for future HCV screening programs, policy 
and further research in the Netherlands.
5.1 Hepatitis C screening programs worldwide
A systematic review was performed to synthesize the literature on screening programs for HCV 
infection and distil effective characteristics and strategies for the identification of HCV-infected 
individuals hidden among the general population (see chapter 2). We identified 67 screening programs 
for HCV infection in 15 countries. Of these, 41 programs were integrated within already existing 
health care facilities, 24 programs were not integrated and exclusively set up for screening, and two 
programs used both strategies. The programs identified a total of ~25,500 HCV-infected individuals: 
only a small proportion of the estimated total HCV-infected population (i.e., 130-170 million people 
(2)). Most programs were carried out in low prevalence countries for HCV infection, such as the 
Netherlands. Comparison of the programs was hindered by the lack of reported data on program 
characteristics and clinical outcomes, and the heterogeneity in organization and screening procedures. 
Moreover, only few programs used a comparison group to assess effectiveness. Therefore, no firm 
conclusions could be made as to which program characteristics or strategies (e.g., free versus low-
cost screening, anonymous versus non-anonymous screening, opt-in versus opt-out screening, use 
of particular media to promote screening) are most effective in attracting or motivating individuals 
for screening, or in attracting those at higher risk for HCV infection. However, some patterns in 
the data were observed. In general, low prevalence rates of HCV infection were found in programs 
targeting health care workers, in antenatal clinics programs, and in programs conducted in sexually 
transmitted diseases (STD) and general practitioner (GP) clinics in which no pre-screening risk 
selection was used. In general, high prevalence rates of HCV infection were observed in programs 
that used a pre-screening selection based on risk factors for HCV infection (especially a history of 
injecting drug use, elevated alanine aminotransferase [ALT] or migrant status), in programs that 
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were carried out in high prevalence countries or regions for HCV infection, and in programs in 
psychiatric clinics.
It was striking that only one study reported the use of motivational communication based on 
psychosocial theory to promote the screening program. Health promotion programs that are theory-
based are more likely to be effective than those that are not (3). In addition, none of the screening 
programs reported the use of simple but effective tools to increase test uptake, such as reminder 
messages or goal setting tools (e.g., 4). Another surprising finding was that none of the programs, not 
even those of recent years, reported the use of Internet as a medium to promote the screening and 
inform individuals about HCV infection. The Internet offers the opportunity to provide information 
that is tailored to the individuals’ needs and reaches and interacts with a large audience beyond the 
setting of health care facilities. Moreover, its anonymous character may prove particularly suitable 
for providing information and screening for a stigmatized disease such as HCV infection.
Implications for hepatitis C screening programs
The review clearly indicates that more effective, large-scale screening programs are needed to 
decrease the HCV-related burden of disease in an era of potent therapy for chronic HCV infection. 
With respect to the development of screening programs for HCV, results from the systematic 
review suggest that in low prevalence populations the use of pre-screening selection criteria should 
be considered to increase efficiency. Program characteristics and outcomes, including start of 
treatment, should be reported systematically to improve comparability of programs. In addition, 
programs should use comparison groups, or ideally conduct randomized trials to be able to better 
assess effectiveness, and improve future programs. We also suggest that screening programs should 
be based on psychosocial theory, and incorporate tools such as reminder messages to increase testing 
uptake. Finally, we propose that the Internet may be a useful medium for promotion and facilitation 
of HCV screening. 
5.2 Internet-based screening for hepatitis C 
The first HCV screening program in the Netherlands commenced in 2007. At that time, 
epidemiological data on prevalence of HCV infection in various risk groups in the Netherlands 
were yet to be collected. For most individuals in the general Dutch population, HCV infection was 
a rather unknown disease, associated with a career in drug use, and often confused with hepatitis 
A virus or HBV infections for which vaccines are available. Data on socio-cognitive determinants 
of HCV testing were lacking. However, treatment options for chronic HCV infection had improved 
significantly. Therefore, it was considered that there was no time to wait for these data or postpone 
the development of HCV screening programs. To identify undiagnosed HCV-infected individuals, 
a pilot Internet-based screening program was initiated. The program aimed to evaluate whether 
HCV screening of risk groups hidden among the general population would be feasible and effective 
through a public media campaign in combination with a low-threshold blood testing procedure (see 
chapter 3). The screening program applied most of the suggestions for screening that resulted from 
the systematic review of HCV screening programs. The screening program included a pre-screening 
risk selection tool, psychosocial theory-based communication for its promotion, Internet as a 
delivery tool to ensure a low-threshold and anonymous character, and tools to stimulate the uptake 
of testing. The following section describes how these features were incorporated into the program.  
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Organization of the Internet-based screening program
On the basis of prevalence studies that were previously published, risk factors for HCV infection 
were determined and a questionnaire was developed that assessed risk for HCV infection (see 3.1). 
The questionnaire was evaluated among a population of liver patients with known HCV status prior 
to its online use in the screening program. Sensitivity was relatively high and specificity somewhat 
lower; although sensitivity and specificity were low compared with levels applicable to blood 
screening tests, they were considered to be fairly good for a questionnaire relying on the memory 
(and reporting) of potential risk factors for HCV infection, with the purpose of functioning as a pre-
screening selection tool. The positive predictive value depends on the prevalence in the population 
using the questionnaire (5). The higher the prevalence in the population filling out the questionnaire, 
the better its predictive value. Therefore, the promotional campaign of the screening program was 
designed to especially motivate participation of risk groups for HCV infection. 
Since data on socio-cognitive determinants of HCV testing were lacking, the campaign was based on 
concepts from the revised health belief model (6). It aimed to increase perceived susceptibility among 
those at risk for HCV infection by addressing potential risk factors for acquiring HCV infection. In 
addition, perceived severity of HCV infection, and benefits of screening through the program were 
communicated to the public. Since the screening program served as a pilot in the urban region of 
Amsterdam and the sub-urban region of South Limburg, only regional media could be used to attract 
participants. Because of budgetary constraints, we were limited in the number of radio, television 
and newspaper advertisements and banners that could be employed. Free publicity for the screening 
program was sought through press releases and support from a PR specialist.
The campaign referred individuals to the risk assessment questionnaire at the project’s Website. The 
Website and questionnaire were available in Dutch, English, Spanish, French, Turkish and Arabic to 
facilitate participation for migrants who did not have sufficient knowledge of the Dutch language. 
Translation of the Website was time consuming and a technical challenge due to the many foreign 
characters and the right alignment of the Arab language. 
After participation in the risk assessment questionnaire, those at risk for HCV infection were 
motivated to get a blood test via a low threshold testing procedure. The Website provided a referral 
letter to a testing laboratory, along with instructions and addresses of the participating laboratories. 
Each referral letter carried a unique identification code. Participants could print, download, or send 
the referral letter to an email address. They could also opt to receive an email and/or short message 
service (SMS) reminder message, which was sent 5 days later. In addition to the reminder service, 
the project included a virtual appointment planner as a tool to increase testing uptake. The screening 
program design included extensive data gathering mechanisms and access to all screening and 
test results, in order to document each step related to coverage; the number of unique individuals 
recruited to screening and testing; the proportion identified as “at risk”; the proportion that tested 
positive for anti-HCV antibodies; and the number treated. 
Feasibility and effectiveness of the Internet-based screening program
Although the volume of the program was lower than anticipated, we found that risk- and Internet-
based screening for HCV infection was feasible and effective. Over 95% of those who started the risk 
assessment questionnaire completed it. Of those who completed the questionnaire and were advised 
to seek HCV testing via the Internet-based testing procedure, 28% complied and opted for testing. 
We believe this is substantial considering the large step between filling out an online questionnaire 
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and visiting a laboratory for a blood draw. An HCV screening program in Hungary that also used 
an Internet-based approach, including a risk assessment questionnaire and referral of those who 
reported risk for HCV infection to the GP for testing, did not measure compliance with the advice to 
seek testing, which limited a testing uptake comparison with that program (7). Since we are not aware 
of any other Internet-based screening programs for HCV, we used a similar STD-screening program 
for comparison. An Internet-based screening program for syphilis that was targeted at men who have 
sex with men (8) had a much lower testing uptake (10%) compared with our program.
Among those who were tested, prevalence of anti-HCV antibodies was 3.6% (95% CI=2.1%-5.7%), 
which is more than 16 times the estimated prevalence in the general Dutch population (0.22%) (see 
3.2). This indicates that the risk assessment questionnaire succeeded in selecting a population at 
higher risk of HCV infection. Using the prevalence among those who tested via the project, the pre-
test probability of disease, i.e., the prevalence of HCV infection among those who completed the 
risk assessment questionnaire was estimated at approximately 1.5% using Fagan’s nomogram (see 
3.1, page 77). This indicates that the theory-based media campaign did especially motivate those 
at higher risk for HCV infection, and not the ‘worried well’, to visit the Website and complete the 
questionnaire. The Internet-based procedure for confirmation testing was successful. Communicating 
preliminary test results for HCV infection anonymously via the Internet, followed by a face-to-face 
consultation for confirmation testing and referral, did not lead to infected individuals being lost 
to follow up. All individuals who were found with chronic HCV infection belonged to the hidden 
population of HCV-infected individuals, and would probably not have been identified without the 
public media screening program. They were referred to follow-up care, and half of them started 
treatment. 
Usability and acceptability of the screening procedure as perceived by participants was high (data 
not presented in this thesis). Usability and acceptability were measured following methods by Davis (9). 
All individuals who completed the risk assessment questionnaire were asked to participate in the 
usability and acceptability study, and 22.2% (2146/9653) agreed to participate. They filled out an 
online questionnaire measuring perceived ease-of-use of completing the online risk assessment 
questionnaire (Cronbach’s α=.81, n=4), and the usefulness (Cronbach’s α=.89, n=5) and acceptability 
(Cronbach’s α=.87, n=4) of the online risk assessment. Scores on all three measures were very 
high (4.8 [SD=0.4], 4.4 [SD=0.7], and 4.6 [SD=0.6] on five-point Likert scales [1=low; 5=high], 
respectively), indicating that Internet-based screening is easy to use, useful, and an acceptable 
method for risk assessment for HCV infection. Although promising, there may be some limitations 
to this study. First, one might expect that individuals who agreed to participate in such a program 
have a more positive attitude towards it compared with those who did not participate. However, 
the participants did not have any experience with the service beforehand, and could also have 
been disappointed. Furthermore, there may be selection bias as this sub-study was done in a self-
selected sample of participants in which women, those of older age, and those with medium-to-high 
educational level were overrepresented.
Potential improvements to the Internet-based screening program
Although we conclude that risk- and Internet-based screening for HCV infection is feasible and 
acceptable, there are some potential effectiveness improvements that could be made. The first 
relates to the volume of the project’s reach. The screening program attracted over 40 thousand 
individuals within a 21-month period. Almost 10 thousand individuals completed the risk assessment 
questionnaire, only 5300 of these were from the pilot regions Amsterdam and South Limburg, and 
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of these, 1480 individuals were at risk for HCV infection. Although the Website was available in 
six languages, non-Western migrants were underrepresented among participants, and only 1.1% of 
those who completed the questionnaire used the Website in a language other than Dutch.
The limited volume of the project’s reach is attributed to the restricted reach of the regional media 
campaigns that were used in the project. Towards the end of the project, a 1-day national media event 
was arranged, and an immediate peak in exposure and testing was observed (data not shown in this 
thesis). Besides the higher number of individuals who are exposed to national media compared with 
regional media, national media also tend to create a snowball effect in information dissemination: 
Once a topic gains national media exposure in the Netherlands, it is often observed that various 
media, both national and regional, will also cover the topic (e.g., various television and radio 
stations, newspapers and news websites). In a similar, but national, screening program for HCV 
infection in Hungary (population size: 9.96 million (10)), nearly 200 thousand individuals completed 
an online risk assessment questionnaire during a two-year campaign (7). Although the two programs 
are not completely comparable due to differences in media budget, media effectiveness and cultural 
differences, we recommend that national media be used to achieve the maximal exposure needed to 
reach hidden populations at risk for HCV infection in the future. To reach non-Western migrants, 
we suggest conducting community-based activities in addition to national media and Internet-based 
programs, since uptake through the Internet may not be sufficient, and migrants can also be targeted 
at specific venues such as churches and mosques. Such an approach is only feasible for relatively 
large migrant groups.
Another potential improvement to the Internet screening program for HCV infection relates 
to user acceptance and attrition. A relatively small proportion (39%) of the initial visitors to the 
screening program Website started the risk assessment questionnaire. It is unknown whether those 
who dropped out were at risk for HCV infection or not. In addition, although we were pleased 
with the uptake of blood-testing of 28%, a further increase in testing uptake (and thus decrease in 
attrition) could improve the effectiveness of screening programs. We identified several variables 
that were independently associated with compliance with advice to test for HCV. Individuals of 
older age, higher educational levels, with residence in a less urbanized region, and those without 
health insurance were more likely to be tested. Those who reported non-injecting drug use were less 
likely to be tested compared with other risk groups for HCV infection. Two more practical variables 
were found: those who received a reminder message and those who lived closer to the laboratory 
that carried out the testing were more likely to be tested than those who did not receive a reminder 
message and those who lived further away from the laboratory, respectively. Hence, we suggest that 
screening programs should use reminder messages and facilitate testing close to the community of 
interest.
However, for improvement of future screening programs, we wished to gain more in-depth 
understanding of why some people who receive online advice to test for HCV infection comply 
with that advice while others do not, and the role of the online testing procedures in compliance 
and noncompliance with testing advice. Therefore, we studied the reasons for compliance or 
noncompliance with advice to test for HCV infection through the service by means of qualitative 
research (see 3.3). We found that features specific to the online testing procedure, such as the 
autonomous nature of the testing procedure and the personalized testing advice, played a significant 
role in motivation to test for HCV infection. However, some features were considered problematic. 
For example, the lack of obligatory procedures for testing, and the lenient deadline for testing (which 
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was set at a calendar year) led to a lack of commitment among participants and were identified as 
reasons for not getting tested. Also, some participants had problems printing the laboratory form. 
For improvement of future Internet-based screening programs, we suggest that commitment with 
the program should be established by providing individuals with a clearly defined and relatively 
tight deadline for testing. Technical printing problems could be overcome by offering to send the 
laboratory form by post or by having the forms emailed to mobile phones or to the laboratories 
directly. To further lower traveling and/or printing barriers, future screening programs may consider 
the use of home collection tests or at-home tests (self tests) for HCV, once reliable tests become 
available for consumer use. A recently developed oral fluid-based rapid test for HCV, which is 
currently licensed for professional use only, could become a promising tool for future screening 
programs (11;12). 
In addition to the practical reasons for noncompliance related to the Internet-based testing 
procedure, low perceived vulnerability, low perceived severity, discouraging individuals in the 
social environment, the avoidance of threatening information, and fear for the consequences of a 
positive test result were reported reasons for not testing for HCV infection. Although quantitative 
research is needed to study the association between the reported reasons and testing, it suggests 
that both procedure-related and psychological factors need to be addressed to increase testing 
uptake. Although most psychosocial determinants were addressed within the screening program’s 
information, several strategies can be used to increase effectiveness of communication. For example, 
low perceived vulnerability was based on downplaying of personal risk. The program’s Website did 
address personal risk, but apparently not convincingly enough for all participants. Scenario-based 
risk information that addresses doubts about personal risks and the consequences of downplaying 
risk can be an effective strategy to improve the understanding and perception of personal risk.
Slow diffusion, low acceptance, and attrition are major challenges for Web-based services. Although 
the low-threshold nature of the Internet offers many advantages, its nonobligatory character makes 
it difficult to keep users and create commitment. The use of participatory design methods, i.e., 
incorporating the proposed end user’s perspective into the design of the intervention (that is, user-
centered design), can lead to eHealth interventions better customized to individual preferences and 
user profiles, and therefore may positively influence the uptake of Web-based services (13). User-
centered design strategies are, for example, the development of user profiles or persona (14), and 
prototyping (15). If a user-centered design had been used in the Internet-based screening program for 
HCV infection, several of the reported barriers for screening may have been prevented. As a result 
we recommend the use of the ceHRes roadmap for the development of future Web-based services: 
a holistic framework for the development of sustainable eHealth technologies that incorporates 
user-centered design and business modeling (16). The business modeling component of that roadmap 
focuses on the development of a service that is sustainable, by identifying and addressing the 
needs of important stakeholders with respect to the service (17). The development of sustainable 
screening programs (i.e., programs that become institutionalized) is another important issue that 
requires attention, especially in screening programs that are not integrated within existing health 
care facilities. This is expanded upon in 5.5.
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5.3	 Community-based	 hepatitis	 B	 and	 C	 screening	 for	 first-
generation migrants
Migrants are considered to account for the majority of HCV infections in many high-income countries 
including the Netherlands. However, migrants were underrepresented among the participants of 
our Internet-based screening program, despite the fact that the risk assessment questionnaire was 
multilingual and migrant-specific media were used to promote the program. We hypothesized that 
a community-based screening program would be an efficient strategy for attracting large migrant 
groups for screening and identifying undiagnosed infections. Therefore, we organized a community-
based screening program targeting first-generation migrants from Egypt who were living in the 
Amsterdam region (see chapter 4). The prevalence of HCV infection in this group was estimated 
to be substantial, since Egypt is the country with the world’s highest prevalence (estimated at 15%) 
due to the use of unsterilized injection material in large-scale parenteral antischistosomiasis therapy 
campaigns from the 1920s to 1980s (18;19). As a result of an expressed desire from the Egyptian 
community for simultaneous screening for both HCV and HBV infection, and considering Egypt 
is a medium endemic country for HBV infection, risk factors for HCV and HBV infection are 
overlapping, and HCV and HBV infection often are confused, we decided to offer screening for both 
HCV and HBV infection. 
Feasibility and effectiveness of the community-based screening program
The outreach community-based screening program turned out to be feasible. During 11 educational 
and screening sessions, a total of 465 first-generation migrants from Egypt were screened. They 
represent a substantial proportion (14.5%) of the target population. The prevalence of anti-HCV 
antibodies and HBsAg were 2.4% (95% CI=1.3-4.2%) and 1.1% (95% CI=0.5-2.5%), respectively, 
considerably higher than the infection prevalence that is observed in the general Dutch population, 
but lower than the estimated prevalence in the country of origin. This is in line with several studies 
in diverse migrant populations (20-22), and suggests that in general, migrants comprise a group at 
lower risk of infection compared with those who remain. Possible explanations are the shorter 
exposure period to risk factors in the home country, the healthy migrant hypothesis (a selected 
healthier group opts for migration), and the salmon bias hypothesis (migrants who retire or suffer 
from disease are likely to return to their country of origin (23)). Alternatively, the prevalence in the 
home country may be overestimated. The study design may also have influenced the prevalence 
findings, since a community-based screening does attract a selected population (i.e., those who are 
already diagnosed are less likely to participate, whereas those who experience symptoms may be 
more likely to participate). Most of the identified infections were newly diagnosed. Exposure to 
parenteral antischistosomal therapy and older age were strongly associated with positive anti-HCV 
status, and phylogenetic analyses suggested that infections were acquired in the region of origin 
before migration to the Netherlands. 
Community-based screening may lower travel- or time-related barriers for screening, but those who 
are identified with an infection still need to visit medical care facilities for follow-up care. This kind 
of follow up in regular care settings after diagnosis through community-based screening may be 
challenging. However, the majority of the individuals who were diagnosed through our program 
visited a GP or hepatologist. Perhaps the low threshold consultation with a visiting hepatologist 
for those with chronic HCV infection which was arranged at the Public Health Service facilities 
motivated individuals to attend and visit the hospital thereafter. Although the follow up to medical 
care was successful, the treatment outcomes were somewhat disappointing. All individuals were 
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infected with HCV genotype 4, which is relatively difficult to treat with the standard therapy options. 
New therapies currently being developed may improve the future treatment benefits for Egyptians 
and others infected with this genotype. Despite the fact that treatment success was limited, the 
detection of HBV or HCV infection may still be beneficial. First, patients can limit their alcohol 
intake to reduce liver damage, take precautionary measures to prevent transmission to others, and, for 
HBV infection, susceptible contacts can be protected by vaccination. In addition, detection of viral 
hepatitis can offer an explanation for long standing health complaints. In our screening program, we 
found that some of the patients who were identified with chronic HCV infection had unexplained 
physical complaints (e.g., fatigue and malaise) for which they had seen specialist doctors at the 
hospital. Surprisingly, they were not tested for HCV infection at that time, although Egypt is well-
known for its HCV epidemic. It suggests that health care professionals should be more aware of 
risk groups for HCV infection, and should suggest screening sooner for those who were born in 
intermediate to high prevalence countries. The psychological effects for those who are diagnosed 
but untreated are unknown, but they can be both positive and negative; it could be beneficial when 
diagnosis gives an explanation for long-term physical complaints, while it could prove detrimental 
for otherwise healthy individuals. 
Challenges and practical lessons learned from the community-based screening program 
Although the program was considered feasible, the efficient use of resources in the community-based 
screening program was challenging. The screening strategy remains labor-intensive and therefore 
relatively expensive and the number of individuals who will present themselves for screening is hard 
to estimate. Sometimes only few people attended, while on other occasions people had to wait in line 
for hours to be screened. The screening sessions at the Coptic church had the highest attendance, 
probably because of the large number of people that attended the church services prior to the 
screening sessions. We observed that the Coptic church serves not only as a location for practicing 
religion, but also as a social meeting place where community members meet each other on a weekly 
basis. Reaching the Islamic community was more difficult, as the leaders of the local mosque only 
agreed to one screening session for men and women, respectively. The sessions were organized in 
between two religious services, and some individuals who were in line for the screening left when 
the next service started. The other organizations (e.g., an organization for Egyptian women) had far 
less members compared with the church and mosque, and, although the educational sessions were 
very interactive, the number of individuals who were screened was limited.
Drawing blood from individuals in the Egyptian population was time-consuming. Despite the fact 
that the nurses were very experienced at drawing blood from individuals with veins that are difficult 
to locate (i.e., injecting drug users), many Egyptians (mostly women) had thin and deep veins. The 
use of non-invasive screening methods (e.g., using oral fluid or dried blood spot tests) may shorten 
the on-site screening procedure per person. However, they have the disadvantage that individuals 
cannot be given a definite test result and have to return for confirmation blood testing. A community-
based HCV and HBV screening program in the United Kingdom found that a substantial proportion 
of patients with reactive oral fluid test results during community-based screening declined to access 
support for their infection, despite home visits of health care professionals to persuade individuals 
to attend the hospital, and a free taxi service to and from the local hospital (20).
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5.4 Other hepatitis C screening programs for risk groups among 
the general Dutch population 
This paragraph reflects on HCV screening programs in the Netherlands that were not included in the 
systematic review (see chapter 2) because they were not published, or published after July 2010 (the 
review includes papers published between 1991 and July 2010).
National hepatitis C campaign
Following two pilot studies in 2008 (24;25), a national hepatitis C information campaign was launched 
in the Netherlands in 2009 (26;27). The campaign aimed to increase awareness for HCV infection 
among the general population and health care professionals, and aimed to increase risk perception, 
information seeking behavior and testing among risk groups for HCV infection. The campaign 
consisted of two interventions; a public intervention targeting the general population, specific risk 
groups for HCV infection within the general population (among which first-generation migrants), 
GPs, and Public Health Services; and an intervention targeting hard drug users in addiction care. 
The public intervention was implemented in the six largest cities in the Netherlands. Information 
about HCV infection, risk groups and treatment options were disseminated through mass media, 
brochures and posters at GP clinics, social services and pharmacies, and through community-based 
informative meetings. A website provided additional information about diagnostics and prognosis of 
HCV infection, and offered the online risk assessment questionnaire that is described in 3.1 of this 
thesis. Those at risk for HCV infection were referred to their GP to discuss testing. At the same time, 
GP practice staff was systematically trained by regional GP support organizations, through group 
meetings and individual education. They also received educational material on HCV infection. Public 
Health Services’ staff was trained on how to organize community-based informative meetings for 
migrant groups and received educational material for these groups. The community-based screening 
program, described in chapter 4, was initially one of these initiatives for migrants, but was extended 
into a program in which both education and screening were offered. The public intervention lasted 
for 6 months. The hard drug users intervention was implemented nationally. Hard drug users 
attending addiction care were actively approached and were offered individual consultations, group 
educational sessions, and HCV testing. Addiction care professionals were provided with educational 
materials. This intervention lasted for 18 months. 
The outcomes of the national campaign were modest. Based on annual reports of 25 laboratories in 
the Netherlands, an estimated 1554 additional HCV tests and 49 positive anti-HCV antibody tests 
were attributed to the public intervention (26). In the drug users intervention, a total of 1130 HCV tests 
and 299 positive anti-HCV antibody tests were registered. All were attributed to the intervention 
because it was considered that HCV testing in drug addiction care was scarce beforehand. However, 
the effect of the intervention may have been somewhat overestimated since in some regions (e.g., 
Amsterdam) routine HCV testing of hard drug users in addiction care did already take place before 
the intervention (28). Although the drug users intervention was considered cost-effective, the cost-
effectiveness of the public intervention was modest (26). The somewhat disappointing result of the 
national campaign could be partially explained by the H1N1 influenza virus pandemic that happened 
to occur at that time. The pandemic created a heavy workload for GPs and Public Health Services, 
and captured virtually all the attention of the media, professionals and the public. This demonstrates 
the vulnerability of a largely GP-based screening program. Another explanation for the modest 
result was the relatively short duration of the campaign for gaining access to migrant groups and 
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organizing informative sessions (27). The time-consuming nature of community-based programs has 
been discussed earlier in this chapter. 
Screening programs for migrant groups
Several ad-hoc screening programs for HCV infection targeting migrant groups in the Netherlands 
have been performed. Programs aimed at first-generation Turkish migrants in Arnhem (29), first- and 
second-generation Chinese migrants in Utrecht (30) and Amsterdam (31), and first-generation Egyptian 
migrants in Amsterdam (see chapter 4) used a community-based approach. The programs screened 
13.0%, 28.4%, 18.4%, and 14.5% of the respective target populations, and found anti-HCV antibody 
prevalence rates of 0.4% (95% CI=0.0-1.3%), 0.4% (95% CI=0.0-1.3%), 0.2% (95% CI=0.0-0.9%), 
and 2.4% (95% CI=1.3-4.2%), respectively. To note, the programs targeting migrants from Turkey 
and China were primarily designed to identify HBV infections, but also included HCV in their 
screening offer.
Another screening program in Arnhem selected first-generation migrants from Vietnam, Afghanistan, 
Iraq, Iran, and former Soviet Union countries from the municipal administration and invited them 
for HBV and HCV screening at the Public Health Service (32). The total screening uptake was 26.9% 
(927/3447). Although the screening uptake among migrants from former Soviet Union countries was 
the lowest (10.9%), the prevalence of chronic HCV infection in this group was the highest (3.1%; 
95% CI=0.4-10.7, 2/65). The screening uptake in the other groups was relatively high (26.3%-
36.5%), whereas prevalence of HCV infection was low (varying from 0% [95% CI=0.0-2.4%] to 
0.5% [95% CI=0.0-2.9%]). As with most programs that were mentioned in the preceding paragraph, 
this project was primarily designed to identify HBV infections but included HCV in the screening 
offer.
From these screening programs for migrant groups, we can conclude that the total number of 
identified HCV infections is low. Although estimations indicate that migrants account for most HCV 
infections in the Netherlands, most of the migrant groups that were reached so far do probably not 
account for these infections. Other explanations may be that a selected sub-group at lower risk 
for HCV infection participated, or, although unlikely, that a substantial proportion of the HCV-
infected migrant population is already diagnosed. Alternatively, the estimation that migrants from 
HCV endemic countries account for most HCV infections in the Netherlands may be incorrect. 
The parameters for the prevalence of HCV infection in this group that were used in that study 
(0.4% [min] to 1.6% [max]) are based on relatively small sample sizes. Especially the maximum 
prevalence estimate (1.6%) has a relatively wide 95% confidence interval (0.4% to 2.9%). In addition, 
prevalence estimates for HCV infection of the countries of origin were used to determine which 
migrants groups are at a high risk for HCV infection (i.e., migrants from countries with an estimated 
prevalence of anti-HCV antibodies of ≥ 2%). Since for many countries these estimates are uncertain, 
the size of the high-risk migrant population in the Netherlands may have been overestimated. 
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5.5 Future directions for hepatitis C screening in the Netherlands
The studies in this thesis show that the strategies that have been used so far are limited in their 
effectiveness in diagnosing HCV-infected individuals. Moreover, effectiveness of screening 
programs refers to successfully improving long-term health outcomes. The reported outcomes 
of most screening programs are usually the number of detected infections and do not include the 
clinical outcomes that may result from screening. Furthermore, data from randomized controlled 
trials that follow screened and unscreened populations through to morbidity and mortality are not 
available. Therefore, HCV screening has only been considered to be effective because many HCV-
infected persons are presumed to be undetected, treatment for chronic HCV infection has shown to 
be beneficial, and the HCV-related morbidity and mortality in the absence of screening interventions 
have been estimated to increase (33).
There is no one screening strategy that seems most effective in diagnosing HCV-infected individuals 
hidden among the general population, and all strategies have their limitations. In addition, the local 
context (e.g., risk group distribution, background prevalence, health care facilities) influences the 
potential effectiveness of a strategy. Therefore, a joint venture between local public health entities 
and GPs and other already existing clinics using a variety of strategies may be the best approach. The 
following paragraphs discuss various screening strategies for HCV infection.
Screening at GP clinics
Integrated screening at the GP clinic seems the most logical way to offer screening because of its 
integration within community health care. There are several strategies for HCV screening at the 
clinic. First, through opportunistic screening in which the GP proposes HCV screening of patients 
potentially at risk for HCV infection during their consultation for something that is unrelated to 
HCV infection. However, studies in the United States and the United Kingdom have shown that 
knowledge about HCV infection among GPs is suboptimal (34-36). In a Dutch study, only half of the 
HCV-infected patients in primary care were referred to secondary care, even after publication of the 
Practice Guideline for GPs (37). A lack of knowledge regarding risk factors and improved treatment 
options for HCV infection for which referral is warranted, limits the effectiveness of case finding 
for HCV infection at the GP clinic. A study in the Netherlands showed that the addition of a practice 
support intervention leads to improvements in medical consciousness regarding HCV infection, 
which in turn may lead to better case finding (24). Medical consciousness regarding HCV infection 
can also be improved by offering refresher courses for GPs.
Besides opportunistic screening, an automated screening alert for all individuals who are found 
with an ALT elevation at the GP clinic may be promising. A study in the Netherlands estimated the 
prevalence of chronic HCV infection among those with ALT between 50-100 IU/L at 1.4% (95% 
CI=0.7-2.9%), and put forward that through using this strategy in the Netherlands an estimated 1200 
to 1300 HCV-infected patients could be identified at the GP clinic on an annual basis (38). A study 
from the USA showed that HCV screening of those with ALT >40 IU/L would identify 50% of 
those infected with HCV (39). The Dutch scenario is based on follow-up testing of those screened for 
ALT as a part of regular care. The scenario from the USA, however, is unrealistic as it is based on 
a theoretical scenario in which all individuals are screened for ALT. On the other hand it does show 
that when all individuals with elevated ALT would be screened, at least half of all HCV infections 
will remain undetected. Therefore, additional screening strategies are needed.
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Screening at the GP clinic can also be organized by inviting all patients by mail to complete a risk 
assessment questionnaire, and subsequently offer screening to those who report a risk factor for 
HCV infection. The risk assessment questionnaire can be offered both offline and online, limiting 
the workload related to the processing of paper-and-pencil questionnaires. Such a questionnaire 
could include risk factors for all kinds of diseases, for example other infectious diseases (e.g., HBV 
and HIV infection), diabetes, cardiovascular diseases, cancer, etc.
Although integrated screening via GP clinics is promising, there are some difficulties. As mentioned 
previously, once individuals are diagnosed with chronic HCV infection at the GP clinic, they should 
be referred to the hospital for further diagnostics and treatment if indicated. Although the current 
level of knowledge and the referral rate among GPs in the Netherlands are unknown, previous 
publications suggest that these may be suboptimal. This may limit the effectiveness of screening 
at the GP clinic. In addition, the current political movement in the Netherlands towards vertical 
substitution of care (the transfer of tasks from specialist to GP) for the management of chronic 
diseases may decrease the capacity of GPs for case finding of HCV infection. Furthermore, although 
the laboratory costs for screening at the GP clinic are covered by health insurance, as of January 
2013, people in the Netherlands will have to pay the first 350 euro of medical costs themselves. 
Hence, for otherwise healthy individuals, screening for viral hepatitis can be expensive and may 
pose a financial burden on families. In light of this the above mentioned screening strategies could 
be considered unethical in a situation where awareness about personal risk is raised in individuals or 
families who cannot afford the screening costs.
Screening at other clinics
The systematic review (see chapter 2) indicated that screening visitors of psychiatric clinics could 
detect a substantial number of HCV infections. However, since psychiatric disorders may pose 
a contraindication for treatment of chronic HCV infection, screening of patients in such a clinic 
should be discussed thoroughly with treatment specialists, perhaps on an individual patient level. 
Furthermore, screening in STD or antenatal clinics can be useful, but only if risk factors for HCV 
infection (e.g., [former] injecting drug use or HIV infection) are present. A recent study showed a 
favourable cost-effectiveness for adding HCV screening to the already existing screening program 
for all pregnant women (currently including HBV, HIV and syphilis), but only in the best-case 
scenario. In the base-case analysis, cost effectiveness was considered moderate when only first-
generation migrant women from non-western countries were offered screening (40). 
A potential effective screening strategy that has not yet been investigated in the Netherlands is the 
screening of legal migrants from HBV- or HCV-endemic countries upon entry to the Netherlands. 
Such a screening could be integrated within the already existing screening for tuberculosis in which 
migrants, foreign students and foreign workers from high-prevalence countries for tuberculosis 
who intend to stay at least 3 months are referred to the Public Health Service for screening by the 
immigration office (41). The uptake of tuberculosis screening is high (>80% within 3 months of 
arrival), since it is a prerequisite for obtaining a residence permit. We suggest performing a pilot 
study that examines the feasibility of this screening approach.
Population-based screening
In the USA, the cost-effectiveness of a one-time screening intervention of the adult population in 
addition to the current approach of risk-based screening was investigated. It was concluded that, 
when considering a participation rate of 15%, the intervention would likely be cost-effective relative 
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to current practice (42). A sub-analysis showed that screening of only high-risk birth cohorts could 
be even more cost effective if implementation costs, pace of adoption by clinicians, and median age 
of diagnosis were similar. As a result, the US Centers for Disease Control and Prevention recently 
recommended one-time HCV screening of persons born between 1945 and 1965 who are living 
in the USA (33). It was estimated that baby boomers account for 81.6% of all anti-HCV antibody 
positive persons (39). The prevalence of anti-HCV antibodies in baby boomers was estimated at 
3.25%, considerably higher than the estimated prevalence among adults aged 20 years or older who 
were born outside of the birth cohort (0.8%). 
Although one-time birth cohort screening seems well worth examining, there are some drawbacks. 
First, the uptake of screening is essential to its effectiveness. Although a relatively low uptake 
of 15% was assumed in the cost-effectiveness model in the USA, those who participate may not 
be representative for the total population of baby boomers. It may be that those at lower risk for 
HCV infection (i.e., the worried-well) could be more likely to respond. From the population-based 
screening administration for cervical cancer in the Netherlands, it is known that those who respond 
more often are at lower risk than those who do not respond, and those with lower socioeconomic 
status and migrants are less likely to participate (43). Thus, although it may be promising, the 
effectiveness of such an intervention needs to be demonstrated in practice. 
In the Netherlands, the estimated prevalence of HCV infection in the general population is much 
lower compared with the USA, and the majority of infections are estimated to occur in first-generation 
migrants. Therefore, a one-time screening intervention of the general population or a specific birth 
cohort seems less obvious, and research is needed to examine its potential effectiveness. However, 
when considered appropriate, it may be offered in conjunction with the population-based screening 
for bowel cancer which will commence its first screening invitations in 2013. In that program, men 
and women between the ages of 55 and 75 years will be offered a home kit to collect a stool sample 
every two years. In 2019, following its preparatory stage, the program will invite all four million 
persons in that age group who are living in the Netherlands, thus including all persons born between 
1944 and 1964. It may pose an opportunity for a one-time HCV screening of baby boomers in the 
Netherlands. Since the bowel screening program will use home-collection tests, in such a scenario 
the use of a similar test for HCV should also be considered. The effectiveness of this strategy, 
however, is related to the uptake of bowel cancer screening, which needs to be evaluated after 
implementation. 
Screening outside the clinic
Although integration of HCV screening at the GP clinic and/or other already existing health care 
facilities seems most logical, those who do not visit these facilities will not be reached unless extra 
efforts are undertaken to attract individuals to these facilities (e.g., via personal invitations). The 
studies in this thesis have shown that screening beyond the clinic can be feasible. Internet-based 
screening seems useful for identifying HCV infections among former injecting drug users, whereas 
community-based screening seems useful for identifying infections among migrants. 
However, none of the Dutch programs described in this thesis and in 5.4 compared different 
screening strategies. Therefore, in line with the findings from the systematic review (see chapter 2) 
the assessment of effectiveness of various screening strategies is problematic. To our best knowledge 
there is only one study, from the United Kingdom, that compared three screening strategies for 
migrants at risk for HCV and HBV infection (44). In this study, a community awareness campaign 
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was organized and five thousand testing cards were distributed to mosques. The cards contained 
an integrated virology form, and encouraged individuals to visit their GP for viral hepatitis testing. 
Secondly, a GP clinic offered all Pakistani/British Pakistani patients screening (opportunistic 
approach). Thirdly, another clinic evaluated an opt-out approach where all target patients were 
contacted by letter inviting them to opt out of screening. Those who did not opt out were telephoned 
and asked to attend screening clinics. The opt-out strategy proved the most effective; 20% of those 
who were contacted were screened, which was 1.4% and 0% for the opportunistic and community 
strategies, respectively. 
Although we believe that screening outside the clinic is useful since in-clinic screening is usually 
limited to those who attend the clinic and dependent on awareness and capacity in primary health care, 
there are some limitations and challenges that need to be addressed. First, as mentioned previously, 
the effectiveness of such programs depends largely on both the self-referral of individuals for 
screening which leads to a selection in participation, and the participation rate. Screening programs 
outside the clinic have to attract their participants and, in the absence of financial resources for 
campaigning, have to invest in contacts with community organizations and press agencies for 
free publicity. Moreover, gaining media attention for HCV screening programs that are scattered 
throughout the year is difficult. 
Second, such programs often lack institutionalization and are relatively expensive when compared 
to screening in already existing health care facilities. Hence, when resources become scarce, they are 
likely to end and thus are not a long-term option for screening. In addition, there is no reimbursement 
system for programs that offer anonymous screening, such as Internet-based screening programs. 
Although the Internet is a relatively low-cost medium for organizing screening outside the clinic, 
the costs associated with Internet-based screening comprise not only laboratory costs and costs for 
health professionals who are involved, but also costs for website development, maintenance and 
promotion.
Another disadvantage of screening programs that are aimed at the public but not part of a national 
screening policy is their heterogeneity: they often target different populations (e.g., Chinese 
migrants, Egyptian migrants, Turkish migrants), and are inconsistent in their screening offer (e.g., 
some include both HCV and HBV screening whereas others screen for HCV or HBV infection 
only; some offer free vaccination against HBV infection whereas others do not). This does not 
contribute to a common awareness among the general population about risk groups for HCV and 
HBV infection, and also causes inequality and confusion since individuals with risk factor X living 
in region A will receive free screening and/or HBV vaccination, whereas individuals with risk factor 
X living in region B will not.
National screening policy 
In recent years, many screening programs for HCV (and/or HBV) infection have been performed in 
the Netherlands, and epidemiological data have been collected. It is time to synthesize the knowledge 
and experiences, identify and address the existing gaps in knowledge, and formulate and implement 
a national screening strategy that specifies the groups that should be targeted for screening as well 
as the most appropriate screening strategies and their prerequisites for effectiveness. Such a plan 
should also consider the capacity of specialist care to ensure that patients, once identified, can receive 
adequate care. In several high-income countries, national plans to address the HCV and HBV burden 
of disease have been developed (e.g., 45-48). These plans can serve as a background for Dutch screening 
policy, but need to be adapted to the epidemic and context in the Netherlands. 
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In order to determine which groups best to target for screening, first, insight into the undiagnosed 
population of HCV- (and HBV-)infected individuals is needed. This can be achieved by mapping 
the size of the HCV-infected population and the diagnosed population per risk group. In the current 
Dutch situation, however, it will be difficult to gain insight into the size and characteristics of the 
diagnosed population. First, for chronic HCV infection there is no surveillance system since only 
acute HCV infections have to be notified; chronic HCV infection is not a notifiable disease. Second, 
there is no national database in which chronically infected patients’ characteristics and treatment 
data are registered. Such a database does exist for HIV (49), and has proven its value. A database 
of similar design should be set up for HCV (and HBV) infection. We also suggest changing the 
notification policy for HCV infection since notification of all HCV RNA positive-individuals would 
benefit the surveillance of HCV infection. 
Future screening in the general population
Given the current knowledge and experiences, we suggest that screening at GPs should be intensified 
by implementing an automated screening alert for HCV screening for patients with elevated 
ALT, and by inviting GP patients at higher risk for infection for screening via an opt-out testing 
procedure. The latter might be accompanied by practice support and education for GP clinic staff. In 
addition, Internet-based and community-based screening programs beyond the GP clinic should be 
organized to lower testing barriers and give individuals the opportunity to opt for screening without 
discussing risk factors with the GP. Such programs should be organized and promoted nationally 
during a limited period once a year to benefit from the reach of national media. They should use 
theory and knowledge regarding determinants facilitating participation in screening programs in 
their communication, and incorporate tools to increase test uptake (e.g., reminder messages). All 
community-based screening programs should be consistent with respect to risk factors and risk 
groups for HCV (and HBV) infection, and include a follow-up trajectory for those identified with 
chronic infection. All screening activities should be incorporated into a national screening policy 
for viral hepatitis and systematically evaluated, and adapted if needed. Public Health Services 
should play an important role in the organization of Internet-based and community-based screening 
programs. Screening of high-risk patients in clinical care (e.g., drug users, HIV-infected individuals) 
should be continued and intensified. 
Cost-effectiveness analyses comparing different screening strategies (e.g., GP-based screening 
only; GP-based and community-based screening; GP-based, community-based and internet-based 
screening) should be performed. In addition, the cost-effectiveness of combined HCV and HBV 
screening in migrant groups compared with screening for one infection only should be determined. In 
migrant populations with relatively high prevalence of HCV infection, but relatively low prevalence 
of HBsAg as is the case for Egyptian migrants, merely screening for HBV infection may not be cost-
effective, and vice versa. However, screening for HBV and HCV can be combined at relatively low 
extra cost and can result in identification of undetected infections. For HBV, it may lead to tracing 
of HBV-infected contacts, treatment if indicated, and prevention of further HBV transmission by 
vaccination of negative contacts. Moreover, a combined approach provides the opportunity for 
clarification of transmission routes and prevention measures, and may increase screening uptake. 
We therefore suggest screening for HCV and HBV infections in first-generation migrants from HBV 
and/or HCV endemic countries simultaneously.
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5.6 Limitations and implications for future research
There are several limitations in the studies described in this thesis. First, the systematic review 
only included screening programs that were published. Not all screening programs are necessarily 
published, and programs that were successful in the identification of infected individuals may be 
more likely to be published than unsuccessful programs. Therefore, the outcomes of the review may 
not be representative of all HCV screening programs worldwide. Second, the Internet-based and 
community-based screening programs that are presented in this thesis did not include a comparison 
group, and therefore cannot assess the effectiveness of their screening strategy for the identification 
of undiagnosed individuals. Also, we did not perform cost-effectiveness analyses to evaluate the 
economic feasibility of both strategies. The qualitative study into reasons for compliance and 
noncompliance with advice to test for HCV infection (see 3.3) was helpful to understand testing 
behavior. However, quantitative research should be performed to assess the association between 
HCV screening and the determinants that were identified to inform future screening campaigns. 
For future research, studies are needed to estimate the undiagnosed HCV-infected population per 
risk group. We also suggest studying the cost-effectiveness of combined screening for HCV and 
HBV infection in migrants, as well as cost-effectiveness of Internet-based and community-based 
screening in addition to GP-based screening, and screening of new entrants in tuberculosis clinics. 
To limit the uncertainty of such analyses through the use of parameters from literature, screening 
programs should routinely collect data regarding the proportion of newly identified individuals, the 
proportion of individuals that require treatment, treatment uptake and outcomes, and for HBV, the 
results of contact tracing. 
5.7 Concluding remarks
The studies presented in this thesis showed that Internet-based and community-based screening 
strategies are feasible and could prove useful in screening for other diseases. The internet-based 
screening program attracted high risk groups for HCV infection, and demonstrated a high blood 
testing uptake. The identified HCV-infected individuals belonged to risk groups that are hidden 
among the general population. However, investments are needed to increase the reach of such 
programs. This thesis and other studies showed that thus far HCV screening programs have only 
identified a small proportion of the estimated number of HCV infections. It illustrates that no one 
screening strategy can reach all target populations and that different screening strategies and large-
scale programs are necessary. 
On the basis of this thesis’ studies and discussion, we present the following recommendations: 
- Screening programs should systematically report program characteristics and outcomes 
including clinical follow-up, and preferably include comparison groups to assess effectiveness 
of their screening strategies.
- Internet-based screening programs should include multiple tools and strategies to increase 
testing uptake, such as reminder messages, a clearly defined relatively tight deadline for 
blood testing, proximate testing locations, and solutions to technical problems. In addition, 
psychosocial determinants of HCV testing should be addressed using persuasive theory-based 
communication strategies.
- Screening programs should use national media and extensive campaigns to maximize their reach.
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- Community-based screening programs for first-generation migrants from endemic countries 
should offer screening for HCV and HBV infection simultaneously.
- Non-invasive HBV and HCV tests should be considered for community-based and internet-
based screening programs. At-home tests may become a promising tool for future screening 
programs. 
- Future research should gain insight into the undiagnosed population per risk group, and compare 
the cost-effectiveness of different screening strategies.
- Ad-hoc HCV screening programs for migrants should be halted. The current knowledge about 
screening program effectiveness should be synthesized, resulting in a uniform national action 
plan in which several screening strategies are combined.
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Hepatitis C virus (HCV) infection is a major worldwide public health problem with millions of 
individuals infected but yet to be diagnosed. Over time undiagnosed chronic HCV infections may 
lead to liver cirrhosis, liver cancer, and death. Since antiviral therapeutic options for chronic HCV 
infection have improved substantially over recent years and are likely to improve further in the 
near future, effective screening strategies are needed to identify undiagnosed HCV infections. 
This thesis focuses on innovative approaches for the identification and screening of HCV-infected 
individuals hidden among the general population. This population that, among others, is comprised 
of individuals who experimented with injection drugs in the remote past, individuals who received a 
blood product transfusion before 1992, and first-generation migrants, has been estimated to account 
for 66% of the total HCV-infected population in the Netherlands. This thesis examines the feasibility 
and effectiveness of HCV screening strategies targeting this population.
Hepatitis C screening programs worldwide
Chapter 2 describes the results of a systematic review of the international literature concerning 
HCV screening programs designed to reach the hidden population of HCV-infected individuals. We 
aimed to identify screening program characteristics and strategies that were effective in identifying 
undiagnosed infections. We found that the published programs identified only a small proportion 
of the estimated HCV-infected population. They were very heterogenic in their organization and 
screening procedures. Comparison of the programs was hindered by a lack of reported data on 
program characteristics and clinical outcomes, such as the initiation of treatment after diagnosis. 
Most programs did not include a control or comparison group to assess effectiveness. In general, high 
prevalence rates of HCV infection were observed in programs that used a pre-screening selection 
based on risk factors for HCV infection (in particular a history of injecting drug use, elevated alanine 
aminotransferase, or migrant status), in programs that were carried out in countries or regions with 
high prevalence of HCV infection, and in programs in psychiatric clinics. In general, low prevalence 
rates of HCV infection were found in programs targeting health care workers, in antenatal clinic 
programs, and in programs conducted in sexually transmitted diseases and general practitioner clinics 
in which no pre-screening risk selection was used. The reported use of motivational communication 
based on theory and/or determinants facilitating screening, and tools to increase HCV screening 
uptake were virtually absent. 
We suggest that in low prevalence populations pre-screening selection criteria should be considered 
to increase efficiency. In addition, to be able to assess screening program effectiveness, there is 
a need for programs using a comparison group. To improve comparability of future screening 
programs and outcomes, we propose parameters for the reporting of screening programs worldwide. 
Finally, we suggest that screening programs should incorporate theory-based motivation-increasing 
components in order to increase screening uptake.
Internet-based screening for hepatitis C infection
The third chapter of this thesis describes the development and evaluation of an Internet-based 
HCV screening program in the Netherlands. As was proposed through the systematic review, a pre-
screening risk selection was used to identify those at risk for HCV infection. In 3.1 the development 
of a risk assessment questionnaire for HCV infection is described. The sensitivity and specificity 
of the risk assessment questionnaire were evaluated in a sample of liver patients with known HCV 
status, yielding sensitivity and specificity of 84.6% and 63.8% respectively.
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A Web-based, multilingual version of the questionnaire was used for the Internet-based screening 
program (see 3.2). In that program, a theory-based public media campaign was set up in the regions 
of Amsterdam and South Limburg to increase awareness and stimulate HCV testing among risk 
groups. The campaign communicated risk factors for HCV infection and referred individuals to 
the online risk assessment questionnaire. Those who were determined to be at risk through the 
questionnaire were advised to seek blood testing for HCV. An Internet-based, low-threshold, 
anonymous blood testing procedure was organized through the project’s Website. Reminder 
messages and a virtual appointment planner were incorporated to increase testing uptake. Blood test 
results could be obtained via the Internet using a personal identification code. Those with reactive 
test results were referred to the Public Health Service for confirmation testing, and referral to a 
hepatologist was arranged for those chronically infected with HCV. Clinical follow-up data were 
collected >12 months after the screening program. 
Over one quarter of the individuals who completed the questionnaire reported a risk factor for HCV 
infection and were advised to seek blood testing. Reporting a risk factor for HCV infection was 
independently associated with female gender, a low or unknown educational level, older age, being 
born outside of the Netherlands, and not having health insurance. The uptake of blood testing was 
substantial. Seeking HCV testing was independently associated with older age, a medium or high 
educational level, living in South Limburg compared to living in Amsterdam, living closer to a 
laboratory, not having health insurance, receiving a reminder for testing, and risk group for HCV 
infection (those who reported non-injecting drug use were less likely to take the test compared with 
other risk groups). The prevalence of HCV infection among participants was considerably higher 
than the estimated prevalence in the general Dutch population. Most of those with chronic HCV 
infection reported former injecting drug users, and about half started treatment. Although the project 
was feasible and effective in the identification of HCV-infected individuals in the general population, 
the reach of the regional media campaigns was limited, and migrants were underrepresented among 
the project’s participants.
In 3.3 a qualitative study of reasons for compliance and noncompliance with advice to seek blood 
testing through the Internet-based screening program is described. Features specific to the online 
testing procedure played a significant role in motivation to test for HCV infection. For example, 
the fact that the testing procedure allowed individuals access to a test without having to discuss or 
explain their desire to be tested with their general practitioner, motivated individuals to take the test. 
However, some features were considered problematic. For example, the lenient deadline for testing 
caused low commitment to the service, which was a reason for noncompliance. In addition to reasons 
for compliance and noncompliance related to the Internet-guided testing procedure, we identified 
reasons unrelated to the online testing procedure. For example, perceived benefits of testing and high 
perceived vulnerability were reported reasons for testing for HCV infection, whereas low perceived 
vulnerability and fear for the consequences of a positive test result were reported reasons for not 
testing for HCV infection. 
Community-based screening for hepatitis B and C infection
As migrants were underrepresented in the Internet-based screening program, we sought an 
alternative approach to reach that population. Therefore, we organized and evaluated a community-
based screening program for HCV and hepatitis B virus (HBV) for first generation migrants from 
Egypt living in the Amsterdam region (see chapter 4). Since Egypt is the country with the world’s 
highest prevalence of HCV infection, we hypothesized that a substantial number of undiagnosed 
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HCV-infected individuals could be identified through the screening of Egyptian migrants. The 
program also included screening for HBV infection because of its overlapping risk factors with 
HCV infection, and the fact that treatment options for HBV infection have improved in recent 
years. Egyptian migrants were recruited for educational and screening sessions at various Egyptian 
organizations (e.g., mosques, churches). Data regarding demographics and risk factors for HCV 
infection were collected using a standardized questionnaire. Chronically infected patients received 
referrals and follow up. Clinical follow-up data were collected from clinicians >12 months after the 
screening program. Phylogenetic analyses were used to ascertain the geographic origin of infections. 
The program reached a substantial proportion of the Egyptian migrant population for screening. 
Prevalence of HCV and HBV infection were higher compared with the estimated prevalence in 
the general Dutch population, but lower compared with the estimated prevalence in the general 
Egyptian population. HCV infection was independently associated with exposure to parenteral 
antischistosomal therapy and older age. Strains of those chronically infected with HCV and HBV 
were typical of those of Egypt and the Middle East, suggesting that infection occurred in the region 
of origin before migration. About half of those diagnosed with chronic HCV infection started 
treatment. 
Concluding remarks
The studies presented in this thesis showed that Internet-based and community-based screening 
strategies are feasible and could prove useful in screening for other diseases. The internet-based 
screening program attracted high risk groups for HCV infection, and demonstrated a high blood 
testing uptake. The identified HCV-infected individuals belonged to risk groups that are hidden 
among the general population. However, investments are needed to increase the reach of such 
programs. This thesis and other studies showed that thus far HCV screening programs have only 
identified a small proportion of the estimated number of HCV infections. It illustrates that no one 
screening strategy can reach all target populations and that different screening strategies and large-
scale programs are necessary. 
On the basis of this thesis’ studies and discussion, we present the following recommendations: 
●  Screening programs should systematically report program characteristics and outcomes 
 including clinical follow-up, and preferably include comparison groups to assess effectiveness 
 of their screening strategies.
●	 Internet-based screening programs should include multiple tools and strategies to increase 
 testing uptake, such as reminder messages, a clearly defined relatively tight deadline for blood 
 testing, proximate testing locations, and solutions to technical problems. In addition, psychosocial 
 determinants of HCV testing should be addressed using persuasive theory-based communication 
 strategies.
●		 Screening programs should use national media and extensive campaigns to maximize their reach. 
●	 Community-based screening programs for first-generation migrants from endemic countries 
 should offer screening for HCV and HBV infection simultaneously.
●		 Non-invasive HBV and HCV tests should be considered for community-based and internet-based 
 screening programs. At-home tests may become a promising tool for future screening programs. 
●		 Future research should gain insight into the undiagnosed population per risk group, and compare 
 the cost-effectiveness of different screening strategies.
●		 Ad-hoc HCV screening programs for migrants should be halted. The current knowledge about 
 screening program effectiveness should be synthesized, resulting in a uniform national action 
 plan in which several screening strategies are combined.
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Hepatitis C virus (HCV) infectie is een belangrijk probleem voor de volksgezondheid met wereldwijd 
miljoenen mensen die besmet zijn, maar nog niet gediagnosticeerd. Ongediagnosticeerde chronische 
HCV-infecties kunnen op den duur leiden tot levercirrose, leverkanker en de dood. Aangezien 
antivirale therapeutische middelen voor chronische hepatitis C infectie onlangs aanzienlijk zijn 
verbeterd en de komende jaren waarschijnlijk nog beter zullen worden, zijn effectieve strategieën 
voor screening nodig om ongediagnosticeerde HCV-infecties op te sporen. Dit proefschrift richt 
zich op innovatieve strategieën voor het opsporen en screenen van HCV-geïnfecteerde personen die 
verborgen zijn in de algemene bevolking. Deze populatie, onder andere bestaande uit mensen die in 
het verleden experimenteerden met injecterend druggebruik, mensen die een bloedtransfusie kregen 
vóór 1992 en eerste generatie migranten, vormt naar schatting 66% van de totale HCV-geïnfecteerde 
populatie in Nederland. De haalbaarheid en effectiviteit van screeningstrategieën voor hepatitis C 
gericht op deze populatie werden onderzocht.
Screeningprogramma’s voor hepatitis C wereldwijd 
Hoofdstuk 2 beschrijft de resultaten van een systematische review van de internationale literatuur 
naar hepatitis C screeningprogramma’s gericht op het opsporen van de verborgen populatie van 
HCV-geïnfecteerde personen. Het doel van deze studie was het vinden van kenmerken en strategieën 
van screeningprogramma’s die mensen met niet-gediagnosticeerde HCV infecties op een effectieve 
manier identificeerden. We vonden dat de gepubliceerde programma’s slechts een klein deel van 
de totale geschatte HCV-geïnfecteerde populatie identificeerden. De programma’s waren erg 
verschillend in hun organisatie en screeningprocedures. Door het ontbreken van gerapporteerde 
gegevens met betrekking tot programmakenmerken en klinische uitkomsten, zoals het starten van 
behandeling, konden de programma’s slecht met elkaar vergeleken worden. De meeste programma’s 
gebruikten geen controle- of vergelijkingsgroep om hun effectiviteit te kunnen vaststellen. In het 
algemeen werden hoge prevalentiecijfers gevonden in programma’s die een pre-screening selectie 
op basis van risicofactoren voor HCV infectie hanteerden (in het bijzonder ooit-injecterend 
druggebruik, verhoogde alanine aminotransferase, en het behoren tot een migrantengroep), in 
programma’s die werden uitgevoerd in landen of regio’s met een hoge prevalentie van HCV infectie 
en in programma’s in psychiatrische klinieken. In het algemeen werden lage prevalentiecijfers 
gevonden in programma’s gericht op personeel in de gezondheidszorg, in programma’s in klinieken 
voor zwangere vrouwen en in programma’s in soa-polikliniek of huisartspraktijken waar geen pre-
screening risicoselectie werd gebruikt. Er werd vrijwel niet gerapporteerd over het gebruik van 
motiverende communicatie op basis van sociaal psychologische theorieën of over hulpmiddelen voor 
het vergroten van de participatie aan de programma’s, zoals herinneringsberichten. Onze aanbeveling 
voor landen met een lage prevalentie van HCV infectie is om pre-screening selectiecriteria te 
gebruiken om de efficiëntie van screeningprogramma’s voor HCV infectie te vergroten. Om de 
effectiviteit van screeningprogramma’s te kunnen bepalen, zijn programma’s nodig die een controle- 
of vergelijkingsgroep gebruiken. Daarnaast zouden screeningprogramma’s vaste parameters moeten 
rapporteren om toekomstige programma’s en hun uitkomsten te kunnen vergelijken en evalueren. 
Tot slot zouden screeningprogramma’s zich moeten baseren op theorie en hulpmiddelen moeten 
gebruiken om de participatie aan de programma’s te vergroten.
Screening voor hepatitis C met behulp van het internet
Het derde hoofdstuk van dit proefschrift beschrijft de ontwikkeling en evaluatie van een internet-
screeningprogramma voor HCV infectie in Nederland. Zoals uit de systematische review naar voren 
kwam, werd een pre-screening risicoselectie gebruikt om mensen met risico op HCV infectie te 
identificeren. In 3.1 wordt de ontwikkeling van dit instrument, namelijk een risicovragenlijst voor 
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HCV infectie, beschreven. De sensitiviteit en specificiteit van de risicovragenlijst werden geëvalueerd 
in een populatie leverpatiënten met een bekende HCV status. De sensitiviteit en specificiteit waren 
respectievelijk 84,6% en 63,8%. Een online versie van deze vragenlijst werd vervolgens meertalig 
aangeboden in het internet-screeningprogramma (zie 3.2). In dat programma werd een op sociaal-
psychologische theorieën gebaseerde publieke mediacampagne opgezet in de regio’s Amsterdam 
en Zuid-Limburg om het bewustzijn voor HCV infectie te vergroten en risicogroepen te stimuleren 
zich te laten testen. De campagne communiceerde risicofactoren voor HCV infectie en verwees 
mensen naar de online risicovragenlijst. Mensen die volgens de vragenlijst risico hadden gelopen op 
HCV infectie werden geadviseerd om een HCV bloedtest te laten doen. Zij konden zich met behulp 
van het internet op een laagdrempelige manier anoniem laten testen. Herinneringsberichten en een 
virtuele afspraakplanner werden in het programma opgenomen om het testgedrag te bevorderen. 
De bloedtestresultaten konden via het internet worden opgevraagd met behulp van een persoonlijke 
identificatiecode. Degenen met positieve testresultaten (antilichamen) werden doorverwezen naar de 
GGD voor een bevestigingstest en mensen met een chronische HCV infectie werden verwezen naar 
een hepatoloog. Klinische follow-up gegevens werden >12 maanden na de screening verzameld. 
Ruim een kwart van de mensen die de vragenlijst invulden rapporteerde een risicofactor voor HCV 
en werd geadviseerd om een bloedtest te laten doen. Het rapporteren van een risicofactor was 
onafhankelijk geassocieerd met vrouwelijk geslacht, laag of onbekend opleidingsniveau, hogere 
leeftijd, geboren zijn buiten Nederland en het niet hebben van een ziektekostenverzekering. De 
proportie mensen die een bloedtest liet doen was aanzienlijk. Het doen van een HCV bloedtest was 
onafhankelijk geassocieerd met een hogere leeftijd, een gemiddeld of hoog opleidingsniveau, het 
woonachtig zijn in Zuid-Limburg in vergelijking met Amsterdam, het dichter bij een laboratorium 
wonen, het niet verzekerd zijn voor ziektekosten, het ontvangen van een herinnering voor het testen, 
en de risicogroep voor HCV infectie (mensen die niet-injecterend drugsgebruik rapporteerden 
waren minder geneigd om zich te laten testen in vergelijking met andere risicogroepen). De 
hepatitis C prevalentie onder de deelnemers was aanzienlijk hoger dan de geschatte prevalentie 
onder de algemene Nederlandse bevolking. De meeste mensen met chronische HCV infectie 
rapporteerden ooit-injecterend druggebruik en ongeveer de helft startte met behandeling. Hoewel 
het project haalbaar en effectief was voor de identificatie van HCV-geïnfecteerde personen in de 
algemene bevolking, was het bereik van de regionale mediacampagnes beperkt en waren migranten 
ondervertegenwoordigd onder de deelnemers van het project. 
In 3.3 wordt een kwalitatieve studie beschreven naar de redenen voor het al dan niet opvolgen van 
het advies voor een bloedtest in het internet-screeningprogramma. Specifieke kenmerken van de 
online testprocedure speelden een belangrijke rol in de motivatie om te testen op HCV infectie. Zo 
vormde het feit dat mensen een test konden doen zonder hun risico of motivatie met hun huisarts 
te bespreken een reden voor mensen om zich te laten testen. Echter, sommige elementen waren 
problematisch. Zo zorgde het ontbreken van een strakke deadline voor het doen van de bloedtest 
voor een lage betrokkenheid bij de service. Dat was een reden voor het niet opvolgen van het 
testadvies. We vonden ook redenen voor het al dan niet opvolgen van het testadvies die niet waren 
gerelateerd aan de testprocedure. Zo werden de voordelen van testen en een hoge perceptie van 
kwetsbaarheid aangemerkt als redenen voor testen, terwijl lage waargenomen kwetsbaarheid en 
angst voor de consequenties van een positief testresultaat genoemd werden als redenen voor het niet 
testen op HCV infectie. 
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Screening op hepatitis B en C op locatie
Omdat migranten ondervertegenwoordigd waren in het internet-screeningprogramma werd naar een 
andere strategie gezocht om deze groep te bereiken. Hierop werd een (community-based) screening 
op locatie voor HCV en hepatitis B virus (HBV) infectie georganiseerd. Het programma was 
bedoeld voor eerste generatie migranten uit Egypte die woonachtig waren in de regio Amsterdam 
(hoofdstuk 4). Aangezien Egypte het land is met ‘s werelds hoogste prevalentie van HCV 
infectie, veronderstelden we dat we met de screening van Egyptische migranten een groot aantal 
ongediagnosticeerde HCV-geïnfecteerde personen konden identificeren. Het screeningprogramma 
omvatte ook screening op HBV infectie vanwege de overlap in risicofactoren met HCV infectie 
en het feit dat de behandelingsmogelijkheden voor chronische HBV infectie in de afgelopen 
jaren verbeterd zijn. Egyptische migranten werden via verschillende Egyptische organisaties 
(bijvoorbeeld moskeeën en kerken) benaderd voor voorlichting- en screeningsessies. Gegevens 
met betrekking tot demografie en risicofactoren voor HCV infectie werden verzameld met behulp 
van een gestandaardiseerde vragenlijst. Chronisch geïnfecteerde deelnemers werden verwezen 
naar het ziekenhuis en opgevolgd. Klinische follow-up gegevens werden >12 maanden na de 
screening verzameld. Fylogenetische analyses werden gebruikt om de geografische herkomst van 
de gevonden infecties vast te stellen. Het programma heeft een aanzienlijk deel van de Egyptische 
migrantenbevolking bereikt en gescreend. De prevalentie van HCV en HBV infectie was hoger in 
vergelijking tot de geschatte prevalentie onder de algemene Nederlandse bevolking, maar lager in 
vergelijking tot de geschatte prevalentie onder de algemene Egyptische bevolking. HCV infectie was 
onafhankelijk geassocieerd met blootstelling aan injecties tegen schistosomiasis en hogere leeftijd. 
De virusstammen van de mensen met een chronische HCV of HBV infectie waren kenmerkend voor 
die uit Egypte en het Midden-Oosten, wat suggereert dat de infecties hebben plaatsgevonden in de 
regio van herkomst, voor migratie. Ongeveer de helft van de mensen met chronische HCV infectie 
startte met behandeling. 
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Conclusies 
De studies in dit proefschrift laten zien dat screeningstrategieën voor HCV infectie via internet 
en op locatie haalbaar zijn en mogelijk ook nuttig voor screening op andere ziekten. Het internet-
screeningprogramma slaagde erin om hoogrisicogroepen voor HCV infectie aan te trekken en een 
groot deel van de mensen met risico liet zich testen. De personen die gevonden werden met een HCV-
infectie bleken tot risicogroepen te behoren die verborgen zijn in de algemene bevolking. Echter, 
investeringen zijn nodig om het bereik van een dergelijk programma te vergroten. Dit proefschrift 
en andere studies laten zien dat de screeningprogramma’s voor HCV infectie tot nu toe slechts een 
klein deel van het wereldwijd geschatte aantal HCV-infecties hebben geïdentificeerd. Het illustreert 
dat er niet één strategie is die alle doelgroepen kan bereiken en dat verschillende strategieën en 
grootschalige progamma’s nodig zijn. 
Op basis van de studies en discussie in dit proefschrift presenteren we de volgende aanbevelingen:
 
●  Screeningprogramma’s zouden systematisch hun kenmerken en resultaten moeten rapporteren, 
 inclusief de uitkomsten van klinische follow-up. Idealiter zouden zij vergelijkingsgroepen 
 moeten gebruiken om de effectiviteit van hun screeningstrategie te kunnen beoordelen.
●		 Internet-screeningprogramma’s zouden hulpmiddelen en meerdere strategieën moeten 
 gebruiken om het testgedrag te vergroten, zoals herinneringsberichten, een duidelijk omschreven 
 en relatief krappe deadline voor bloedtesten, nabijgelegen testlocaties en een oplossing voor 
 technische problemen. Daarnaast zouden deze programma’s gebruik moeten maken van op 
 theorie gebaseerde persuasieve communicatiestrategieën gericht op psychosociale determinanten 
 van testen op HCV infectie.
●		 Screeningprogramma’s zouden nationale media en grootschalige campagnes moeten gebruiken 
 om hun bereik te maximaliseren.
●		 Screeningprogramma’s op locatie voor eerste generatie migranten uit endemische landen voor 
 HCV en/of HBV infectie zouden gelijktijdige screening voor zowel HCV en HBV infectie
 moeten aanbieden. 
●		 Niet-invasieve testen voor HBV en HCV infectie zouden kunnen worden overwogen voor 
 outreach- en internet-screeningprogramma’s. Zelftests kunnen een veelbelovend instrument zijn 
 voor toekomstige screeningprogramma’s. 
●		 Toekomstig onderzoek zou verder inzicht moeten geven in de ongediagnosticeerde populatie 
 per risicogroep voor HCV infectie en zou de kosteneffectiviteit van verschillende strategieën 
 van screening moeten vergelijken.
●	 Ad-hoc HCV screeningprogramma’s voor migranten zouden moeten worden stopgezet. 
 De huidige kennis over de effectiviteit van screeningprogramma’s moet worden samengevat, 
 resulterend in een uniform nationaal actieplan waarin verschillende screeningstrategieën worden 
 gecombineerd. 
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“We live in a multivariable world” (Katz, 2011). Er zijn dan ook meerdere personen die er voor 
gezorgd hebben dat dit proefschrift tot stand is gekomen. Deze meest gelezen pagina’s wil ik beginnen 
met het bedanken van alle deelnemers die aanvullende vragenlijsten invulden of meewerken aan 
interviews ten behoeve van het onderzoek in dit proefschrift. Zonder hen was er geen proefschrift 
geweest. 
Veel dank gaat uit naar mijn promotores en co-promotor, ik heb veel van jullie geleerd. Gerjo, bedankt 
voor je behulpzame input en geduld. Ik ken niemand die mijn stukken zo snel van commentaar wist 
te voorzien als jij. Maria, bedankt voor je vertrouwen, je toegankelijkheid en je altijd kritische 
blik. Jij kunt met je onuitputtelijke energie en ideeënstroom als geen ander mensen inspireren en 
enthousiasmeren. Udi, bedankt voor de goede discussies, je humor, je inventiviteit. Never a dull 
moment with you around! Het is nog de vraag of je bij mijn promotie aanwezig kan zijn, maar ach, 
tenslotte is dat maar bijzaak: העיקר הבריאות.
Graag bedank ik de promotiecommissie voor het beoordelen van mijn proefschrift.
Voor zover nog niet elders in dit dankwoord genoemd, wil ik alle co-auteurs bedanken voor hun 
bijdrage aan de studies in dit proefschrift: Annekatrien Depla, Jim van Steenbergen, Susan Hahné, 
Charles Helsper, Paula van Leeuwen-Gilbert, Miranda Langendam, Peter Jansen en Roel Coutinho. 
Roel, een persoonlijk woord voor jou: hoewel je officieel geen promotor was voelde dat soms 
wel een beetje zo toen je nog wekelijks op de afdeling zat. Bedankt voor je betrokkenheid en je 
ongelooflijke helikopterview die me erg heeft geholpen bij het schrijven van de stukken.
Graag wil Christian, Natacha, Hans, Rick, Elleke en Henriëtte van de GGD Zuid Limburg bedanken 
voor de prettige samenwerking en hun ondersteuning bij het organiseren en uitvoeren van het 
internet-screeningproject. Ook dank aan Christine, Marc, Ruth en Martine van de polikliniek 
leverziekten van het AMC voor jullie hulp bij het werven van respondenten en het opvangen van 
opgespoorde mensen met een hepatitis C infectie. Joyce, bedankt voor de fijne samenwerking vanuit 
GGD Flevoland! 
Voor het bedanken van mijn collega’s binnen de GGD Amsterdam zou ik graag eerst Francis Bacon 
aanhalen, filosoof uit de 17e eeuw. Hij typeerde het volk van onderzoekers volgens ‘the Ant, the 
Spider, and the Bee’: “The men of experiment are like the Ant, they only collect and use; the reasoners 
resemble Spiders, who make cobwebs out of their own substance. But the Bee takes a middle course: 
it gathers its material from the flowers of the garden and of the field, but transforms and digests it 
by a power of its own.” (Bacon, 1620). 
Deze typologie is ook losgelaten op mensen in het algemeen:“The Ant type of people: they never do 
anyone any harm but they exist totally for their own living and pay no attention to others’ well being. 
The Spider type of people: they exist to feed their self-interest alone at the expense of others and 
harm others in the process. The Bee type of people: they pursue their own interest and well being but 
in the process always help others as well.”
Mijn collega’s van de GGD Amsterdam zou ik willen typeren als ‘bee-people’: altijd bereid om 
te helpen, of dat nou overdag, ’s avonds of in het weekend was. De enorme collegialiteit maakt 
het werken bij de GGD Amsterdam heel plezierig. Graag een woord van dank voor iedereen, te 
beginnen met Jannie, de perfecte kamergenoot! Te gek dat ik je West-Friese, Drentse en Surinaamse 
uitspraken nog niet hoef te missen en we ook de komende jaren samen voor de orchideeën kunnen 
blijven zorgen. Bedankt dat jij mijn paranimf wilt zijn! Anouk, van stagiaire naar collega naar ex-
collega, vriendin en paranimf. Wat fijn om de promotiestress te kunnen delen en het feest binnenkort 
samen af te sluiten! Titia, mijn maatje in kwalitatief onderzoek: bedankt voor de goede discussies 
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en gezelligheid! Marjolein: Wat was het leuk om samen met jou kennis te maken met de Egyptische 
gemeenschap in Amsterdam, bedankt voor je fantastische hulp! Charlotte, ons radio-optreden in 
Zuidoost zal ik niet snel vergeten, fijn dat jij erbij was! Rik, mijn eerste kamergenoot en inmiddels 
mijn vaste reispartner voor de eHealth congressen, bedankt!
De hulp bij de screening voor Egyptenaren op locatie: Wendy, Laura, Marc, Bart, Femke, Sofie, 
Mirjam, Jeltje, Hannah, Cindy, Evelien, Emmy, Daniël, Marijke, Saskia en de voorlichters eigen taal 
en cultuur: ik kon altijd op jullie rekenen, bedankt voor jullie hulp!
Ook alle andere (oud-)collega’s wil ik graag bedanken: de mannenkamer (Joost, Wijnand, Martijn), 
Karen, Sasja (fleurigste noot op de afdeling), Jane, Sandra, Leonie, Merlijn, Colette, Annemieke, 
Anneke K., Hanna, Janneke, Bart-Jan, Carolien, Peter, Amy, Linda, Gerben-Rienk, Marlies, Bart 
M., Milo, Daniëla, Ray, Maarten, Ineke, Joost, Nienke, Reinier, Livia, José en John. Ook wil ik Han 
en Martien, het secretariaat met Will, Maria O., Nora en Marleen en de één-dag-per-week-collega’s 
Rosa, Christiaan, Maaike, Eline, Rianne, Anneke de V. en Ronald bedanken voor hun belangstelling.
Mijn (andere) collega’s van afdeling algemene infectieziekten, in het bijzonder Anneke, Dorothé, 
Jacqueline, Lian, Gini, Sanne, Gijs, Gerard, Leny: bedankt voor jullie enthousiasme en hulp! De 
collega’s van het streeklaboratorium, Arjen, Sylvia, Douwe, Thijs, Robin, Karin en alle anderen: 
bedankt voor jullie flexibiliteit als ik maar enkele samples of toch ineens honderd samples aanleverde. 
Het behulpzame team van Jan Vlierhuis, dank jullie wel voor het zoeken naar onvindbare artikelen 
voor de systematische review! Alle stagiaires die een bijdrage hebben geleverd aan dit proefschrift: 
Kirsten, (Anouk), Padamjit, Nicole, Sander, Ilhan, Jonathan: jullie frisse blik en enthousiasme heb 
ik erg gewaardeerd.
Oude buurtjes Will en Ria, bedankt voor jullie betrokkenheid en Will’s fantastische dtp-werk! 
Nieuwe buur Jeroen, ik ben heel blij met het cover design, dank je wel! 
Mijn vrienden en vriendinnen en in het bijzonder Claudia en Gijs, Anuschka en Jeroen,  George en 
Anne, Martin en Marlies, (Anouk en) Michiel, (Marjolein en) Florian, Marjolein en Sander, Petrie 
en Jeroen, Rian en Pieter, bedankt voor jullie steun, de ontspannende avondjes, spelletjes, bootje 
varen, gezellig samen eten, film kijken, praten over andere dingen dan werk… ik hoop jullie snel te 
zien!
Mijn schoonfamilie: Siep, Klaske, Beppe, Fimke, Jorke, Bianca & Morris, een warmer tweede nest 
kan ik me niet voorstellen. Bedankt voor jullie betrokkenheid en alle gezellige en ontspannende 
momenten samen. 
Mijn familie: opa en oma’s, ooms en tantes en neven en nichten, maar bovenal mam, pap en Beer, 
jullie steun op vele fronten is onvergetelijk. Ik ben heel dankbaar en gelukkig dat ik zo’n fantastische 
familie heb. Berit, wat mooi om jou als derde paranimf te hebben!
Jaap, de laatste zinnen zijn voor jou. Dank voor je humor, je zorgzaamheid, het samen genieten (en 
op z’n tijd de ontnuchterende hit van Pater Moeskroen). De afgelopen 13 jaar waren al mooi, maar 
het kan blijkbaar nóg mooier! Ik kijk er nu al naar uit. 
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Freke Zuure werd geboren op 21 maart 1980 in Naarden. In juni 1998 behaalde zij haar gymnasium 
diploma aan openbare scholengemeenschap De Meergronden in Almere Haven. Daarna vertrok zij 
voor een jaar naar Australië en Nieuw-Zeeland om te reizen en te werken. Direct na terugkomst 
in Nederland verhuisde Freke naar Enschede om “Toegepaste communicatiewetenschap” te gaan 
studeren aan de Universiteit Twente met als hoofdrichting gezondheidscommunicatie en als minor 
kennisoverdracht in bedrijfs- en onderwijssituaties. Deze studie rondde zij in november 2005 af met 
een afstudeeronderzoek naar het gebruik van internet voor gezondheidsdoeleinden.
In februari 2006 startte Freke met haar promotieonderzoek op de afdeling Onderzoek van de 
GGD Amsterdam, waarvan dit proefschrift het resultaat is. Tijdens deze periode heeft zij gewerkt 
aan diverse onderzoeken en projecten op het gebied van hepatitis B, hepatitis C, hiv en eHealth. 
Hiernaast voerde ze ook andere werkzaamheden uit, onder andere als communicatieadviseur voor 
het Sarphati Initiatief, de Academische Werkplaats Publieke Gezondheid regio Noord-Holland en 
Flevoland (voorheen: Academische Werkplaats Publieke Gezondheid GGD Amsterdam – AMC). 
In 2012 vergaarde Freke samen met Jannie van der Helm financiering voor de ontwikkeling en 
evaluatie van een trial waarin zelftests voor hiv in combinatie met begeleiding via internet worden 
aangeboden aan hoogrisicogroepen voor hiv infectie die zich niet elders laten testen. Sinds juli 2012 
is zij als postdoc werkzaam op de afdeling Onderzoek van de GGD Amsterdam.
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